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ABSTRACT 
 
A myriad of human behaviors, such as mood, awareness and motivation, are 
modulated by the monoamine neurotransmitters serotonin, norepinephrine and dopamine, 
respectively. Consequently, dysfunction of these monoaminergic systems underlies 
numerous medical conditions. In particular, disturbances in the serotonergic system are 
implicated in depression, bipolar disorder, and autism, whereas the dopaminergic system 
is implicated in Parkinson’s disease and addiction. During neurotransmission high 
concentrations of monoamine neurotransmitters are released from presynaptic neurons 
into the synaptic cleft where they diffuse to bind and activate pre- and postsynaptic 
receptors. The primary way to terminate neurotransmission involves monoamine 
transporters, which shuttle monoamines back into presynaptic neurons where they 
replenish synaptic vesicle contents. The monoamine transporters are molecular targets for 
antidepressants and psychostimulants that function to increase monoamine levels in the 
brain. For example, serotonin transporter (SERT) reuptake is inhibited by Prozac to 
increase serotonin levels and treat various mood disorders. Similarly, dopamine 
transporter reuptake is altered with drugs, such as cocaine or amphetamine, which results 
in enhanced dopaminergic signaling and is thought to underlie reward and addictive 
behaviors. Transport through the monoamine transporters is not thoroughly understood, 
and the traditional model with fixed substrate-ion stoichiometry has been challenged in 
recent years with the discovery of ionic currents mediated by monoamine transporters. In 
an effort to better understand the activity of monoamine transporters, a variety of 
substrates and inhibitors are utilized. In particular, in my work I characterize fluorescent 
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compounds that are based on a known monoamine transporter substrate and describe their 
utility as reporters to study serotonin transporter activity in real-time. In addition, I 
describe a novel effect induced by amphetamine and related compounds at both DAT and 
SERT whereby even after external removal of these compounds, a persistent current 
remains. These studies provide information about various substrates that exert an array of 
distinct effects on SERT and DAT, which may enable further studies to elucidate the 
nature of transporter biophysics.  
 
1. APP+ is a Fluorescent Substrate for the Serotonin Transporter 
One limitation to transporter research is the inability to monitor substrate uptake in 
real-time. Traditional methods such as radiolabeled uptake assays, though highly specific, 
yield poor temporal resolution. Electrophysiology on the other hand provides excellent 
time resolution, but currents are mediated mostly by ionic fluxes and therefore do not 
yield direct information about substrate transport. To investigate this issue, we 
collaborated with Dr. Ian D. Tomlinson and the laboratory of Dr. Sandra Rosenthal to 
develop compounds based on a known monoamine transporter substrate. We identified 
and characterized a fluorescent compound called APP+ that is suitable to monitor SERT 
transport in real-time. We employed a range of techniques to elucidate thoroughly the 
specificity of this compound for SERT expressed in Xenopus laevis oocytes and 
mammalian cells. Finally, we used APP+ to study binding and transport through SERT. 
This work will help to uncover fundamental information about hSERT, and to improve 
our ability to study these transporters. 
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2. Amphetamine Induces a Persistent Leak Current in the Dopamine Transporter 
Amphetamine (AMPH) and related compounds increase dopamine (DA) levels in 
the brain and cause profound behavioral effects. One target for these drugs is the 
dopamine transporter (DAT) that normally regulates synaptic DA levels. DAT agonists, 
such as DA and AMPH, induce DAT-mediated currents driven by sodium. By measuring 
DAT currents on voltage-clamped Xenopus laevis oocytes, we discovered a DAT leak 
current induced by external exposure to the S(+)amphetamine (S(+)AMPH) enantiomer 
that persists long after its removal. We determined that the AMPH-induced leak current 
in DAT depends on sodium and is blocked by cocaine. In addition, intracellular 
application of S(+)AMPH can induce the leak current effectively, which suggests an 
internal secondary binding site in DAT. Understanding this novel effect of AMPH on 
DAT has implications in the understanding of human behavior because AMPH-induced 
persistent currents likely impact dopaminergic signaling, DA release mechanisms, and 
AMPH abuse.   
 
3. A Comparison of Leak and Persistent Leak Currents Induced by Methamphetamine 
and 3,4-Methylenedioxymethamphetamine in the Human Dopamine and Serotonin 
Transporters 
After establishing the S(+)amphetamine-induced persistent leak current at DAT, we 
expanded this work to test if other DAT-mediated releaser agents related to AMPH 
would also induce the persistent leak current. In particular, we focused on 3,4-
methylenedioxy-methamphetamine (MDMA) and methamphetamine (METH) because it 
is known that although MDMA and METH are structurally related they exert distinct 
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behavioral effects in people. However, since MDMA has preference for the serotonin 
transporter and METH acts more potently at DAT, we made a comparison of the effects 
of METH and MDMA on both SERT and DAT. Lastly, we uncovered that the AMPH 
derivative para-chloroamphetamine (pCA) confers a substantial persistent leak current at 
the human serotonin transporter. These findings could open new avenues towards the 
study of the effect drugs of abuse have on behavior.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   5 
CHAPTER I 
 
MONOAMINE NEUROTRANSMITTER TRANSPORTERS 
 
Overview of Monoamine Neurotransmitters 
Biogenic amine transmitters are found throughout the central nervous system (CNS), 
the peripheral nervous system (PNS), and the enteric nervous system (ENS) where they 
play a role in a variety of functions. The five well-known biogenic amines are histamine, 
serotonin (5-hydroxytryptamine, 5HT), and the three catecholamines (DA, 
norepinephrine (NE), and epinephrine (Epi)) having a catechol group in their chemical 
structure. Histamine is synthesized in neurons found in the hypothalamus and is known to 
mediate arousal and attention via central projections. In addition, it plays a role in 
vestibular system reactivity, immune response, and possibly even in brain blood flow. 
Compared to the other catecholamine transmitters, epinephrine (also called adrenaline) is 
found in the brain at low levels and in a smaller number of neurons. Although the 
distribution of Epi neurons and their projections in the brain have been described, the 
function of this system is unknown (Purves 2008).  
A significant emphasis has been placed on the remaining three biogenic monoamine 
neurotransmitters (NE, DA, and 5HT) because they are important in regulating numerous 
critical human behaviors. Consequently, disturbances in these monoaminergic systems 
are associated with a plethora of medical conditions, and pharmaceutical approaches are 
aimed at altering levels of these three monoamine neurotransmitters.  
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DA is synthesized in neurons found in the substantia nigra (SN) and ventral 
tegmental area (VTA) in the midbrain, as well as in the hypothalamus. The precursor for 
DA (dihydroxyphenylalanine, DOPA) is synthesized from the hydroxylation of the amino 
acid tyrosine by the enzyme tyrosine hydroxylase (TH). DOPA is converted to DA by the 
decarboxylation by DOPA decarboxylase. Dopaminergic neurons release DA to many 
areas of the brain and give rise to several important dopaminergic pathways. For instance, 
neurons from the SN project to the striatum through the nigrostriatal pathway that plays a 
role in the regulation of motor coordination and is deficient in diseases such as 
Parkinson’s disease (Purves 2008). In another example, the VTA gives rise to the 
mesolimbic and mesocortical dopaminergic pathways that are both thought to be 
involved in schizophrenia. The mesolimbic pathways projects from the VTA to the 
nucleus accumbens that is part of the limbic system, and the mesocortical pathway 
projects from the VTA to several regions in the frontal cortex. Crucial behaviors that are 
regulated by DA include cognition, attention, working memory, motivation, and 
voluntary movement. Medical conditions that are associated with the dopaminergic 
system in the CNS include attention deficit/hyperactivity disorder (ADHD), addiction, 
Parkinson’s disease, and schizophrenia, and in the PNS fibromyalgia.  
The primary noradrenergic nucleus where NE is synthesized is the locus coeruleus, 
which is located in the dorsal pons. Although noradrenergic neurons make projections to 
most areas in the brain, there are two main noradrenergic ascending projections: the 
dorsal noradrenergic bundle, which projects to the hippocampus, cerebellum, forebrain, 
and the ventral noradrenergic bundle, which projects to the hypothalamus, midbrain, and 
extended amygdala (Weinshenker and Schroeder 2007). NE is synthesized from the 
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hydroxylation of DA by dopamine-β hydroxylase. Noradrenergic neurons innervate many 
regions in the body including the spinal cord, cerebellum, amygdala, thalamus, 
hypothalamus, and cortex among others. NE plays a major role in the PNS to regulate 
many crucial autonomic nervous system functions, such as heart rate, respiration, 
digestion, sexual arousal, the fight-or-flight response, and other visceral functions. In 
addition, in the CNS the noradrenergic system regulates behaviors such as cognition, 
attention, and learning and memory. Some diseases associated with the noradrenergic 
system include (for CNS) post-traumatic stress disorder (PTSD), Alzheimer’s disease, 
and depression and (for PNS) orthostatic intolerance, hypertension, and cardiomyopathy.  
The ENS is considered a subdivision of the autonomic nervous system though it can 
function independently to directly control the gastrointestinal system in vertebrates. Most 
of the 5HT in the body (about 90%) is found in the ENS in enterochromaffin cells that 
line the gut mucosa, where it regulates gastrointestinal movements. Furthermore, platelets 
take up and store 5HT secreted from enterochromaffin cells, and use the monoamine to 
regulate homeostasis and blood clotting. The remaining 5HT is found in the CNS and is 
synthesized in several clusters of neurons along the brainstem called Raphe nuclei. 
Serotonergic neurons from Raphe nuclei project to many regions throughout the CNS and 
PNS including the forebrain, thalamus, and reticular formation. 5HT is synthesized from 
the amino acid tryptophan in two steps. Tryptophan is converted to 5-hydroxytryptophan 
by tryptophan-5-hydroxylase, and then, decarboxylation of 5-hydroxytryptophan by 
aromatic L-amino acid decarboxylase yields 5HT. Many behaviors including aggression, 
appetite, sleep, and libido are regulated by 5HT. Moreover, medical conditions associated 
with dysfunction in the serotonergic system include (for CNS) obsessive-compulsive 
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disorder (OCD), major depression, bipolar disorder, autism spectrum disorders, anxiety, 
and eating disorders, such as anorexia and bulimia, (for PNS) pulmonary hypertension, 
and (for ENS) irritable bowel syndrome. 
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Overview of Transport Proteins 
There are a large number of membrane-bound proteins that serve the function to 
transport all kinds of molecules across membranes and have been grouped into many 
classes that include ion channels, ATP-binding cassette (ABC) transporters, water 
channels (aquaporins), ion pumps (ATPases), and the solute carriers (Hediger, Romero et 
al. 2004; Fredriksson, Nordstrom et al. 2008). With at least 384 genes in humans, the 
solute carriers (SLCs) make up the second largest family of membrane proteins 
(following G protein-coupled receptors) and the largest transporting protein group 
(Hoglund, Nordstrom et al. 2011). There are at least 46 distinct SLC families in the 
human genome that encode for passive transporters, ion transporters, and exchangers that 
carry many molecules across membranes, including inorganic ions, amino acids, 
neurotransmitters, sugars, purines, fatty acids, and drugs (Fredriksson, Nordstrom et al. 
2008; Hoglund, Nordstrom et al. 2011). The two major neurotransmitter transporter gene 
families are solute carrier 1 (SLC1) – classically termed Na+/K+-dependent – and solute 
carrier 6 (SLC6) – classically referred to as Na+/Cl—dependent. More recently, these 
transporter gene families are grouped as the neurotransmitter sodium symporter (NSS) 
family (Nyola, Karpowich et al. 2010). Whereas members of the SLC1 family transport 
dicarboxylate amino acids, such as glutamate and aspartate, members of the SLC6 family 
transport a variety of substrates including amino acids, such as γ–aminobutyric acid 
(GABA), glycine, proline, and taurine, osmolytes (betaine, creatine), and the biogenic 
amines 5HT, DA, and norepinephrine (Singh 2008).  An underlying property of SLC1 
and SLC6 family members is that they use an ionic gradient to energize the transport of 
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substrate across plasma membranes (Fredriksson, Nordstrom et al. 2008; He, Vasiliou et 
al. 2009). 
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Overview of the Monoamine Neurotransmitter Transporters at the CNS Synapse 
The neurotransmitters NE, DA, and 5HT are released via vesicular fusion by their 
respective neurons into the synaptic cleft in response to depolarization of the presynaptic 
terminal. After neurotransmitter diffuses and activates the postsynaptic neuron, 
transmitter is taken back into the presynaptic neuron through transporters located at 
perisynaptic areas (Hoffman, Hansson et al. 1998; Tao-Cheng and Zhou 1999). The 
monoamine transmitter is then re-packaged into synaptic vesicles via vesicular 
monoamine transporters (VMATs). In particular, the vesicular monoamine transporter 2 
(VMAT2), which is primarily found in the CNS, is responsible for transmitter reuptake 
into synaptic vesicles of dopaminergic, serotonergic and noradrenergic neurons 
(Wimalasena 2011).  
An illustration of a serotonergic synapse (Figure 1) is shown to illustrate a specific 
monoamine neurotransmitter system. In response to depolarization, serotonergic nerve 
terminals release 5HT into the synaptic cleft, which activates postsynaptic 5HT receptors, 
and SERT, located at the presynaptic membrane, transports the extracellular 5HT from 
the cleft into the presynaptic terminal where 5HT can be re-packaged into synaptic 
vesicles. Similarly, in the dopaminergic synapse, the primary means to terminate the DA 
signal at the synapse occurs through DAT, the corresponding presynaptic plasma 
membrane protein at this synapse that takes up released DA back into the presynaptic 
terminal where the neurotransmitter is recycled and re-packaged into synaptic vesicles. 
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Figure 1. Serotonergic Synapse. After an action potential depolarizes the presynaptic 
neuron, Ca2+ channels at the presynaptic terminal let in Ca2+, which binds to vesicular 
proteins triggering exocytosis of synaptic vesicles and releasing neurotransmitter 5HT 
into the synaptic cleft. 5HT binds to postsynaptic 5HT receptors to transmit the signal, 
and 5HT that diffuses from the cleft is taken up through SERT that is located in 
perisynaptic areas at the presynaptic terminal (Tao-Cheng and Zhou 1999), thereby 
terminating neurotransmission.   
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The Role of Serotonin in Disease 
5HT is a neurotransmitter that plays a role in the regulation of many behaviors, such 
as mood, sleep, appetite, temperature, sexual behavior, and aggression (Schloss and 
Williams 1998; Stahl 1998). Defects of the serotonergic system in disease were 
postulated by early studies showing that plasma levels of 5HT’s precursor, tryptophan, 
were reduced in patients with depression (Coppen, Shaw et al. 1967). Subsequent studies 
have implicated disturbances in the serotonergic system in many more diseases, including 
bipolar disorder, autism, and a spectrum of psychiatric disorders, such as anorexia 
nervosa, bulimia, and obsessive-compulsive disorder (OCD) (Feighner 1994; Vaswani, 
Linda et al. 2003; Vaswani and Kalra 2004).  
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The Role of the Human Serotonin Transporter in Disease 
Evidence for specific roles of human SERT (hSERT) in disease comes from many 
genetic studies. In humans, the gene that encodes for SERT, solute carrier family 6 
neurotransmitter transporter, 5HT, member 4 (SLC6A4), is located on chromosome 17 at 
17q11.1-q12, and is organized into 14 exons (Sghendo and Mifsud 2012). Mutations 
associated with the hSERT gene have been shown to affect SERT function and specific 
polymorphisms that alter hSERT expression and activity are correlated with autism, 
rigid/compulsive traits related to OCD, and major depression (Murphy, Lerner et al. 
2004; Prasad, Zhu et al. 2005; Sutcliffe, Delahanty et al. 2005; Prasad, Steiner et al. 
2009). For instance, the promoter region of the SLC6A4 contains a polymorphism with 
‘short’ and ‘long’ repeats (termed the serotonin transporter-linked polymorphic region or 
5HTTLPR), and the short variation has been associated with decreased hSERT 
expression, anxiety-related personality traits, an increased risk of major depression, and 
poorer response to antidepressants in people with major depression (Lesch, Bengel et al. 
1996; Sghendo and Mifsud 2012). Additionally, a gain-of-function phenotype associated 
with hSERT, Ile425Val, that causes constitutive activation of transport activity (Kilic, 
Murphy et al. 2003), has been traced to subjects exhibiting complex psychiatric 
phenotypes, including OCD and Asperger's Syndrome (Ozaki, Goldman et al. 2003). 
Ile425Val illustrates how abnormal hSERT activity can affect serotonergic signaling. In 
this case, it is thought that reuptake activity by the hSERT variant is abnormally 
increased, leading to lower 5HT concentrations at the synaptic cleft and diminishing 
serotonergic signaling (Kilic, Murphy et al. 2003).  
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Serotonin Transporters as Therapeutic Targets 
The discovery in the early 1950s that the antitubercular drug, iproniazid, a 
monoamine oxidase inhibitor (MAOI) that blocks the effect of monoamine oxidase 
(MAO) to break down and inactivate monoamine neurotransmitters, had mood-elevating 
effects, led to the monoamine hypothesis of depression. Iproniazid increased levels of 
5HT and other monoamines by inhibiting its degradation by the enzyme monoamine 
oxidase. Since MAOIs produced many adverse side-effects, efforts focused on the 
development of several classes of drugs targeting monoamine transporters, such as 
tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) that 
inhibit reuptake of 5HT into presynaptic terminals, and prolong the neurotransmitter’s 
action at the synapse (White, Walline et al. 2005). In addition to increasing 5HT levels, 
TCAs exert effects as a norepinephrine reuptake inhibitor, an anticholinergic-
antimuscarinic agent, an alpha1-adrenergic antagonist, an antihistamine, and even a 
sodium channel inhibitor, which can potentially cause lethal cardiac arrhythmias and 
seizures (Stahl 1998). Thus, the adverse side effects of TCAs led to focus on the 
development of SSRIs that targeted only SERT. Fluoxetine (FLX, Prozac) was the first 
drug of this kind approved as a therapeutic agent by the regulatory authorities in the USA 
(Sghendo and Mifsud 2012). Further SSRIs have been synthesized to lessen the adverse 
side effect profile of FLX, such as citalopram, escitalopram, fluvoxamine, and sertraline. 
These SSRIs have fewer activating side effects, such as insomnia, anxiety, and tremors, 
and fewer gastrointestinal side effects, such as nausea, diarrhea, anorexia, and vomiting; 
therefore, they are preferred over use of FLX (Sghendo and Mifsud 2012). Presently, 
SSRIs are the most widely prescribed drugs for the treatment of depression, OCD, and 
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bipolar disorder, as well as other diseases such as anxiety, anorexia, and panic disorders 
(Stahl 1998). In addition, the recreational drug 3,4-methylenedioxy-methamphetamine  
(MDMA, ecstasy) has been effectively used in the treatment of anxiety disorders; in 
particular, MDMA has been shown to improve post-traumatic stress disorder (PTSD) 
patients (Johansen and Krebs 2009; Mithoefer, Wagner et al. 2011). MDMA targets the 
monoamine neurotransmitter transporters, but possesses greater potency for hSERT. It is 
thought that MDMA increases monoamine transmitter levels in the brain by reversing the 
direction of transport of hSERT, hDAT, and hNET, and inducing the release of the 
corresponding endogenous monoamine transporter substrates (5HT, DA, and NE, 
respectively) (Schloss and Williams 1998).  
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The Role of Dopamine in Disease 
Disturbances in the dopaminergic system have been implicated in numerous brain 
illnesses, including Huntington’s chorea, Parkinson’s disease, schizophrenia, attention-
deficit/hyperactivity-disorder (ADHD), depression, and addiction (Barbeau 1970; Javitch 
and Snyder 1984; Gainetdinov and Caron 2003; Gainetdinov 2008). Perhaps the most 
striking illness associated with the dopaminergic system is Parkinson’s disease, which is 
the second most common neurological disorder in the United States, and is characterized 
by impairment of motor function that is attributed to massive death of dopaminergic 
neurons comprising the nigrostriatal pathway (Javitch and Snyder 1984; Jellinger 1991).  
ADHD is another illness associated with a deficient dopaminergic system, which has 
become one of the most common neurobehavioral disorders of childhood (Bedard, Schulz 
et al. 2010). ADHD is a highly heritable psychiatric disorder affecting anywhere from 4-
10% of children and 5% of adults (Barr, Wigg et al. 1999; Krause, Dresel et al. 2000; 
Mazei-Robison, Couch et al. 2005; Mazei-Robinson and Blakely 2006; Bedard, Schulz et 
al. 2010). A more recent review of the scientific literature estimated the worldwide 
prevalence of ADHD in children to be 5.29% (Polanczyk, de Lima et al. 2007). Although 
the cause of ADHD is far from understood, overwhelming evidence points toward the 
dopaminergic system, and altered DA signaling appears to be central to the disease.  
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The Role of the Human Dopamine Transporter in Disease 
The human dopamine transporter (hDAT) gene (SLC6A3) is located on chromosome 
5 at 5p15.3 and contains 15 exons and 14 introns (Kawarai, Kawakami et al. 1997). 
Genetic studies have implicated variations to this gene in specific illnesses. In particular, 
polymorphisms in a variable number tandem repeat (VNTR) in the 3’ untranslated region 
of hDAT has been linked to the ADHD phenotype (Bedard, Schulz et al. 2010), and an 
hDAT variation, lacking the hDAT 10-repeat allele, confers differences in how ADHD 
children respond to methylphenidate hydrochloride (MPH, Ritalin) treatment (Froehlich, 
Epstein et al. 2011). In addition, the human DAT coding variant Ala559Val identified in 
children diagnosed with ADHD displays anomalous AMPH-mediated DA efflux and 
responds differently to ADHD medications than wild-type hDAT (Mazei-Robison, 
Bowton et al. 2008). Moreover, a loss-of-function mutation in DAT that impairs DA 
reuptake is thought to cause autosomal recessive infantile parkinsonism-dystonia (Kurian, 
Zhen et al. 2009). More recently, single nucleotide polymorphisms (SNPs) in the DAT 
gene have been associated with positive symptoms of schizophrenic patients (Zheng, 
Shen et al. 2012). In total, at least 63 DAT variants have been described from which two 
SNPs, one in intron 8 and one in intron 13, were found to be moderately associated with 
bipolar disorder (Greenwood, Schork et al. 2006).  
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Dopamine Transporters as Therapeutic Targets 
Management of DA levels in the brain is essential for proper function, and DA 
reuptake is critical to maintain DA homeostasis. In the human nervous system, DAT is 
largely responsible for performing this function. The human DAT (hDAT) is found 
presynaptically at dopaminergic synapses, on the cell body, and in neuronal dendrites. 
Along with DA release mechanisms and DA degradation, hDAT controls the 
concentration profile of extracellular DA (Spielewoy, Gonon et al. 2000); therefore, 
hDAT contributes to the normal function of the nervous system and to mental disorders 
(Hahn and Blakely 2002). Consequently, hDAT is a major molecular target for 
therapeutic agents, such as methylphenidate hydrochloride (MPH, Ritalin) and AMPH 
(Adderall). Both compounds, which are often prescribed to treat ADHD, act directly on 
hDAT to increase extracellular DA levels, but they do so via different actions on hDAT. 
Whereas MPH is a DAT reuptake inhibitor, AMPH is a DAT substrate thought to 
stimulate DA release through non-vesicular reverse DA transport through DAT (Wall, Gu 
et al. 1995; Wu and Gu 1999).  
Drugs of abuse, such as methamphetamine (METH) and cocaine (COC), increase 
DA levels via similar mechanism as the aforementioned therapeutic agents. For example, 
similarly to MPH, drugs like COC inhibit DA transport by DAT, and thus increase 
extracellular DA. METH and related compounds, such as AMPH and Adderall, are 
transported by DAT to subsequently cause DA release by reversing DAT transport. 
Interestingly, because an abnormal increase in DA may be at the core of psychiatric 
disorders and drug abuse (Henry and Blakely 2008), these compounds can produce 
adverse reactions, such as psychosis, and the strong DA release underlies their strong 
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abuse potential. Regardless, they present the best treatment available for certain mental 
illnesses (Fleckenstein, Volz et al. 2007). 
Since the psychostimulants AMPH and METH lead to the release of catecholamines 
(DA and NE) in the frontal lobe and limbic system (by transmitter reuptake inhibition at 
hDAT and hNET and transmitter efflux by hDAT and hNET), they have been used 
clinically to treat medical conditions that benefit from an increase in catecholaminergic 
neurotransmission, such as attention-deficit/hyperactivity disorder and narcolepsy 
(Burnette, Bailey et al. 1996; Fleckenstein, Volz et al. 2007). Due to the higher potency 
of the dextro-rotary AMPH isomer (S(+)AMPH) over the levo-rotary AMPH isomer (R(–
)AMPH) to release DA through hDAT (Phillips, Brooke et al. 1975; Holmes and 
Rutledge 1976; Kuczenski, Segal et al. 1995), therapeutic agents are composed primarily 
of S(+)AMPH. For example, Adderall is composed of 3:1 S(+)AMPH to R(–)AMPH 
(Cody, Valtier et al. 2003), and Vyvanse (lisdexamphetamine) is a pro-drug composed of 
S(+)AMPH conjugated to L-lysine, which is metabolized entirely to S(+)AMPH (Heal, 
Cheetham et al. 2009; Najib 2009). Even the dextro-rotary isomer of METH is marketed 
as Desoxyn for the treatment of ADHD and narcolepsy (Mendelson, Uemura et al. 2006).  
Clinical manifestations associated with the abuse of AMPH or its precursors or 
derivatives, such as phenethylamine or METH, are well documented (Potkin, Karoum et 
al. 1979; Romanelli and Smith 2006; Winslow, Voorhees et al. 2007). In an attempt to 
bypass the reward system, the non-stimulant selective NE reuptake inhibitor (NRI) 
atomoxetine (Strattera) has been introduced for the treatment of ADHD (Heal, Cheetham 
et al. 2009). Lastly, bupropion (Wellbutrin) is used to treat depression (Wu and Gu 1999; 
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Mazei-Robinson and Blakely 2006) through unique actions as a dual DA and NE 
reuptake inhibitor (Arias 2009). 
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Transport Mechanism of the Human Serotonin and Dopamine Transporters 
Traditionally, hSERT was classified as a Na+/Cl--coupled co-transporter since it 
requires both Na+ and Cl- to transport substrates; more recently, hSERT and related 
transporters, such as the GABA and norepinephrine transporters, have been termed 
neurotransmitter sodium symporters, which reflects the limitation of knowledge about the 
ionic contribution for substrate transport (Ramamoorthy, Bauman et al. 1993). In order to 
transport substrate, co-transporters use the gradients of ions to concentrate their substrate 
against their concentration gradient. Na+ levels are ten times higher outside than inside 
cells, creating a gradient that is used by hSERT to transport and concentrate 5HT against 
its concentration gradient (DeFelice and Blakely 1996; Rudnick 1998; Rudnick 1998). 
Traditionally, co-transport is described by alternating access models (see Figure 2), in 
which ions (Na+ and Cl-) and substrate (5HT) bind the transporter in its outward-facing 
conformation, an inward-facing conformational change is catalyzed, and the substrate and 
ions are transported from outside to inside. Subsequently, a counter-ion, either a proton 
(H+) or a K+, is transported from inside to outside of the plasma membrane returning the 
transporter to the outward-facing conformation. This model is supported by biochemical 
and radiolabeled uptake data (Naftalin 1984; Stein 1986; Naftalin 2005) and seems 
consistent with recent structural data for co-transporters (Abramson, Smirnova et al. 
2003; Abramson, Smirnova et al. 2003; Yernool, Boudker et al. 2004; Yamashita, Singh 
et al. 2005). Similarly, it has been proposed that DAT also abides by the alternating 
access model, in which the transport of DA is coupled with fixed stoichiometry to the 
downhill movement of Na+ ions, and that the stoichiometry for transport of substrate 
consists of two Na+, and one Cl-, coupling to a DA in the outward-facing hDAT 
	   23 
conformation, and either a K+ or H+ binds to the inward-facing conformation to return 
hDAT to the outward-facing conformation (McElvain and Schenk 1992; Gu, Wall et al. 
1994; Sonders, Zhu et al. 1997). 
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Transport-associated Currents of the Serotonin and Dopamine Transporters 
Early studies using biochemical approaches and radiolabeled flux led to the 
emergence of the “Alternating Access” model for SERT transport (illustrated in Figure 
2), which proposed that the stoichiometry for each transport cycle in the mammalian 
SERT to be one Na+, one Cl-, and one 5HT co-transported into the cells, and one K+ 
counter-transported (Keyes and Rudnick 1982; Rudnick and Wall 1993). As stated above, 
DAT was also proposed to abide by the alternating access model (AAM), but the 
stoichiometry for transport of substrate consists of two Na+ and one Cl- for each DA 
transported (McElvain and Schenk 1992; Gu, Wall et al. 1994; Sonders, Zhu et al. 1997). 
Subsequent studies have led to an emerging idea about the existence of uncoupled 
currents, in which transporters possess channel-like activity (“Channel in Transporter” 
mode shown in Figure 2) (Quick 2003; DeFelice 2004; DeFelice and Goswami 2007). In 
coupled currents, associated with co-transport, ions are ‘coupled’ to substrate and both 
ions and substrate are transported according to a defined stoichiometry. Since the early 
1990s, uncoupled currents, in which currents associated with substrate transport are much 
larger than what can be accounted for by the measured stoichiometry, have been found in 
many neurotransmitter transporters (Mager, Min et al. 1994; Galli, DeFelice et al. 1995; 
Galli, Blakely et al. 1996; DeFelice and Galli 1998; DeFelice and Galli 1998; Galli, 
Blakely et al. 1998; Petersen and DeFelice 1999; Adams and DeFelice 2002; Ramsey and 
DeFelice 2002; Adams and DeFelice 2003; Li, Zhong et al. 2006).  
Uncoupled currents in transporters are largely unexplained and their function is 
unknown, but one possibility is that these currents play a functional role in 
neurotransmission by depolarizing or hyperpolarizing neurons (Sonders and Amara 1996; 
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Ingram, Prasad et al. 2002; Quick 2002; Quick 2003; Carvelli, McDonald et al. 2004; 
Ryan and Mindell 2007). Even though most of the evidence for channels in SERT comes 
from heterologous expression systems, large 5HT-induced currents are also generated in 
SERT at actual serotonergic synapses (Bruns, Engert et al. 1993; Bruns 1998).  
Uncoupled DAT currents have been described, but in at least one study, Cl- seems to 
contribute to their ionic composition (Carvelli, McDonald et al. 2004); however, in our 
work Na+ is a major contributor to DAT-mediated substrate-induced currents (Rodriguez-
Menchaca, Solis et al. 2012). Studies using molecular biology and fluorescence 
resonance energy transfer microscopy suggest SERT prefers to assemble into a 
multimeric complex, probably consisting of dimers or tetramers (Kilic and Rudnick 2000; 
Schmid, Just et al. 2001; Schmid, Scholze et al. 2001), and a recent study of transporter-
associated currents in glutamate transporters proposed that channels maybe be located in 
the individual subunits (Larsson, Picaud et al. 1996; Leary, Stone et al. 2007). However, 
for the monoamine neurotransmitter transporter (SLC6 gene) family, it is still not 
thoroughly established if the currents are mediated through each individual oligomer or if 
they function once they are assembled into multimeric complexes.   
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Figure 2. Substrate transport models of hSERT. The ‘Alternating Access Model 
(AAM)’ abides by a fixed stoichiometry in which 1 Na+, 1 5HT+ and 1 Cl- are co-
transported together and 1 K+ is counter-transported returning hSERT to its outside-
facing conformation. In the AAM, hSERT would be electroneutral (net charge = 0), 
which would yield negligible currents even if 2 Na+ ions are co-transported (along with 
the 5HT and Cl-) as has also been predicted. On the other hand, the “Channel in 
Transporter Model” yields uncoupled currents in which the ratio of Na+ ions to 5HT is 
larger than what is accounted for by the fixed stoichiometry of the AAM. This renders 
hSERT electrogenic (net charge larger than what is accounted by fixed AAM 
stoichiometry); therefore, hSERT produces large uncoupled currents.  
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Serotonin and Dopamine Transporters Display a Leak Current 
Since a study by Mager and colleagues in 1994, it has become well established in 
electrophysiological studies that monoamine transporters possess an alternate current that 
can be seen when inhibitors are applied to these transporters. One of the first instances 
was the identification of currents manifested by the rat SERT, which were termed leak 
currents (Mager, Min et al. 1994). For SERT many studies have employed two-electrode 
voltage-clamp (TEVC) in Xenopus laevis oocytes over-expressing SERT (clamped to 
potentials near physiological resting membrane potentials) to clearly show that many 
different inhibitors reveal the SERT leak current, which is characterized as an outward, 
hyperpolarizing current and is thought to be mediated primarily by Na+. Some examples 
include studies using the selective serotonin reuptake inhibitors fluoxetine (FLX) (Wang, 
Li et al. 2006) and citalopram (both (R)- and (S)-citalopram isomers) (Storustovu, 
Sanchez et al. 2004), and the tricyclic antidepressants desipramine (DES) (Lin, Lester et 
al. 1996) and imipramine (IMI) (Barker, Moore et al. 1999).  
The majority of SERT inhibitors used in research, including the ones mentioned 
above, have been shown to elicit long-lasting electrophysiological effects after their 
removal that are indicative of a distinct action on SERT compared to that of substrates 
(which typically induce effects that are easily washed out). For example, from our 
studies, we know that after exposure to FLX, there is a much weaker action of 5HT (or 
other substrates) at hSERT. Also, when FLX is applied alone, even removal of FLX and 
perfusion of standard solution does not bring the holding current back to baseline, which 
is different than substrates that usually wash out quickly returning to baseline. To bring 
this persistent FLX-induced outward current (in absence of FLX) to original baseline 
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levels and then to inward currents, 5HT can be applied, however, this requires perfusion 
for a duration that far exceeds the time it takes to induce SERT-mediated inward currents 
in the absence of FLX (at least 3 minutes) and the response looks dissimilar to the 5HT-
induced current prior to FLX application. In agreement, the aforementioned Wang et al. 
study shows that exposure to FLX leads to a greatly diminished 5HT-induced hSERT-
mediated current response (as measured by the peak current time constant): “the time 
constant for 5HT-induced current became much greater than that for the first 5HT 
perfusion”. This study further exemplifies the long-lasting FLX effect on hSERT that 
distinguishes inhibitors and argues against a balance between the two currents.  
Lastly, under physiologically relevant experimental concentrations, the FLX-induced 
outward current supersedes inward 5HT-induced currents (when 5HT and FLX are 
simultaneously applied – even with high 5HT concentrations). This further suggests FLX 
acts tightly at SERT (like a cork in a bottle) that both inhibits the endogenous transporter 
leak current and disables substrate-induced currents at SERT. These results are shown 
consistently in different studies with other SERT inhibitors, including desipramine (Lin, 
Lester et al. 1996), imipramine (Barker, Moore et al. 1999), and paroxetine (personal 
observations). In addition, the similar phenomena are seen with both isomers of 
citalopram (Storustovu, Sanchez et al. 2004). Storustovu et al. demonstrate that applying 
citalopram during an evoked 5HT-induced SERT response takes the current back to 
baseline (even to an outward current when using the (S)-citalopram isomer). Moreover, it 
is shown that treatment with citalopram (prior to 5HT application) leads to a diminished 
subsequent 5HT response (especially with the (S)-citalopram isomer) (Storustovu, 
Sanchez et al. 2004).  
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Analogous inhibitor-induced outward (leak) currents that occur in the absence of 
extracellular DA have been identified in DAT. Inhibitors for DAT, such as cocaine and 
cocaine analogs, induce outward currents in DAT-expressing voltage-clamped Xenopus 
laevis oocytes (Sonders, Zhu et al. 1997). The DAT-mediated outward current elicited by 
cocaine does wash out and return back to baseline, albeit at a slower rate than the 
substrate (DA)-induced inward current, and this is attributed to its action as an inhibitor – 
rather than a substrate – at DAT. Inhibitors with much higher affinity, such as the cocaine 
analog (1R)-2beta-Carbomethoxy-3beta-(4-iodophenyl)tropane (β-CIT), behave much 
tighter when inhibiting DAT since its evoked outward-current is difficult to wash out, not 
unlike the behavior seen with FLX on SERT. 
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Structure of the Human Serotonin and Dopamine Transporters 
The SLC6 gene family encodes for transporters having 12 transmembrane (TM) 
domains (TMDs) with intracellular N- and C-termini, and a large extracellular loop 
between TM domains 3 and 4 (topology shown in Figure 3A) that contain glycosylation 
sites (Chen, Reith et al. 2004). Specifically, the gene SLC6A3 encodes for the 620-amino 
acid protein hDAT with a relative molecular weight of 68.4 kDa. SLC64A encodes for the 
630-amino acid protein hSERT having a relative molecular weight of 70.22 kDa (Chen, 
Reith et al. 2004). A breakthrough in the elucidation of the tertiary structure of the 
monoamine neurotransmitter transporters came when the crystal structure a bacterial 
homologue, the leucine transporter from Aquifex aeolicus (LeuTAa), was obtained 
(Yamashita, Singh et al. 2005). The structure of LeuTAa, a member of the SLC gene 
family, was solved at 1.65 Å resolution in complex with its substrate and two Na+ ions 
bound halfway across the bilayer in the unwound portions of TMD 1 and 6. There is an 
anti-parallel structure relating TMD 1-5 to TMD 6-10 (illustrated with grey triangles in 
Figure 3A). Although the overall sequence identity between the eukaryotic and 
prokaryotic counter parts is only 20-25%, the sequence identity in the binding pocket is 
thought to be up to 45-50%. Still, due to its similarities, especially at the central binding 
site, the crystal structure of LeuTAa has been employed by many groups to produce 
molecular homology models of the monoamine transporters, including models for hSERT 
(Celik, Sinning et al. 2008; Sarker, Weissensteiner et al. 2010; Combs, Kaufmann et al. 
2011; Gabrielsen, Kurczab et al. 2012) and hDAT (Indarte, Madura et al. 2008; Shan, 
Javitch et al. 2011). Primarily, these models are used to study interactions between the 
transporters and their substrates or inhibitors. An example of a homology model of SERT 
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showing its endogenous substrate 5HT docked within the active region of SERT (Figure 
3B), and a closer view of the active region with the interactions 5HT makes within SERT 
(Figure 3C) illustrates how these models provide information about the interaction 
between substrate and transporter.  
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Figure 3. Topology and homology model of SERT. (A) SERT is composed of 12 
transmembrane domains. Helices 1-5 are structurally similar to helices 6-10, but fold in 
opposing directions (represented with gray triangles) to form an anti-parallel structure. 
Green arrows represent β-sheets, orange rectangles represent extracellular loops, blue 
rectangles represent intracellular loops, and the red hexagon shows 5HT at the active 
region. Based on Yamashita, Singh et al. 2005.  (B) Tertiary structure of hSERT based on 
the crystal structure of the bacteria Aquifex aeolicus leucine transporter. (C) The 
endogenous substrate 5HT (shown in pink) binds at the active region of hSERT and 
interacts with amino acid residues on transmembrane helices 1, 3, 6, and 8. B and C were 
based on the Yamashita, Singh et al. 2005 leucine transporter crystal structure and 
obtained from Igor Zdravkovic. 	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Fluorescence Substrates to Study Monoamine Transporter Activity 
Previous studies in the lab took advantage of the fluorescent compound ASP+ (4-(4-
(dimethylamino)-styryl)-N-methylpyridinium) to study the human norepinephrine 
transporter (hNET) and the human dopamine transporter (hDAT) (Schwartz, Blakely et 
al. 2003; Schwartz, Novarino et al. 2005). ASP+ was successfully utilized to study 
mechanistic properties of hNET fluorometrically. For example, it was discovered that 
ASP+ could be used to monitor two distinct components of hNET activity, binding and 
uptake (Schwartz, Blakely et al. 2003). Furthermore, the ability to fluorometrically 
measure ASP+ binding to hNET allowed for advanced microscopy techniques to be 
performed (in particular fluorescence fluctuation correlation spectroscopy), and the 
substrate-protein stoichiometry was determined, which provided the information that 
each ASP+ molecule resided on an hNET for 526 µs before being transported (Schwartz, 
Novarino et al. 2005).  
Although ASP+ was well-transported by both hNET and hDAT with good km (~2 
µM) for uptake, it yielded a very weak km (up to 100 µM) for transport by hSERT 
(Schwartz, Piston et al. 2006); therefore, development of alternative fluorescent 
substrates to study hSERT was warranted. ASP+ conferred fluorescence due to resonance 
within its structure and the contribution of the free electrons from the dimethyl amino 
moiety (Figure 4). Following on this chemical property to fluoresce, compounds 
synthesized were based on an ASP+ analog, 1-methyl-4-phenylpyridinium (MPP+), which 
is a known monoamine transporter substrate that has reasonable affinity for monoamine 
transporter uptake. The addition of an electron donating dimethyl amino group to the 
phenyl ring of MPP+ results in a fluorescent compound called APP+ (Figure 4 and Figure 
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7A), which is also known as IDT307. This fluorescence is not evident in solution but 
only arises after stabilization of the two rings in a fixed conformation that is achieved 
after transport and immobilization by binding to intracellular proteins. The dimethyl 
amino group of APP+ interacts with the rest of the structure by donating electrons to the 
pyrimidine ring producing resonance and yielding fluorescence within the visible range. 
In an effort to study mechanistic properties of SERT fluorometrically, additional 
fluorescent MPP+ analogs were synthesized (Figure 7B) (Mason, Farmer et al. 2005); 
however, based on its brightness APP+ proved to be the optimal fluorescent substrate to 
specifically study SERT activity. In fact, this compound has been marketed in a 
neurotransmitter uptake kit, and has applications for high-throughput screening (HTS) 
assays in solution using a FlexStation (Jorgensen, Nielsen et al. 2008) and for monitoring 
SERT regulation (Chang, Tomlinson et al. 2012). To further understand how these 
fluorescent compounds can be used to measure SERT activity at the cellular level, in a 
study described in Chapter 2, I employ fluorescence microscopy to visualize and compare 
APP+ and ASP+ in single cells expressing hSERT. Also, by use of electrophysiology I 
make an additional distinction between the effect these related compounds have on 
hSERT (Solis, Zdravkovic et al. 2012).  
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Figure 4. Structures of MPP+ and its fluorescent analogs APP+ and ASP+. The 
addition of an electron donating dimethyl amine group to the phenyl ring of MPP+ results 
in the fluorescent compound APP+, which can be compared with ASP+, the previously 
characterized fluorescent substrate for hNET (chemical structures shown in two-
dimensional (2D) views, top row). Two three-dimensional (3D) views showing energy 
minimized MPP+, APP+, and ASP+ (bottom row). Although the aromatic rings in APP+ 
do not attain a co-planar conformation and favor twisted dihedral angles, ASP+ adopts a 
co-planar conformation. Energy was calculated at increments of 18° rotation around the 
dihedral angle linking the two rings providing a torsional scan. The coordinate files 
created in Molden and optimized in Gaussian03, provided us with the most energetically 
favorable structure in vacuo and the most physiological relevant structure. Energy 
minimization performed by Igor Zdravkovic. Adapted from Solis, Zdravkovic et al. 2012.   
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Drugs of Abuse that Target the Monoamine Transporters 
AMPH (α-methylphenethylamine) is a homologue of phenethylamine and the parent 
compound of a wide range of psychoactive derivatives, from the N-methylated 
methamphetamine (METH, N-methyl-1-phenylpropan-2-amine) to 3,4-methylenedioxy-
methamphetamine (MDMA, also known as ecstasy). AMPH is widely abused and the 
clinical manifestations associated with the abuse of AMPH, its precursors, or its 
derivatives, such as phenethylamine or METH, are well documented (Potkin, Karoum et 
al. 1979; Romanelli and Smith 2006; Winslow, Voorhees et al. 2007). Because DAT is 
the primary target for AMPH, DAT is most frequently implicated in the reinforcing 
properties and abuse potential of AMPH (Sulzer, Maidment et al. 1993; Sulzer, Chen et 
al. 1995; Seidel, Singer et al. 2005). Conversely, MDMA, which is commonly used as a 
recreational drug and has possible neurotoxic effects (Lyles and Cadet 2003), is similar in 
structure to METH, and like DA it bears oxygen moieties at the meta- and para- ring-
positions. MDMA can produce AMPH-like effects in various animal species (Green, 
Mechan et al. 2003), and in humans, it induces a sense of euphoria and diminished 
anxiety, leading to the therapeutic potential of MDMA for post-traumatic stress disorder 
(Johansen and Krebs 2009; Mithoefer, Wagner et al. 2011). Similar to AMPH and 
METH, the stimulant actions of MDMA are believed to involve the release of DA in the 
nucleus accumbens (Gold, Hubner et al. 1989); however, MDMA has higher potency 
(than METH) to induce 5HT release through hSERT (Rothman and Baumann 2006). This 
outcome, in which METH and MDMA elicit distinct behavioral and neurochemical 
responses in rodents and human despite their structural similarities, is explored in 
Chapter 4. In particular, we seek to find a relationship between these METH- and 
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MDMA-induced behavioral and neurochemical differences and the electrophysiological 
effect METH and MDMA elicit on their targets, hDAT and hSERT.  
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Mechanism of Reverse Transport of the Serotonin and Dopamine Transporters 
The reward and addiction properties of AMPH, METH, and MDMA rely on their 
ability to increase extracellular DA and 5HT levels by mechanisms as yet only partially 
understood. These agents exhibit competitive inhibition on monoamine transporters, 
which leads to diminished uptake of their neurotransmitters, and therefore, increased 
levels of endogenous neurotransmitters at the synaptic cleft. An additional view for the 
action AMPH and related compounds have on monoamine transporter to increase 
monoamine neurotransmitter levels is efflux of endogenous neurotransmitters through the 
transporters via a mechanism called ‘reverse transport’ (Khoshbouei, Wang et al. 2003). 
Although SERT, NET, and DAT all are capable of reverse transport, DAT is the 
predominant monoamine transporter studied presumably due to its implications in 
addiction. The efflux of DA stimulated by AMPH would result in higher DA 
concentrations at the synaptic cleft and increased excitation of presynaptic and 
postsynaptic DA receptors. The principal proposed mechanisms for AMPH-induced 
DAT-mediated DA efflux are 1) the facilitated exchange diffusion model (Burnette, 
Bailey et al. 1996), 2) the channel-in-transporter DA efflux model (Kahlig, Binda et al. 
2005), 3) the oligomer-based counter-transport model (Seidel, Singer et al. 2005), and 4) 
the vesicular depletion model (or weak-base model), in which interaction of the releasing 
substrate (AMPH) with the vesicular monoamine transporter disrupts vesicular storage 
leading to an increase in free cytoplasmic levels of transmitter (Sulzer, Maidment et al. 
1993; Sulzer, Chen et al. 1995). In addition, regulation of DAT-mediated DA efflux has 
been reported; examples include protein kinase C (PKC)-activated DA efflux 
(Khoshbouei, Sen et al. 2004) and Ca2+/calmodulin-dependent protein kinase II 
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(CaMKII) facilitating phosphorylation and leading to DAT-mediated DA efflux (Fog, 
Khoshbouei et al. 2006).  
In contrast to the existing models, a study described in Chapter 3 explores a novel 
mechanism of the action of AMPH on DAT that is based on new electrophysiological 
data. In this model, AMPH is transported by DAT and concentrated inside the cell where 
the drug persists and is available to bind to the transporter at an internal site. The binding 
of AMPH at this internal site may maintain the transporter in a conductive state even 
when the external substrate is removed, leading to a persistent leak (“shelf”) current; 
furthermore, it is proposed that external DA and other substrates can hold DAT in a 
constitutively-active state once internal AMPH is present. In addition, Chapter 4 
describes a study that shows the persistent leak current can be elicited with additional 
select releasing substrates and in different monoamine transporters; in particular 
S(+)METH can produce a persistent leak current in hDAT, and S(+)METH and both 
stereoisomers of MDMA produce the same response in hSERT. There are important 
implications this novel mechanism would have on synaptic neurotransmission. Thus, 
more work still needs to be done to address the importance and implications of this novel 
monoamine transporter mechanism. Lastly, there might be a relationship between the 
ability of these releasing substrates (AMPH, METH, MDMA) and their ability to produce 
the persistent leak current that needs to be studied further.  
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CHAPTER II 
 
4-(4-(DIMETHYLAMINO)PHENYL)-1-METHYLPYRIDINIUM (APP+) IS A 
FLUORESCENT SUBSTRATE FOR THE HUMAN SEROTONIN 
TRANSPORTER 
 
Parts of Chapter 2 are adapted from Solis, E., Jr., I. Zdravkovic, I. D. Tomlinson, S. Y. 
Noskov, S. J. Rosenthal and L. J. De Felice (2012). "4-(4-(dimethylamino)phenyl)-1-
methylpyridinium (APP+) is a fluorescent substrate for the human serotonin transporter." 
J Biol Chem 287(12): 8852-8863. 
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STUDY OVERVIEW 
 
Background and Purpose 
Monoamine transporters terminate synaptic neurotransmission and are molecular 
targets for antidepressants and psychostimulants. Fluorescent reporters that can monitor 
real-time transport are amenable for high-throughput screening. However, until now their 
use has mostly been successful to study the catecholamine transporters, but not the 
serotonin (5HT) transporter (SERT).  
 
Experimental Approach  
We use fluorescence microscopy, electrophysiology, pharmacology, and molecular 
modeling to compare fluorescent analogs of 1-methyl-4-phenylpyridinium (MPP+) as 
reporters for the human serotonin transporter (hSERT) in single cells.  
 
Key Results and Conclusions 
The fluorescent substrate 4-(4-(dimethylamino)phenyl)-1-methylpyridinium (APP+), 
also known as IDT307, exhibits superior fluorescence uptake in hSERT-expressing 
HEK293 cells than other MPP+ analogs tested. APP+ uptake is Na+- and Cl--dependent, 
displaced by 5HT, and inhibited by fluoxetine, suggesting APP+ specifically monitors 
hSERT activity. ASP+, which was previously used to study catecholamine transporters, is 
10 times less potent than APP+ at inhibiting 5HT uptake and has minimal hSERT-
mediated uptake. Furthermore, in hSERT-expressing oocytes voltage-clamped to –60 
mV, APP+ induced fluoxetine-sensitive hSERT-mediated inward currents, indicating 
	   42 
APP+ is a substrate, whereas ASP+ induced hSERT-mediated outward currents, and 
counteracted 5HT-induced hSERT currents, indicating that ASP+ acts as an inhibitor. 
Extra-precise ligand-receptor docking of APP+ and ASP+ in an hSERT homology model 
showed both ASP+ and APP+ docked favorably within the active region; accordingly, 
comparable concentrations are able to elicit their opposite electrophysiological responses.  
 
Implications  
We demonstrate that APP+ is better suited than ASP+ to study hSERT transport 
fluorometrically. APP+ represents a new tool that will help move transporter research 
forward. 
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INTRODUCTION 
 
The Serotonin Transporter 
Serotonin (5HT, 5-hydroxytryptamine) plays a role in the regulation of many 
behaviors (Schloss and Williams 1998; Stahl 1998) and disturbances in the serotonergic 
system are implicated in a myriad of diseases (Feighner 1994; Budygin, John et al. 2002; 
Vaswani, Linda et al. 2003; Murphy, Lerner et al. 2004; Vaswani and Kalra 2004). 
Following neurotransmission SERT clears 5HT from the synaptic cleft (Richelson 1996; 
Amara and Sonders 1998; Hoffman, Hansson et al. 1998). Numerous antidepressants, 
such as fluoxetine (FLX) or citalopram, inhibit reuptake of 5HT by SERT (White, 
Walline et al. 2005), and drugs of abuse, such as 3,4-methylenedioxy-methamphetamine 
(MDMA), induce reverse 5HT transport through the transporter (Kahlig, Binda et al. 
2005). SERT is a member of the solute carrier 6 gene family consisting of numerous ion-
coupled co-transporters, such as the norepinephrine and dopamine transporters 
(Ramamoorthy, Bauman et al. 1993; Gether, Andersen et al. 2006; Hahn and Blakely 
2007). These transporters use the Na+ ionic electrochemical potential to concentrate 
substrates against their concentration gradient (DeFelice and Blakely 1996; Rudnick 
1998; Rudnick 1998; Hahn and Blakely 2007). Traditionally, co-transport is described by 
the alternating access model (AAM) where ions and substrate are transported with a fixed 
stoichiometry (Keyes and Rudnick 1982; Rudnick and Wall 1993); however, a competing 
model describes a channel within the transporter capable of conducing currents mediated 
by substrate and ions. These substrate-induced uncoupled currents have been measured 
repeatedly for hSERT and have also been observed in the Drosophila SERT (Petersen 
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and DeFelice 1999; Adams and DeFelice 2002; Ramsey and DeFelice 2002; Adams and 
DeFelice 2003). Additionally, in the absence of substrate, a constitutive leak current 
exists, that for SERT, can be uncovered with inhibitors, such as FLX (Li, Zhong et al. 
2006). 
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Assays to Measure Transporter Uptake 
Traditionally, monoamine transporter activity has been assessed by radiolabeled 
uptake assays. However, these biochemical assays have poor temporal resolution and do 
not yield spatial information of the transport process. Furthermore, radiolabeled 
compounds are hazardous and require significant efforts in waste management. 
Conversely, fluorescent substrates of monoamine transporters are advantageous tools to 
study mechanistic properties of SERT since they provide a continuous signal that can be 
measured with single live-cell imaging. In addition to the temporal and spatial advantages 
of fluorescent substrates, their use is amenable for high-throughput screening (Haunso 
and Buchanan 2007; Jorgensen, Nielsen et al. 2008). 
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ASP+ as a Fluorescent Substrate for hNET and hDAT  
Previously, we characterized 4-(4-(dimethylamino)styryl)-N-methylpyridinium 
(ASP+) as a fluorescent reporter for uptake activity for both hNET and hDAT, and 
utilized it to study biophysical properties of hNET. Due to the inherent ability of ASP+ to 
fluoresce on the plasma membrane, we were able to take advantage of ASP+ to study 
ASP+-hNET stoichiometry and measure the residence time of ASP+ on hNET before 
being transported (Schwartz, Blakely et al. 2003; Schwartz, Novarino et al. 2005).  
Subsequent studies successfully utilized this compound to study the regulation of 
hDAT activity by several DA receptors (Bolan, Kivell et al. 2007; Zapata, Kivell et al. 
2007), and further studies validated the use of ASP+ as a useful substrate amenable for 
high-throughput methods, and uptake by hNET was deemed effective with high affinity 
(Mason, Farmer et al. 2005; Haunso and Buchanan 2007). However, while ASP+ was 
transported well by both hNET and hDAT, it had marginal effectiveness as an hSERT 
substrate (Schwartz, Blakely et al. 2003; Mason, Farmer et al. 2005; Schwartz, Novarino 
et al. 2005). In fact, to see substantial hSERT-mediated uptake, incubation for long time-
periods was required, and the km was calculated to be between 9.9 and 20 µM from 
measurements taken 10-60 min after ASP+ incubation (Fowler, Seifert et al. 2006). 
Furthermore, ASP+ binding to hSERT proved to be relatively weak and non-specific, yet 
it still exhibits the binding pattern previously observed in hNET-HEK cells, in which a 
rapid initial binding phase is followed by a slower uptake phase (Schwartz, Blakely et al. 
2003; Schwartz, Novarino et al. 2005).  
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Novel Fluorescent Substrates for hSERT 
To perform the biophysical studies for hSERT that were performed on hNET with 
ASP+, a fluorescent substrate for hSERT would be required to fluoresce on hSERT. 
Specifically, information about the residence (dwell) time of a fluorescence substrate on 
the transporter before its transport can be determined with this property – as was 
performed with ASP+ on hNET (Schwartz, Novarino et al. 2005). We designed 
alternative fluorescent substrates of hSERT based on the structure of 1-methyl-4-
phenylpyridinium (MPP+), a known monoamine transporter substrate that has high-
affinity for transport by the catecholamine transporters (Buck and Amara 1994; Wright, 
Bempong et al. 1998; Bryan-Lluka, Siebert et al. 1999). The addition of an electron 
donating dimethyl amino group to the phenyl ring of MPP+ results in a fluorescent 
compound called 4-(4-(dimethylamino)phenyl)-1-methylpyridinium (APP+). Additional 
modifications to this compound have been synthesized. The fluorescent analog of MPP+, 
APP+ (also known as IDT307), has been marketed by Molecular Devices, tested as a 
reagent for high-throughput screening (Jorgensen, Nielsen et al. 2008; Tsuruda, Yung et 
al. 2010) and used to study regulation of SERT (Chang, Tomlinson et al. 2012). 
However, many properties for this class of fluorescent MPP+ analogs are unknown, such 
as their electrophysiological profile, their interaction within the transporter, their 
subcellular localization, and their fluorescent characterization in single live-cell imaging. 
In this study, we tested several fluorescent MPP+ analogs, selected the most efficient 
fluorescent substrate for hSERT, which turned out to be APP+, and thoroughly 
characterized its fluorescent activity profile for hSERT in single cells. 
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Findings of Study 
We compared the efficiency of APP+ to target hSERT against the fluorescent 
compound ASP+ that has previously been used to study hDAT and hNET (Schwartz, 
Blakely et al. 2003; Schwartz, Novarino et al. 2005; Schwartz, Piston et al. 2006; Bolan, 
Kivell et al. 2007; Haunso and Buchanan 2007; Zapata, Kivell et al. 2007). We 
discovered several differences between the two fluorescent compounds. In particular, 
ASP+ exhibits negligible uptake through hSERT, and unlike APP+, ASP+ exhibits 
binding-associated fluorescence on the plasma membrane; however, this ASP+ signal in 
hSERT-expressing cells is indistinguishable from signal in non-transfected cells. 
Furthermore, APP+ is much stronger at inhibiting uptake of radiolabeled 5HT as 
compared to ASP+. More strikingly, electrophysiological data indicate that ASP+ interacts 
with hSERT and exhibits inhibitor-like behavior, whereas APP+ behaves as an hSERT 
substrate. Lastly, ligand-receptor docking of the substrates in a homology model based on 
the crystallized bacterial leucine transporter (Yamashita, Singh et al. 2005) shows that 
both APP+ and ASP+ dock favorably within the active region of hSERT at different 
residues, which could explain their functional efficacy to induce their opposing 
electrophysiological effects on hSERT. These findings indicate APP+ is a superior 
fluorescent substrate than ASP+ to study hSERT. 
  
 
 
 
 
	   49 
EXPERIMENTAL PROCEDURES 
 
Maintenance of Parental and HEK293 Cells Stably Expressing hSERT (hSERT-HEK 
Cells) 
Cells were prepared in Dulbecco’s modified Eagle medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS), 2 mM L-glutamine, penicillin (100 units/ml), 
streptomycin (100 µg/mL), and G418. Trypsin-released cells were plated in MatTek 
glass-bottom dishes pretreated with poly-L-lysine (MatTek, Ashland MA) at 100,000-
150,000 cells per dish and allowed to grow for 24-48 hr before measurements. Media for 
parental HEK293 cells lacks G418.  
 
Transient Transfections 
Cells were handled similarly to stable cell lines described in the manuscript. 
According to previously described procedures (Torres-Altoro, White et al. 2008), 
HEK293 cells were incubated with a mixture of Lipofectamine 2000 (Invitrogen) and 
cDNA plasmid (either hSERT or C109A/G338C hSERT mutant) for 24 hr before 
experiments. The DNA plasmid containing the C109A/G338C hSERT gene was kindly 
provided by Randy Blakely of Vanderbilt University. 
 
Solutions For All Experiments Using hSERT-HEK Cells  
Krebs-Ringer Hepes (KRH) buffer consists of (in mM): 120 NaCl, 1.3 KCl, 2.2 
CaCl2, 1.2 MgSO4, 10 HEPES, and 1 g/L glucose, pH 7.4. For the ionic-dependence 
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experiments, Na+ is replaced with equimolar choline and Cl- is replaced with equimolar 
gluconate.  
 
Fluorescence Image Acquisition  
Experiments are performed at room temperature (RT, 23-25°C) unless otherwise 
noted. hSERT-HEK or HEK293 cells are mounted on a Zeiss 510 confocal laser scanning 
microscope (LSM, Zeiss, Germany) and are focused with differential interference 
contrast (DIC). The culture medium is discarded, and the cells are immediately mounted 
on the microscope, and re-focused. As soon as image acquisition begins, the desired 
treatment is applied. An argon laser tuned to 488 nm was used to excite APP+, its 
analogs, and ASP+. Emission filters used were 505-550 nm for APP+ and its analogs and 
585-615 nm for ASP+. Gain (contrast) and offset (brightness) of the photomultiplier tube 
(PMT) was set to avoid saturation at the highest fluorophore concentration. Microscopy 
was performed with a 10x 0.8 numerical aperture (NA) water objective, a 40x 1.3 NA 
water objective, or a 40x 1.4 NA oil objective.  
 
Total Fluorescence Intensity 
The cellular spectra were acquired under ‘lambda’ mode after exposure to each 
synthesized fluorescent compound for 5 min, in which emitted fluorescence was acquired 
at 10 nm intervals. To determine total fluorescence, the spectra curves are integrated 
(Excel, Microsoft). 
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Time-lapse Acquisition and Analysis 
Time-lapses consist of a series of images taken over a defined period of time (from 
30 s to 10 min as indicated) with acquisition rates ranging from one image every second 
to one image every five seconds (sample of images in a time-lapse shown in Figure 5, top 
panel). Fluorescent image analysis is performed using LSM software, AIM (Zeiss, 
Germany). Fluorescence accumulation is measured as average pixel intensity within 
specified regions of interest (ROI) identified in the DIC channel images, which represent 
individual cells. Fluorescence accumulation is averaged for at least 30 cells per time-
lapse. The fluorescence intensity is plotted in arbitrary fluorescent units (AFU) over time 
(Figure 5, bottom panel). To determine Vmax, Vmin, km, and the Hill coefficient n, values 
are fit to the Hill equation y = Vmax + (Vmin - Vmax) * xn / (kn + xn) using Origin 8 
(OriginLab Corporation, Northampton, MA).  
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Figure 5. Time-lapse acquisition and image analysis. A time-lapse is a series of images 
taken over a defined period of time. Images are acquired at varying rates (rates typically 
range from one image per second). (A) Illustration of time-lapse images from a time-
lapse in which images were acquired at a rate of one per second for 10 minutes (the total 
number of images for the entire time lapse was 1000). The images show fluorescence in 
hSERT-HEK cells at the indicated time point (1-10 min). (B) Quantitative fluorescence 
measurements for each cell in a time lapse. Fluorescent images were analyzed using AIM 
software (Zeiss, Germany). Fluorescence accumulation was defined from average pixel 
intensity of time-resolved fluorescent images within specified regions of interest (ROI, 
shown as numbered yellow circles in A) representing cells, which are identified in DIC 
images. The fluorescence intensity is plotted in arbitrary fluorescent units (AFU) over 
time.  
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Plasma Membrane Colocalization and Line Scans  
Colocalization studies were performed by incubating cells at 37oC for 15 min with 
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI, Invitrogen) and 
co-applying 10 µM APP+ for 5 min. Then images were merged for the APP+ channel and 
DiI channel. DiI was excited with an argon laser tuned to 549 nm and the emission filter 
used was 560-615 nm. Line scans are performed by selecting regions from the outer 
edges of cells as determined by DiI labeling of the plasma membrane.  
 
Statistics 
Standard error of the mean (SEM) is calculated for fluorescence accumulation in all 
cells at each time point in a time-lapse, and SEM for each plot are shown as merged Y-
error bars.   
 
Colocalization of Subcellular Organelles 
Colocalization studies were performed by incubating cells at 37oC for 15 min with 
either SYTO-17 (Invitrogen) or MitoTracker Orange (Invitrogen) and co-applying 10 µM 
APP+ for 5 min. Then images were merged for the APP+ channel and either of the 
markers, which have emission at longer wavelengths. 
 
Expression of hSERT in Xenopus Laevis Oocytes  
Oocytes are harvested and prepared from adult Xenopus laevis females following 
standard procedures (Machaca and Hartzell 1998; Iwamoto, Blakely et al. 2006). We 
select stage V-VI oocytes for cRNA injection within 24 h of isolation. cRNA is 
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transcribed from the pOTV vector using mMessage Machine T7 kit (Ambion Inc., 
Austin, TX). Each oocyte is injected with 30 ng cRNA using a Nanoject 
AutoOocyteInjector (Drummond Scientific Co., Broomall, PA) and incubated at 18°C for 
5-10 days in Ringers solution supplemented with NaPyruvate (550 µg/ml), streptomycin 
(100 µg/ml), tetracycline (50 µg/ml) and 5% dialyzed horse serum. 
 
Electrophysiology  
We performed two-electrode voltage-clamp (TEVC) experiments as previously 
described (Wang, Li et al. 2006). TEVC allows recordings of currents from proteins 
expressed on the plasma membrane that are electrogenic, such as monoamine transporters 
(Figure 6 describes the TEVC setup). Recordings were done at RT (23-25°C). Electrodes 
having resistances from 1-5 MΩ are filled with 3 M KCl. Xenopus laevis oocytes are 
voltage-clamped to –60 mV (unless otherwise noted) with a GeneClamp 500 (Axon 
Instruments), and the holding current is recorded using Clampex 10 (Axon Instruments). 
Standard extracellular buffer is perfused until stable baseline currents are obtained, 
followed by experimental drugs. Extracellular buffer consists of (in mM): 120 NaCl, 7.5 
HEPES, 5.4 KGluconate, 1.2 CaGluconate, pH 7.4. 
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Figure 6. Two-electrode voltage-clamp (TEVC) of hSERT-expressing oocyte. The 
membrane of a Xenopus laevis oocyte is penetrated by two microelectrodes, one for 
voltage sensing (E1) and one for current injection (E2). The membrane potential as 
measured by the voltage-sensing electrode is compared with a command voltage (Vcom), 
and the difference is brought to zero by a control amplifier (C), thus clamping the 
potential to Vcom. The resultant current represents the conductance through hSERT. In our 
experiments, Xenopus oocytes expressing SERT are voltage-clamped to -60 mV and 
solutions are gently perfused (typically buffer is perfused until a stable baseline is 
obtained, then the experimental drug is perfused, followed by perfusion with buffer). The 
trace below shows perfusion with 1 µM 5HT. Adapted from figure by Hideki Iwamoto. 
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Competition Assay  
Radiolabeled assay protocols were performed as described previously (Barker, 
Moore et al. 1999; Henry, Adkins et al. 2003). First, hSERT-HEK cells are plated on 
poly-L-lysine coated, 24-well tissue culture plates at 10,000 cells per well for 2-3 days to 
obtain about 90% cell confluence. Then, medium is removed by aspiration and the 
hSERT-HEK cells are washed with RT KRH buffer. Cells are incubated for 10 min at 
37oC with mixtures of radiolabeled substrate and the compounds tested at a broad range 
of concentrations. The assay mixture is aspirated and cells are washed three times with 
ice-cold (4ºC) KRH buffer. Lastly, cells are solubilized with ice-cold Ecoscint H 
(National Diagnostics) and [3H]-5HT remaining is measured using a scintillation counter. 
 
Competition Assay Analysis and Cheng-Prusoff Correction  
Concentration-response curves for APP+ and ASP+ inhibition of [3H]-5HT uptake 
into hSERT-HEK cells are used to obtain the IC50. Briefly, [3H]-5HT accumulation is 
measured in hSERT-HEK cells in the presence of increasing APP+ and ASP+ 
concentrations and these values are normalized to the highest [3H]-5HT reading, which is 
the value in the absence of competing compound. The data are fit to the Hill equation y = 
Vmax + (Vmin - Vmax) * xn / (kn + xn) (Origin 8), and to correct for substrate concentration 
the Cheng-Prusoff equation is employed: ki = IC50 / (1 + [S] / km), where ki is the binding 
affinity of the inhibitor, IC50 is the functional strength of the inhibitor, [S] is the substrate 
concentration, and km is the affinity of the substrate for the enzyme.  
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Torsional Scans and Energy Minimization  
Prior to docking, conformations of the substrates were optimized by performing 
energy minimization on each compound using hybrid density functional B3LYP with 
split-valence 6-31G* basis set (Gaussian03). The torsional surface of the molecules has 
been examined using protocols developed before for force-field parametrization 
(Guvench and MacKerell 2008). Energy was calculated at increments of 18° rotation 
around the dihedral angle linking the two rings providing a torsional scan. The coordinate 
files created in Molden and optimized in Gaussian03, provided us with the most 
energetically favorable structure in vacuo and the most physiological relevant structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   58 
Substrate Models in Ligand Docking Studies  
First, the energy grid for the transporter was created and each of the ligands docked 
individually. A square volume with a length of 14 Å around the location of the active site 
was designated for allowed insertions of the ligands. The center of the insertion region 
was defined around the known substrate-binding site in the leucine transporter (LeuT). 
There is a strong line of evidence that this binding pocket is preserved in hSERT 
(Kaufmann, Dawson et al. 2009; Field, Henry et al. 2010). The docking was performed 
on the basis of a rigid protein approximation and a flexible ligand. Extra precision 
docking (Friesner, Murphy et al. 2006) was subsequently used and the top ten potential 
docks were further optimized. The hSERT homology model was obtained from the 
Meiler lab (Kaufmann, Dawson et al. 2009), and is based on the crystallized structure of 
the leucine transporter (LeuTAa) reported by Yamashita et al. PBDID 2A65 (Yamashita, 
Singh et al. 2005). The ranking of each pose and its energy was calculated using the G-
Score. The G-Score is a sum of the most significant energy constants including 
hydrophobic, van der Waals, and coulomb interactions. Once re-minimized, each dock is 
assigned a G-Score as a sum of interactions and the docks are ranked from most negative 
(favorable) to least. The ligand in each dock is allowed full degrees of motion, within its 
optimal conformation. Hindrance with the transporter or unfavorable torsional angles are 
penalized in the G-Score.  
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RESULTS 
 
Fluorescent MPP+ Analogs 
Addition of an electron donating dimethyl amino group to the phenyl ring of MPP+ 
results in the compound called 4-(4-(dimethylamino)phenyl)-1-methylpyridinium (APP+) 
(Figure 4A, top row) that is transported by hSERT-expressing HEK293 (hSERT-HEK) 
cells and fluoresces inside cells after the 2 rings immobilize by adopting a co-planar 
conformation at organelle membranes (Figure 7A). APP+ colocalizes with MitoTracker 
and SYTO-17, indicating APP+ stains mitochondria and nucleoli, respectively (Figure 8). 
The fluorescence intensity for APP+ and a series of APP+ analogs was measured in 
hSERT-HEK cells. APP+ and compound 321 emitted the most fluorescence, whereas 
compounds 326, 330, and 375 emitted the weakest fluorescence (Figure 7B). All tested 
APP+ analogs displayed similar fluorescence localization inside hSERT-HEK cells, and 
peak emission was measured at 520-525 nm, with the highest emission peak seen with 
APP+ (Figure 9). We pursued characterization of APP+ to assess its utility to study 
hSERT activity in single cells.  
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Figure 7. Screening for a fluorescent substrate of hSERT. (A) Images of hSERT-HEK 
cells exposed to fluorescent compounds (from top to bottom: APP+ only, DIC, and APP+ 
and DIC merged). (B) Fluorescence intensity is calculated by integrating emission spectra 
curves for each compound. Fluorescence is normalized to the brightest compound, APP+. 
Structure nomenclature: 332, N,N-dimethyl-4-(pyridin-4-yl)aniline; APP+, 4-(4-
(dimethylamino)styryl)-N-methylpyridinium; 321, 4-(4-(dimethylamino)phenyl)-1-
ethylpyridinium; 326, 4-(4-(dimethylamino)-2-methylphenyl)-1-methylpyridinium; 330, 
4-(4-(dimethylamino)-3-fluorophenyl)-1-methylpyridinium; 377, N,N-dimethyl-4-
(pyridin-3-yl)aniline; 378, 3-(4-(dimethylamino)phenyl)-1-methylpyridinium. Adapted 
from Solis, Zdravkovic et al. 2012. Compounds provided by Ian D. Tomlinson and 
Sandra Rosenthal.  
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Figure 8. APP+ subcellular fluorescence pattern. hSERT-HEK cells are incubated for 
15 min with either MitoTracker or SYTO-17, and then APP+ (10 µM) is added for 5 min. 
APP+ colocalizes with the mitochondria marker MitoTracker  (top), and with nucleoli 
labeled with SYTO-17 (bottom). Note: when SYTO-17 is employed, APP+ staining of the 
mitochondria disappears as soon as cells are exposed to the laser. Adapted from Solis, 
Zdravkovic et al. 2012. 
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Figure 9. APP+ emission spectra. hSERT-HEK cells were exposed to 2 µM APP+ for 5 
minutes and images were acquired with lambda mode to determine emission spectra at 
10-11 nm intervals. Maximum emission peak for APP+ was 520-525 nM. Adapted from 
Solis, Zdravkovic et al. 2012. 
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APP+ Displays Two Distinct Fluorescence Accumulation Rates  
We first established a concentration-response curve of APP+ by performing time-
lapses of hSERT-HEK cells exposed to APP+ at concentrations ranging from 250 nM to 
10 µM (Figure 10A). APP+ fluorescence accumulation yielded a biphasic plot that 
corresponds with two distinct rates of fluorescence accumulation, an initial “fast” phase 
and a secondary “slow” phase, indicated by dotted lines over the 10 µM APP+ 
accumulation curve (Figure 10A). To compare the rates of APP+ fluorescence 
accumulation, we fit straight lines to the slow and fast components for each 
concentration, plotted these slope values against concentration, and then fit to the Hill 
equation. The Vmax and km for the fast phase were 0.65 ± 0.07 AFU/s and 2.29 ± 0.65 
µM, respectively, and for the slow phase the Vmax and km were 0.38 ± 0.04 AFU/s and 
2.36 ± 0.55 µM, respectively (Figure 10B). The Hill coefficient was 2.91 ± 1.09 for the 
fast component and 2.53 ± 0.68 for the slow component.  
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Figure 10. APP+ displays two rates of uptake. (A) APP+ accumulation depends on 
concentration. Time-lapses of hSERT-HEK cells exposed to different concentrations of 
APP+ (from 250 nM to 10 µM) were acquired at a rate of 1 image per second for 10 min. 
Dotted lines represent the 2 rates observed, the initial (slow) and subsequent (fast) 
components. (B) To determine the Vmax and km, straight lines were fitted and slopes 
obtained for both the slow and fast phases acquired at each concentration. For the fast 
phase, measurements from 20-100 s were used, and for the slow phase, the measurements 
from 200 s to the end of the acquisition were used. Slopes were plotted against 
concentration and these values were fit to the Hill equation y = Vmin + (Vmax - Vmin) * xn / 
(kn + xn). The Vmax, Vmin, and km for the fast phase were 0.65 ± 0.07 AFU/s, 0.062 ± 
0.008 AFU/s, and 2.29 ± 0.65 µM, respectively, and for the slow phase the Vmax, Vmin, 
and km were 0.38 ± 0.04 AFU/s, 0.029 ± 0.003 AFU/s, and 2.36 ± 0.55 µM, respectively. 
The Hill coefficient was 2.91 ± 1.09 for the fast component and 2.53 ± 0.68 for the slow 
component. Adapted from Solis, Zdravkovic et al. 2012. 
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APP+ is an hSERT Substrate 
To characterize APP+ as a suitable substrate to study hSERT activity in single cells, 
we performed a series of time-lapse experiments measuring 2 µM APP+ accumulation. 
Because monoamine transporter uptake is temperature sensitive (Chang, Frnka et al. 
1989), we measured APP+ accumulation at 20°C, 27°C, and 37°C. As expected, 
temperature induced altered APP+ accumulation by hSERT, which was more noticeable 
for the initial “fast” uptake rate (Figure 11A). Removal of Na+ or Cl- eliminated APP+ 
accumulation in hSERT-expressing cells (Figure 11B), which is in agreement with the 
ionic dependence for monoamine transporter uptake (Hoffman, Hansson et al. 1998; 
Nelson 1998). Furthermore, application of the endogenous hSERT substrate 5HT (10 
µM) while measuring APP+ accumulation induced an immediate decrease in APP+ 
accumulation, which suggests APP+ uptake is mediated by hSERT (Figure 11C). Lastly, 
to verify that APP+ is specifically transported through hSERT, we measured APP+ 
accumulation in the presence of the specific hSERT inhibitor fluoxetine. Whereas the low 
FLX concentration (1 µM) only partially diminished the APP+ signal, the higher FLX 
concentrations (5-10 µM) completely abolished APP+ uptake (Figure 11D). We further 
studied the effect on extracellular ionic concentration on APP+ uptake through hSERT by 
substituting Na+ with choline (from 0 to 120 mM) and Cl- with gluconate (from 0 to 120 
mM) (Figure 12). Although hSERT-mediated APP+ accumulation requires values near 
120 mM Na+ (Figure 12A), a concentration of 60 mM Cl- is enough to display maximal 
APP+ accumulation (Figure 12B). By fitting the slopes from straight lines overlapping 
time-lapse measurements from 100-300 s at each Na+ and Cl- concentration to the Hill 1 
equation, we obtained a km for Na+ of 62.52 ± 20.53 mM with Hill coefficient of 1.47 ± 
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0.69 (Figure 12C), and a km for Cl- of 38.04 ± 26.93 mM with a Hill coefficient of 1.15 ± 
0.59 (Figure 12D). 
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Figure 11. APP+ is a fluorescent substrate of hSERT. Time-lapses of hSERT-HEK 
cells exposed to 2 µM APP+. (A) Temperature regulates APP+ accumulation. APP+ 
fluorescence accumulation is greater when measured under physiological (37°C) 
temperature, and much lower at 20°C as compared to the moderate (27°C) temperature. 
(B) Removal of both Na+ and Cl- diminished APP+ accumulation. (C) An immediate 
decrease in APP+ accumulation occurs when 5HT (10 µM) was added 6 min into the 
time-lapse (indicated by arrow). (D) Co-treatment with fluoxetine (from 1-10 µM) 
abolishes APP+ fluorescence accumulation. Adapted from Solis, Zdravkovic et al. 2012. 
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Figure 12. Effect of ionic concentration replacement on APP+ uptake by hSERT. (A) 
To determine Na+-dependence of APP+ accumulation, Na+ was replaced with ChCl from 
full replacement (120 mM ChCl) to increasing NaCl and proportional decreases in ChCl. 
Concentrations of Na+ tested were 0, 2, 10, 30, 60, and 120 mM. (B) To determine Cl--
dependence of APP+ accumulation, NaCl was replaced with NaGluconate from full 
replacement (120 mM NaGluconate) to increasing NaCl and proportional decreases in 
NaGluconate. Concentrations of Cl- tested were 0, 2, 10, 30, 60, and 120 mM. To 
determine the km, straight lines were fitted to time-lapse measurements from 100-300 s. 
Slopes were plotted against (C) Na+ and (D) Cl- concentration and these values were fit to 
the Hill equation y = Vmin + (Vmax - Vmin) * xn / (kn + xn). The km for Na+ was 62.52 ± 
20.53 mM with Hill coefficient (n) 1.47 ± 0.69, and for Cl- the km and n were 38.04 ± 
26.93 mM and 1.15 ± 0.59, respectively. Personal unpublished data. 
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ASP+ is Less Efficient than APP+ at Targeting hSERT  
We have demonstrated that APP+ is an adequate fluorescent substrate for hSERT in 
single-cells. However, because ASP+ has not been thoroughly studied as an hSERT 
fluorescent substrate, we sought to test APP+ against ASP+ under similar conditions. 
ASP+ did not elicit visible levels of fluorescence in hSERT-HEK cells until 10 µM or 
higher concentrations were employed; however, the signal elicited at these ASP+ 
concentrations is similarly bright in both hSERT-HEK and parental cells, and falls within 
the noise for all time points measured (Figure 13A, [ASP+] = 10 µM). In addition, ASP+ 
fluorescence accumulation rates were parallel between hSERT-HEK and parental cells 
for all concentrations tested (1-30 µM), indicating non-specific ASP+ uptake (Figure 14A, 
[ASP+] = 10 µM). Conversely, APP+ (10 µM) signal appears much brighter in hSERT-
HEK cells than in parental cells (Figure 13B), and APP+ (2 µM) fluorescence uptake is 
greater in hSERT-HEK cells as compared to parental cells (Figure 14B). These 
discernable differences are clearly observed at APP+ concentrations from 1-10 µM (data 
not shown). To assess the affinity of APP+ and ASP+ at hSERT we produced 
concentration-response curves for inhibition of [3H]-5HT uptake in hSERT-HEK cells 
with increasing APP+ or ASP+ concentrations (Figure 15). Fitting to the Hill equation and 
subsequent correction for substrate concentration with the Cheng-Prusoff equation 
yielded ki of 19.7 ± 2.23 µM for APP+ and a weaker ki of 180.1 ± 20.3 µM for ASP+. For 
comparison the ki for 5HT is reported as 1.7 ± 1 µM (Talvenheimo, Nelson et al. 1979). 
The Hill coefficients for inhibition of [3H]-5HT uptake were 1.23 ± 0.08 for APP+ and 
0.91 ± 0.15 for ASP+.  
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Figure 13. Comparing fluorescence of ASP+ and APP+ in hSERT-expressing cells. 
Images of hSERT-HEK or parental HEK293 cells before (row labeled with 0) and after 
exposure to 10 µM (A) ASP+ or (B) APP+ for 1 or 3 min. ASP+ fluoresces red and labels 
the exterior membrane of cells in both hSERT-HEK and parental cells, while APP+, 
which fluoresces green, seems to accumulate only inside of hSERT-HEK cells. Adapted 
from Solis, Zdravkovic et al. 2012. 
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Figure 14. APP+ is better suited than ASP+ to report hSERT uptake. Time-lapses 
comparing fluorescence accumulation rates between hSERT-HEK and HEK293 cells for 
(A) ASP+ (30 µM) and (B) APP+ (5 µM). ASP+ exhibits similar uptake rates in both 
hSERT-HEK and parental cells, whereas APP+ accumulation rate is much greater in 
hSERT-HEK cells than in parental cells. Adapted from Solis, Zdravkovic et al. 2012. 
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Figure 15. APP+ and ASP+ inhibit 5HT uptake by hSERT. Concentration curve for 
APP+ and ASP+ inhibition of [3H]-5HT uptake into hSERT-HEK cells. [3H]-5HT 
accumulation was measured in hSERT-HEK cells in the presence of increasing APP+ and 
ASP+ concentrations and normalized to data in the absence of the competing substrate. 
The data were fit to the Hill equation y = Vmax + (V0 - Vmax) * xn / (kn+xn), and ki values 
were determined using the Cheng-Prusoff equation to correct for substrate concentration. 
The fits yield ki (APP+) = 19.7 ± 2.23 µM and ki (ASP+) =180.1 ± 20.3 µM. Values are 
represented as means ± S.E., N = 3. The Hill coefficients for ASP+ and APP+ are 0.91 ± 
0.15 and 1.23 ± 0.08, respectively. Adapted from Solis, Zdravkovic et al. 2012. 
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APP+ Acts as an hSERT Substrate, Whereas ASP+ Behaves Like an hSERT Inhibitor 
Since transporter currents reflect the effect of substrates and inhibitors, we employed 
TEVC and measured hSERT currents in Xenopus oocytes in response to 10 µM 5HT, 
APP+, ASP+, and 1 µM fluoxetine (holding potential = –60 mV). Whereas APP+ induced 
an hSERT-mediated inward current, similar in effect to hSERT’s endogenous substrate 
5HT, ASP+ induced an hSERT-mediated outward current, which is similar to the effect 
the hSERT inhibitor fluoxetine exerts on hSERT (Figure 16A). Control oocytes (not 
expressing hSERT) do not induce currents when exposed to 5HT, ASP+, APP+ or 
fluoxetine (data not shown). Voltage-dependence was assessed by stepping the holding 
potential in oocytes (from -100 to 0 mV), and measuring APP+ and ASP+ induced inward 
and outward hSERT-mediated currents, respectively, which are plotted as drug-induced 
currents relative to baseline set to 0 (Figure 16B). A concentration-response curve of 
hSERT currents in response to APP+ was produced by applying from 0.1 to 25 µM APP+ 
to hSERT-expressing oocytes (Figure 17A), and average data from several recordings 
were fit to the Hill equation, which yielded km = 1.13 ± 0.28 µM and n = 1.23 ± 0.60 
(Figure 17B). The hSERT inhibitor fluoxetine (1 µM) blocked inward currents produced 
in response to 2 µM 5HT and 10 µM APP+ (compare Figure 17C and Figure 17D). A 
concentration-response curve for ASP+ was determined using concentrations from 0.5 to 
100 µM (Figure 18A) and fitting average data from several recordings yielded km = 12.25 
± 2.71 µM and n = 1.34 ± 0.31 (Figure 18B). Since the hSERT-mediated outward current 
induced by ASP+ resembles the action of transporter inhibitors, we tested its utility as an 
inhibitor. Application of ASP+ (1-250 µM) inhibited 5HT-induced hSERT-mediated 
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currents in a dose-dependent manner, and notably, ASP+ imposed an outward current at 
the highest ASP+ concentration tested (Figure 18C and Figure 18D).  
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Figure 16. Electrophysiological effect of substrates on hSERT. (A) Currents in an 
hSERT-expressing Xenopus laevis oocyte clamped to -60 mV are measured in response 
to 10 µM 5HT, APP+, ASP+, and 1 µM fluoxetine. Bars display perfusion duration of 
each compound. Control (uninjected) oocytes show no response to 5HT, ASP+, or APP+ 
(not shown). (B) The effect of voltage (from 0 to -100 mV) on hSERT-induced currents. 
Currents induced by 5HT, APP+, ASP+ are plotted relative to the baseline set as 0 at each 
potential (N = 4). Adapted from Solis, Zdravkovic et al. 2012. 
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Figure 17. APP+ exhibits substrate-like activity at hSERT. (A) APP+ concentration-
response curve. Representative trace of hSERT currents are measured in response to 
APP+ (0.1-25 µM) applied to hSERT-expressing Xenopus laevis oocyte clamped to –60 
mV. (B) Summary data were normalized to 5 µM 5HT-induced currents and fit to the 
Hill equation y = Imax + (Imin - Imax) * xn / (kn+xn), (N = 8). The Imax, Imin, km, and Hill 
coefficient were 23.75 ± 2.51, 3.02 ± 2.08, 1.13 ± 0.28 µM, and 1.23 ± 0.60, respectively. 
(C) Application of fluoxetine (1 µM) blocks the 5HT-induced hSERT current ([5HT] = 2 
µM). (D) Application of fluoxetine (1 µM) blocks the APP+-induced hSERT current 
([APP+] = 10 µM). Adapted from Solis, Zdravkovic et al. 2012. 
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Figure 18. ASP+ exhibits inhibitor-like activity at hSERT. (A) ASP+ concentration-
response curve. Representative trace of hSERT currents are measured in response to 
APP+ (0.5-100 µM) applied to hSERT-expressing Xenopus laevis oocyte clamped to -60 
mV. (B) Summary data were normalized to 2 µM 5HT-induced currents and fit to the 
Hill equation y = Imax + (Imin - Imax) * xn / (kn+xn), (N = 8). The Imax, Imin, km, and Hill 
coefficient were 28.32 ± 2.17, 3.48 ± 0.44, 12.25 ± 2.71 µM, and 1.34 ± 0.31, 
respectively. (C) ASP+ inhibits 5HT-induced hSERT currents. During currents induced 
by 5HT (2 µM) ASP+ is co-applied at indicated concentrations (from 1-250 µM, as 
indicated above upper bars in traces) (N = 8). (D) Summary data of ASP+ inhibition of 
5HT-induced hSERT currents (from currents in C). Adapted from Solis, Zdravkovic et al. 
2012. Adapted from Solis, Zdravkovic et al. 2012. 
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Neither APP+ Nor ASP+ Display Measureable Fluorescence on hSERT  
Due to the inherent ability of ASP+ to fluoresce while interacting at hNET, we were 
previously able to take advantage of ASP+ to study ASP+-hNET stoichiometry and 
measure the residence time of ASP+ on hNET before being transported (Schwartz, 
Novarino et al. 2005). These studies were successful because the ASP+ signal displayed 
on the plasma membrane of hNET-expressing cells was sensitive and specific over 
parental cells (Schwartz, Blakely et al. 2003; Schwartz, Novarino et al. 2005). Although 
we were able to mimic the initial rapid ASP+ binding phase (previously observed in 
hNET-expressing cells) in hSERT-HEK cells (labeled with arrow in Figure 19A, and 
clearly seen in high-resolution images 10 s after ASP+ application in Figure 20A), these 
ASP+ concentrations that elicited signal on the plasma membrane (10 µM and higher) 
displayed comparable fluorescence binding in parental cells (Figure 13A and Figure 
14A). Furthermore, pre-treatment of hSERT-HEK cells with the hSERT inhibitor 
paroxetine did not quell ASP+ plasma membrane fluorescence (Figure 21). These data 
strongly imply that ASP+ is not suitable to discern plasma membrane labeling in hSERT-
HEK cells solely attributed to specific ASP+ interaction on hSERT. 
We moved on to see whether APP+ would elicit specific signal at the plasma 
membrane of hSERT-HEK cells. Since we had noticed APP+ time-lapses (at a rate of 1 
Hz) displayed no rapid fluorescent signal associated with membrane binding (Figure 
11A, Figure 12, and Figure 14B), we tried to resolve a potential initial binding phase on 
the plasma membrane that may not be discernable at slow image acquisition rates; 
however, even increasing the image acquisition rate to 5 Hz failed to yield a plasma 
membrane binding phase (arrow in Figure 19B). Interestingly, APP+ fluorescence 
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increased diffusely inside the cells without any visible APP+ fluorescence while being 
transported by hSERT (seen as lack of a fluorescence accumulation peak in Figure 19B, 
and shown in a high-resolution image in Figure 20B after 10 s APP+ exposure). Another 
attempt to determine whether APP+ yields any visible fluorescence at the plasma 
membrane was to establish APP+ Colocalization with the lipophilic plasma membrane 
marker DiI in hSERT-HEK cells; however, no overlap between the two signals was 
detected (Figure 22A). To look for APP+/DiI colocalization in more detail, dual-channel 
line-scans through individual cells were performed, but no discernable colocalization was 
obtained, as indicated by asynchronous peaks (Figure 22B, plot) corresponding to APP+ 
and DiI fluorescence intensity along a line-scan through an individual hSERT-HEK cell 
(Figure 22B, red arrow). Subsequently, we sought colocalization of DiI to additional 
APP+ analogs that had been shown to induce hSERT-mediated outward currents in TEVC 
recordings (data not shown), which suggests they bind to hSERT in a manner similar to 
inhibitors. However, neither compound produced signal at the plasma membrane as 
shown by their lack of colocalization with DiI (Figure 23). In another effort to detect 
APP+ binding at hSERT, we employed the hSERT mutant C109A/G338C that has been 
shown to lack 5HT transport while maintaining similar substrate binding affinity (Field, 
Henry et al. 2010). Since the strong intracellular fluorescence due to APP+ transport 
would be absent, any fluorescent signal measured would be attributed to APP+-mutant 
hSERT interaction. Following exposure to 3 µM APP+ for 5 min, cells transiently-
transfected with wild-type hSERT cells exhibited bright fluorescence signal; conversely, 
hardly any APP+ signal was observed in parental cells or in cells transiently-transfected 
with C109A/G338C hSERT (Figure 24, top row). The lack of APP+ uptake in the 
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C109A/G338C SERT is consistent with its reported inability to transport substrate (Field, 
Henry et al. 2010). Further, the fact that APP+ displays no discernable fluorescence on 
the plasma membrane in the mutant SERT suggests APP+ does not abide to a co-planar 
conformation amenable to exhibit fluorescence during its transport.  Lastly, increasing 
APP+ concentration to 50 µM did not elicit fluorescent signal on the plasma membrane in 
either parental cells or cells transiently-transfected with wild-type or C109A/G338C 
hSERT (Figure 24, bottom row). As expected, 50 µM APP+ entry was comparable in all 
conditions tested, which is explained by non-specific diffusion or by the presence of 
endogenous organic cation transporters, which transport substrates, such as MPP+ and 
ASP+, with low affinity and high capacity (Busch, Quester et al. 1996; Gorboulev, 
Ulzheimer et al. 1997; Hohage, Stachon et al. 1998; Mehrens, Lelleck et al. 2000; Daws 
2009). 
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Figure 19. APP+ does not display a plasma membrane-associated fluorescent binding 
phase like ASP+ in hSERT-HEK cells. (A) ASP+ (20 µM) displays rapid fluorescence 
accumulation (indicated by arrow) associated with plasma membrane binding in hSERT-
HEK cells. (B) APP+ (20 µM) application at a rate of 5 images per second does not reveal 
a fluorescent binding phase (indicated by arrow) associated with plasma membrane 
binding. Adapted from Solis, Zdravkovic et al. 2012. 
 
 
 
 
 
 
 
 
 
 
 
	   82 
 
 
 
 
 
 
 
 
Figure 20. Fluorescent pattern of ASP+ and APP+ in hSERT-HEK cells. (A) 
Immediately following application, ASP+ displays rapid plasma membrane binding on 
hSERT-HEK cells. (B) APP+ fluorescence accumulation is diffuse within hSERT-HEK 
cells, and plasma membrane fluorescence is not apparent. Adapted from video from 
Solis, Zdravkovic et al. 2012.  
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Figure 21. Paroxetine pre-treatment does not inhibit ASP+ fluorescence 
accumulation. hSERT-HEK cells are untreated (left column) or pre-treated with 
paroxetine (right column). Paroxetine pre-treatment (10 µM) did not prevent fluorescence 
accumulation in hSERT-HEK cells. Adapted from Solis, Zdravkovic et al. 2012. 
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Figure 22. APP+ is not fluorescent at the plasma membrane. (A) Plasma membrane of 
hSERT-HEK cells is labeled with DiI (red, left image) and APP+ (green, middle image) is 
added to cells to determine colocalization (DiI and APP+ merged in right image). (B) 
Line scan (red arrow) through an hSERT-HEK cell with APP+/DiI (left), and plotted 
fluorescence intensity of line scan through cell (right). Adapted from Solis, Zdravkovic et 
al. 2012. 
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Figure 23. APP+ analogs do not display fluorescence accumulation at the plasma 
membrane. Images of DiI-labeled hSERT-HEK cells exposed to 10 µM of either 
compound 322 or 416 show no colocalization between the red-labeled plasma membrane 
and the APP+ analogs, which emit green fluorescence. Structure nomenclature:  322, 4-
(4-(dimethylamino)phenyl)-1-propylpyridinium; 416, 1-benzyl-4-(4-
(dimethylamino)phenyl)pyridinium. Adapted from Solis, Zdravkovic et al. 2012.  
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Figure 24. Non-transporting hSERT mutant did not exhibit plasma membrane 
fluorescence with APP+. HEK293 cells transiently-transfected with WT hSERT or 
C109A/G338C hSERT mutant were exposed to either 3 or 50 µM APP+, and no 
condition exhibited plasma membrane fluorescence. Representative images acquired 5 
min post-APP+ application. Field, Henry et al. 2010 demonstrated the C109A/G338C 
hSERT mutant lacks 5HT transport while maintaining similar substrate binding affinity. 
The C109A/G338C hSERT mutant was kindly provided by Randy Blakely. Adapted 
from Solis, Zdravkovic et al. 2012. 
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Docking of APP+ and ASP+ to hSERT  
We sought to examine how the structural difference between APP+ and ASP+ affects 
their interaction with hSERT by utilizing a homology model of hSERT based on the 
crystal structure of LeuTAa (Yamashita, Singh et al. 2005), and employing extra-precise 
ligand-receptor docking, which yields information about how tightly compounds dock 
within the active region of hSERT. Docking was performed with APP+ and ASP+ at their 
low-energy state (Figure 25, energy-minimized structures are shown in Figure 4, bottom 
row). All three compounds tested (5HT, APP+ and ASP+) displayed most favorable 
docking at the same place (Figure 26A-C shows docking of the compounds individually 
and Figure 26D shows they overlap within the active region of hSERT). Whereas 5HT, 
APP+, and ASP+ all docked favorably within the established active region of hSERT 
(Figure 27A-C) with respective G-scores of -10.95, -7.61, and -8.90 kcal/mol (values for 
energies measured are shown in Table 1), only 5HT displays significantly improved 
docking over both APP+ and ASP+. The difference in binding scores between APP+ and 
ASP+ is within uncertainty of the method. Zoomed images display interactions of docked 
5HT, APP+ and ASP+ at their most energetically favorable positions to residues within 
the active region of hSERT (Figure 27D-F). The hSERT amino acids whose side chains 
are within 3 Å or less of docked compounds (listed in Table 2) are mostly from 
transmembrane helices 1, 3, 6 and 8, which have been shown to form the active region 
where substrates bind (Yamashita, Singh et al. 2005). 
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Figure 25. Energy minimization of APP+ and ASP+. Relative energies were calculated 
for torsional conformations at 18º rotation increments around the dihedral angle for APP+ 
(left) and ASP+ (right). The conformations with the lowest energy were used to dock to 
the homology model. The conformation with the lowest energy for APP+ was a twisted 
conformer at 18º and 162º (due to symmetry 198º and 342º exhibit the same energy 
minima), and the conformation with the lowest energy for ASP+ was at 0º. Adapted from 
Solis, Zdravkovic et al. 2012. 
 
 
 
 
 
 
 
 
 
 
	  
	  
	  
	   89 
	  
	  
	  
	  
	  
	  
	  
	  
	  
 
 
Figure 26. Most favorable position of docked substrates within the active region of 
the hSERT homology model. To validate the homology model of hSERT (A) 5HT, (B) 
APP+, (C) ASP+ were allowed to dock within hSERT and (D) all three compounds (5HT, 
APP+, and ASP+) displayed interactions within the active region of hSERT. Homology 
model based on the Yamashita, Singh et al. 2005 leucine transporter crystal structure and 
obtained from Igor Zdravkovic. 
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Figure 27. An hSERT homology model favors docking of APP+ and ASP+ in the 
active region. (A, D) Most favorable docking position for 5HT within the hSERT active 
region. (D) Relationship between 5HT and side chains of amino acids and coordinating 
ions (2 Na+ and a Cl-). (B, E) Most favorable docking position for APP+ within the 
hSERT active region. (E) Relationship between APP+ and side chains of amino acids and 
coordinating ions (2 Na+ and a Cl-). (C, F) Most favorable docking position for ASP+ 
within the hSERT active region. (F) Relationship between ASP+ and side chains of amino 
acids and coordinating ions (2 Na+ and a Cl-). Homology model based on the Yamashita, 
Singh et al. 2005 leucine transporter crystal structure and obtained from Igor Zdravkovic. 
Adapted from Solis, Zdravkovic et al. 2012. 
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Table 1. Docking values for 5HT, APP+, and ASP+ in the hSERT active region. 
The docking study was performed using GLIDE. The energy grid for the receptor was 
created and each of the ligands docked individually. A square volume with a length of 14 
Å around the location of the active site was designated to allow insertions of the ligands. 
The center of the insertion region was defined around the known substrate-binding site in 
the leucine transporter (LeuT). The docking was performed on the basis of a rigid protein 
approximation and a flexible ligand. Extra precision docking (Friesner, Murphy et al. 
2006) was subsequently used and the top ten potential docks were further optimized. The 
ranking of each pose and its energy was calculated using the G-Score. Once re-
minimized, each dock is assigned a G-Score as a sum of interactions and the docks are 
ranked from most negative (favorable) to least. The ligand in each dock is allowed full 
degrees of motion, within its optimal conformation. The hSERT homology model was 
obtained from the Meiler lab (Kaufmann, Dawson et al. 2009), and is based on the 
crystallized structure of the leucine transporter (LeuTAa) reported by Yamashita et al. 
PBDID 2A65 (Yamashita, Singh et al. 2005). Abbreviations: G-scr (G-score), vdW (van 
der Waals energy), Lipo (lipophilic energy), Hbond (H-bond energy), Clmb (coulombic 
energy). Adapted from Solis, Zdravkovic et al. 2012. 
 
 
 
 
 
 
 
 
 
 
 
G-Scr vdW Lipo Hbond Clmb
5HT -10.95 -24.35 -1.82 -0.06 -10.22
APP+ -7.61 -34.20 -2.01 0.00 -6.48
ASP+ -8.90 -35.34 -2.23 0.00 -5.76
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Table 2. hSERT residues interacting with 5HT, APP+, and ASP+. APP+ and ASP+ 
dock within the same region as for the endogenous ligand 5HT, and all amino acids are 
located near the active region of hSERT. The amino acids listed were in proximity to 
either 5HT, APP+ or ASP+. Residues that are less than 3 Å away from the docked 
compound are indicated by a +. Adapted from Solis, Zdravkovic et al. 2012. 
 
 
 	  
 
 
5HT APP+ ASP+
TM1 95 Tyr     +     +     +
96 Ala     +     +     -
98 Asp     +     +     -
TM3 164 Ala     -     -     +
165 Ile     -     +     +
168 Ile     -     +     +
169 Ala     +     +     +
172 Ile     +     +     +
176 Tyr     +     +     +
TM6 337 Leu     +     +     -
338 Gly     +     +     -
341 Phe     +     +     +
343 Val     +     +     +
344 Leu     +     -     -
TM8 438 Ser     +     +     +
441 Ala     +     +     +
TM10 496 Ala     -     -     +
500 Ala     -     -     +
501 Val     -     +     +
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DISCUSSION 
 
Rationale of Study 
Fluorescent monoamine transporter substrates provide a significant technical 
improvement to study substrate transport and binding over traditional radiolabeled 
substrate uptake assays. Fluorescent substrates in conjunction with confocal microscopy 
enable the measurement of real-time activity in individual cells. When we first 
established the fluorescent compound ASP+ as a substrate for monoamine transporters, 
we determined the substrate-to-transporter stoichiometry and the residence time of ASP+ 
on hNET before being transported (Schwartz, Blakely et al. 2003; Schwartz, Novarino et 
al. 2005; Schwartz, Piston et al. 2006). Subsequently, ASP+ was successfully utilized to 
study the regulation of DAT activity by several DA receptors (Bolan, Kivell et al. 2007; 
Zapata, Kivell et al. 2007). In addition, further studies validated the use of ASP+ as a 
useful fluorescent substrate amenable for high-throughput methods for which ASP+ 
uptake by hNET was effective with low µM affinity (Mason, Farmer et al. 2005; Haunso 
and Buchanan 2007). However, ASP+ had marginal effectiveness as an hSERT substrate; 
in fact, to see substantial hSERT-mediated uptake incubation for long time-periods was 
required. In one instance, measurements taken 10-60 min after hSERT-expressing cells 
were incubated with ASP+ yielded an uptake km between 9.9 and 20 µM (Fowler, Seifert 
et al. 2006). Our previous research also indicated ASP+ was very weak at labeling 
hSERT-expressing cells (Schwartz, Blakely et al. 2003). Therefore, it was unknown what 
the utility of ASP+ as a fluorescent hSERT reporter would be in real-time measurements, 
and the development for improved fluorescent hSERT substrates was evident.  
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In this study we identified APP+ (also known as IDT307) from a series of fluorescent 
MPP+ analogs synthesized by Ian D. Tomlinson and Sandra Rosenthal, and thoroughly 
characterized its utility as an hSERT substrate. The fluorescent APP+ uptake rate by 
hSERT resembles the ASP+ uptake phase by hNET previously observed (Schwartz, 
Blakely et al. 2003). Furthermore, APP+ uptake km values at hSERT are 5 to 10 times 
better than the reported km for ASP+ as an hSERT substrate (Fowler, Seifert et al. 2006). 
This difference in affinity is consistent with TEVC recordings where APP+ induces 
hSERT-mediated inward currents with a km that is roughly 10 times better than the km for 
ASP+-induced hSERT-mediated outward currents. In agreement, the radiolabeled 
substrate uptake competition assay we performed shows APP+ has nearly a 10-fold better 
ki than ASP+ when inhibiting [3H]-5HT uptake through hSERT. By all our measures 
APP+ is superior to ASP+ at targeting hSERT.  
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The Action of APP+ on hSERT 
Consistent with activity as an hSERT substrate, APP+ behaves similarly to the 
endogenous hSERT substrate 5HT. The km for APP+ fluorescence uptake by hSERT is 
comparable to the reported km for [3H]-5HT uptake (Hilber, Scholze et al. 2005; 
Andersen, Taboureau et al. 2009). In agreement, 5HT and APP+ display similar affinity 
when evoking hSERT-mediated currents. Since inward currents by hSERT are observed 
only in response to transported substrates, such as 5HT, MPP+, or MDMA, the presence 
of APP+-induced hSERT-mediated inward currents supports that APP+ is a substrate of 
hSERT. While the km values for APP+ fluorescence uptake and APP+-induced hSERT 
currents are comparable (~2.3 and 1.13 µM, respectively), the APP+ ki for [3H]-5HT 
uptake inhibition is much weaker (nearly 20 µM). This discrepancy in affinity can be 
explained by the assay employed. Both APP+ uptake and APP+-induced currents are 
measured with only the substrate present; on the other hand, the [3H]-5HT inhibition 
assay requires the presence of 5HT, which could confer an alternate conformational state 
of hSERT, and in turn alter the interaction between APP+ and hSERT.  
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Source of APP+ Fluorescence 
To perform biophysical studies for hSERT similar to ones we previously performed 
for hNET, the fluorescent substrate for hSERT should display fluorescence on the plasma 
membrane while interacting with the transporter. Hence, we sought to identify APP+ 
fluorescence on the plasma membrane of hSERT-HEK cells, but were unsuccessful in all 
our attempts, which included colocalization studies using DiI and additional APP+ 
analogs, and experiments employing an hSERT mutant. The absence of fluorescence of 
APP+ and its analogs while interacting with the transporter may be explained by the 
physical properties of this class of compounds. APP+ and its analogs are twist-
intramolecular-charge-transfer-state-forming (TICT) compounds (Murali and Rettig 
2006), which display energy emission under specific structural conditions. In order for 
APP+ to be fluorescent, the phenyl and pyridyl rings must assume a co-planar 
conformation. Molecular modeling studies have suggested that the lowest energy 
conformer of APP+ is in the twisted conformation (Figure 4 and Figure 25), and it is 
likely that this conformation is the most abundant conformer in an aqueous environment. 
Since the co-planar conformer may become more energetically favorable when the 
molecule binds to intracellular biomolecules such as proteins or DNA, APP+ will 
fluoresce only after entering cells. It is likely that the co-planar APP+ conformer 
intercalates between the base pairs of DNA and RNA because this conformer would 
produce π-π stacking interactions with nucleic acid base pairs, and confer π-π stacking 
interactions among nucleic acid base pairs. Intriguingly, the lack of APP+ fluorescence on 
the plasma membrane of hSERT-expressing cells suggests the co-planar fluorescent state 
of APP+ is not achieved during transport by hSERT. Instead, APP+ fluorescence 
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accumulation in hSERT-HEK cells seems diffuse in the cytosol and gathers preferentially 
at mitochondria and nucleoli. It is well known that MPP+ and its analogs exert their 
neurotoxic effects by disrupting the electron transport chain at mitochondria (Krueger, 
Sablin et al. 1993; Gluck, Youngster et al. 1994; Desai, Feuers et al. 1996), which 
supports the preference APP+ (an MPP+ analog) has to stain mitochondria. In addition, 
since the membrane potential of mitochondria is highly negative (Johnson, Walsh et al. 
1980; Johnson, Walsh et al. 1981), positively charged compounds such as APP+ would 
display favorable mitochondrial accumulation. Nucleoli are the most dense compartments 
in the nucleus consisting of tightly packed DNA, RNA, and proteins, and were recently 
shown to exhibit the slowest rate of protein diffusion, which implies limited mobility 
(Bancaud, Huet et al. 2009). Perhaps this dense and spatially restricted environment 
within nucleoli favors APP+ accumulation and subsequent binding to nucleic acids in its 
fluorescence-emitting conformation.  
It is worth noting that we observed minimal reversal of APP+ signal in response to 
5HT application (Figure 11C). As mentioned, for APP+ to display fluorescence, it must 
abide to a rigid co-planar conformation, which occurs when it binds to specific regions in 
the cell. Thus, in order for transported hSERT substrates, such as 5HT, or releasing-
agents like MDMA, to induce hSERT-mediated APP+ efflux, they would need to displace 
bound APP+, which requires affinity at the same binding sites. Furthermore, if APP+ 
intercalates the base pairs in DNA and RNA it would form strong hydrophobic 
interactions between the base pairs of DNA and RNA. The intrinsic positive charge of 
APP+ might form charge-charge interactions between the positively charged pyridyl 
nitrogen and the phosphate backbone of these polymers. Since these interactions are 
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energetically favorable, they would result in strong binding making it very difficult for 
APP+ to be displaced from nucleic acids. Lastly, if bound APP+ could be displaced, it 
might bind to other subcellular compartments before undergoing hSERT-mediated efflux. 
Further studies employing strong releasing compounds are warranted.  
The Hill coefficient for APP+ fluorescence accumulation through hSERT ranged 
from 2.5 to 2.9 (depending on accumulation rate), which is in contrast to the Hill 
coefficient obtained from TEVC recordings and the [3H]-5HT uptake inhibition assay 
(1.23). APP+ fluorescence accumulation consists of several processes that could influence 
the Hill coefficient, including rate of uptake through hSERT, distinct accumulation sites 
within the cell that are at different distances from the entry point (besides displaying 
fluorescence at nucleoli and mitochondria, APP+ emits diffuse fluorescence in the 
cytosol), manner of APP+ incorporation into subcellular compartments, and the 
mechanism whereby APP+ abides to the co-planar conformation. On the other hand, 
TEVC recordings and the [3H]-5HT uptake inhibition assay measure single processes by 
hSERT (currents mediated primarily by Na+ or [3H]-5HT uptake), which are the limiting 
step. Since these measures are solely dependent on hSERT activity, a Hill coefficient 
near unity seems reasonable.  
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The Action of ASP+ on hSERT 
Although ASP+ does not report specific hSERT uptake or binding, our study 
demonstrates that ASP+ interacts with hSERT. Most strikingly is the result in TEVC 
oocyte recordings showing ASP+ induce hSERT-mediated outward currents, which 
resemble the outward currents induced by hSERT inhibitors, such as fluoxetine (Li, 
Zhong et al. 2006), and are usually interpreted as the inhibition of the constitutive inward 
leak current seen by many transporters (Mager, Min et al. 1994; Adams and DeFelice 
2003). However, ASP+ proves to be very poor when acting as an inhibitor, as 
demonstrated by the high ASP+ concentrations required to inhibit 5HT-induced hSERT 
currents, and the poor ki obtained for ASP+ inhibition of [3H]-5HT uptake. Still, we 
cannot rule out that ASP+ is transported through hSERT and that its interaction with 
hSERT is distinct from bona fide hSERT inhibitors. ASP+ could even serve dual 
functions at hSERT, as both an inhibitor (in electrophysiology measurements) and a 
substrate (in uptake measurements), albeit likely having a very slow uptake rate. To 
determine if a fraction of ASP+ is taken up through hSERT, radiolabeled ASP+ could be 
employed in uptake assays. Interestingly, ASP+ is effectively transported by hNET and 
electrophysiology experiments show ASP+ elicits inward currents through hNET 
(Schwartz, Novarino et al. 2005). The distinct effect of ASP+ as an inhibitor on hSERT 
and as a substrate on hNET highlights the structural and functional differences between 
these two monoamine transporters.  
The difference observed in affinity for ASP+ on hSERT in the [3H]-5HT competition 
assay versus TEVC oocyte recordings could be explained by the existence of two distinct 
binding sites, the established substrate-binding active region and the recently discovered 
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secondary antidepressant binding site in the extracellular vestibule of the homologous 
LeuT (Singh, Yamashita et al. 2007; Zhou, Zhen et al. 2007; Zhou, Zhen et al. 2009), 
which has been further substantiated for SERT (Andersen, Taboureau et al. 2009; Sarker, 
Weissensteiner et al. 2010). ASP+ might not be readily accessible to the substrate-binding 
site, and hence, it is weak at displacing 5HT, whereas it can induce an hSERT-mediated 
outward current at a much lower concentration possibly because in the absence of 5HT, 
hSERT is at a conformation that provides easy access for ASP+ at the outer 
antidepressant-binding site. Supporting this possibility are recent studies showing that 
two structurally dissimilar classes of drugs, the TCAs and the SSRIs, interact at 
this promiscuous binding site (Zhou, Zhen et al. 2009; Sarker, Weissensteiner et al. 
2010).  
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Docking to an hSERT Homology Model 
To understand the interaction of APP+ and ASP+ with hSERT, we performed a 
docking study, which yielded favorable docking scores for 5HT, APP+, and ASP+ at the 
active region of hSERT, and agrees well with the electrophysiology data, in which, when 
applied individually, 5HT, APP+ and ASP+ induce visible hSERT-mediated currents at 
low µM concentrations. The hSERT model predicts amino acid side chains in proximity 
to docked substrates within the active region. Of interest are residues that displayed 
interactions with the three compounds tested in our model that are involved in substrate 
or antidepressant affinity to hSERT, including Tyrosine 95, Isoleucine 172, Alanine 169, 
and Serine 438 (Barker and Blakely 1996; Henry, Field et al. 2006; Celik, Sinning et al. 
2008; Andersen, Taboureau et al. 2009). Additionally, while 5HT shares 80% of hSERT 
interacting residues with APP+, it only shares ~57% residues to docked ASP+ (Table 2). 
The similarity between 5HT and APP+ interaction with hSERT is consistent with 
comparable affinity at hSERT, and their action as transported substrates. On the other 
hand, ASP+, which interacts with distinct residues than 5HT in the hSERT model, has the 
weakest affinity for hSERT in all the assays performed in this study and it exhibits 
minimal transport. We speculate that the interactions a docked compound makes to 
residues in this model can help predict whether the compound will function as a substrate 
or inhibitor. 
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Conclusions  
Despite exhibiting no measureable fluorescence on the plasma membrane, we have 
established that APP+ is a suitable fluorescent substrate to study hSERT uptake activity in 
single cells, which may introduce new protocols to study hSERT transport in real-time. 
ASP+, on the other hand, is not adequate to study hSERT activity.  
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CHAPTER III 
 
S(+)AMPHETAMINE INDUCES A PERSISTENT LEAK IN THE HUMAN 
DOPAMINE TRANSPORTER: MOLECULAR STENT HYPOTHESIS 
 
Parts of Chapter 3 are adapted from Rodriguez-Menchaca, A. A., E. Solis, Jr., K. 
Cameron and L. J. De Felice (2012). "S(+)amphetamine induces a persistent leak in the 
human dopamine transporter: molecular stent hypothesis." Br J Pharmacol 165(8): 2749-
2757. 
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STUDY OVERVIEW 
 
Background and Purpose  
Wherever they are located, DA transporters (DATs) clear DA from the extracellular 
milieu to help regulate dopaminergic signaling. Exposure to amphetamine (AMPH) 
increases extracellular DA in the synaptic cleft, a process that has been ascribed to DAT 
reverse transport. Increased extracellular DA prolongs postsynaptic activity and 
reinforces abuse and hedonic behavior. The mechanisms underlying AMPH-induced DA 
release are only partially understood.  
 
Experimental Approach 
Currents were recorded from Xenopus laevis oocytes expressing hDAT and voltage-
clamped to –60 mV in response to exposure to DA, R(–)AMPH, or S(+)AMPH 
externally and internally by injection.  
 
Key results and Conclusions  
Here we report a hitherto unknown action of S(+)AMPH on hDAT that potentially 
impacts AMPH-induced DA release. At –60mV, near the resting potential of neurons, 
S(+)AMPH induces a depolarizing current through hDAT that surprisingly, after 
removing the drug, persists for up to 30 minutes. This persistent leak current in the 
absence of substrate (shown in Figure 27) is in contrast to the R(–)AMPH- and DA-
induced currents, which return to baseline immediately after their removal. In addition, 
the persistent current depends on Na+ and is blocked by cocaine. Our data suggests that 
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S(+)AMPH and Na+ carry the initial S(+)AMPH-induced current, whereas Na+ and Cl- 
carry the persistent leak current. We propose that the persistent current results from the 
internal action of S(+)AMPH on hDAT because the temporal effect is consistent with 
S(+)AMPH transport influx and intracellular injection of S(+)AMPH produces the effect. 
Remarkably, following S(+)AMPH injection into the oocyte, external application with 
DA can induce the persistent leak current.  
 
Implications  
We propose that S(+)AMPH acts as a molecular stent that holds the transporter open 
even after it is removed externally. AMPH-induced persistent currents, if found in DA 
neurons, are likely to impact dopaminergic signaling, DA release mechanisms, and 
AMPH abuse.   
 
 
 
 
 
 
 
 
 
 
 
	   106 
INTRODUCTION 
 
The Dopamine Transporter 
Cocaine (COC) and AMPH profoundly influence dopaminergic neurotransmission 
through their action on DAT. In response to prolonged exposure to these drugs, DAT 
displays reduced capacity for DA transport (Iversen 2006; Samuvel, Jayanthi et al. 2008). 
In contrast to the DAT inhibitor COC, AMPH acts as a DAT substrate that fluxes into 
cells through the transporter (Volz, Hanson et al. 2007; Erreger, Grewer et al. 2008).  
Thus, COC and AMPH both increase extracellular DA by diminishing uptake, but they 
do so by entirely different mechanisms. Whereas COC blocks DA uptake, AMPH 
replaces DA as a substrate and, in addition, releases DA into the synaptic cleft (Iversen 
2006). In striatal slices, as one example, AMPH causes a gradual increase in extracellular 
DA that lasts for over 30 min in normal mice, whereas no analogous increase exists in -/- 
DAT mice (Giros, Jaber et al. 1996). Although DAT is required for the DA releasing 
action of AMPH, its presence is not necessary for the vesicle-depleting action of AMPH; 
furthermore, in the absence of AMPH, cytoplasmic DA is considered insufficiently 
concentrated to reverse DAT, implying that AMPH releases DA from vesicular stores 
prior to DA efflux (Jones, Gainetdinov et al. 1998). In some cases, however, as in 
dendrodendritic autoinhibition, DAT block abolishes DA efflux even in the absence of 
AMPH (Falkenburger, Barstow et al. 2001). 
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AMPH as a Therapeutic Agent 
Because AMPH releases DA from terminals in the frontal lobe and limbic system, it 
has been used clinically to treat medical conditions such as attention-deficit hyperactivity 
disorder and narcolepsy (Burnette, Bailey et al. 1996; Fleckenstein, Volz et al. 2007). 
Due to the higher potency of the dextroamphetamine isomer (S(+)AMPH) over 
levoamphetamine (R(–)AMPH) (Phillips, Brooke et al. 1975; Holmes and Rutledge 1976; 
Kuczenski, Segal et al. 1995), therapeutic agents are composed primarily of S(+)AMPH. 
For example, Adderall is composed of 3:1 S(+)AMPH to R(–)AMPH (Cody, Valtier et 
al. 2003), and Vyvanse (lisdexamphetamine) is a pro-drug that is metabolized entirely to 
S(+)AMPH (Najib 2009). Clinical manifestations associated with the abuse of AMPH or 
its precursors or derivatives, such as phenethylamine or METH, are well documented 
(Potkin, Karoum et al. 1979; Romanelli and Smith 2006; Winslow, Voorhees et al. 2007).   
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AMPH as an Abused Substance  
AMPH is a homologue of phenethylamine and the parent compound of a wide range 
of psychoactive derivatives, from the N-methylated methamphetamine (METH) to 3,4-
Methylenedioxy-N-methamphetamine (MDMA, commonly known as ecstasy). AMPH is 
widely abused and the clinical manifestations associated with the abuse of AMPH, its 
precursors, or its derivatives, such as phenethylamine or METH, are well documented 
(Potkin, Karoum et al. 1979; Romanelli and Smith 2006; Winslow, Voorhees et al. 2007). 
Because DAT is the primary target for AMPH, DAT is most frequently implicated in the 
reinforcing properties and abuse potential of AMPH (Sulzer, Maidment et al. 1993; 
Sulzer, Chen et al. 1995; Seidel, Singer et al. 2005).  The reward and addiction properties 
of AMPH rely on its ability to increase extracellular DA levels by mechanisms as yet 
only partially understood. 
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Findings of Study 
The principal mechanisms proposed for AMPH-induced increases in extracellular 
DA are the facilitated exchange model (Fischer and Cho 1979), the DAT efflux channel 
and reverse transport model (Kahlig, Binda et al. 2005), and the vesicular depletion 
model, which is also called the weak-base model (Sulzer, Maidment et al. 1993; Sulzer, 
Chen et al. 1995). Here we introduce a mechanism garnered from electrophysiological 
data that is based on a novel action of S(+)AMPH. In our model, hDAT transports 
S(+)AMPH inside the cell where it is available to bind hDAT at an internally accessible 
site. S(+)AMPH transport and induced current depend on extracellular Na+, which also 
carries part of the current. S(+)AMPH binding to an internal site maintains hDAT in a 
constitutively-active state long after removing external S(+)AMPH. The state defines a 
use-dependent leak named for the previously described substrate-independent leak 
(Sonders, Zhu et al. 1997).  Once hDAT has been exposed to S(+)AMPH, subsequent 
exposure to DA also results in a persistent leak.  In a free running cell, the persistent leak 
current, if carried by Na+, would depolarize the presynaptic terminal and increase the 
likelihood of vesicular fusion and DA release. Future studies are warranted to elucidate 
the relationship between the persistent leak current and the AMPH-induced DAT-
mediated DA efflux, as well as determining whether the required players in DAT efflux, 
such as Ca2+, protein kinase B, and CaMKII, play a role to produce the persistent leak 
current.  
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EXPERIMENTAL PROCEDURES 
 
Expression of hDAT in Xenopus Laevis Oocytes  
Oocytes are harvested and prepared from adult Xenopus laevis females following 
standard procedures (Machaca and Hartzell 1998; Iwamoto, Blakely et al. 2006).  We 
select stage V-VI oocytes for cRNA injection within 24 h of isolation. cRNA is 
transcribed in the pOTV vector (gift of Mark Sonders, Columbia University) using 
Ambion mMessage Machine T7 kit (Ambion Inc., Austin, TX). Each oocyte is injected 
with 50 nl of 1 µg/µl hDAT cRNA (final amount 50 ng) (Nanoject AutoOocyteInjector, 
Drummond Scientific Co., Broomall, PA) and incubated at 18oC for 4-8 days in Ringers 
solution supplemented with NaPyruvate (550 µg/ml), streptomycin (100 µg/ml), 
tetracycline (50 µg/ml) and 5% dialyzed horse serum.  
 
Electrophysiology 
We performed two-electrode voltage-clamp (TEVC) experiments as previously 
described (Wang, Li et al. 2006). Electrodes have resistances from 1-5 MΩ. Xenopus 
laevis oocytes expressing hDAT are voltage-clamped to -60 mV (unless otherwise noted) 
and buffer is gently perfused until a stable baseline is obtained. Then, the experimental 
substrates are perfused until stable currents are obtained for time periods indicated. 
 
Oocyte Injection With S(+)AMPH  
We injected a small volume of concentrated drug and calculated the final 
concentration by dilution in the oocyte volume. For example, 50 nl of 0.5 mM 
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S(+)AMPH diluted into an oocyte with estimated cytoplasmic volume of 1 µl (stage V-VI 
oocytes are 1-1.2 mm in diameter) gives a 25 µM final concentration.  Repeated 
injections at the same concentration, or a single injection at a higher concentration 
produced a range of S(+)AMPH inside the oocyte from 0 to 180 µM.  
 
Solutions  
Extracellular (in mM): 120 NaCl, 7.5 HEPES, 5.4 K gluconate, 1.2 Ca2+ gluconate, 
pH 7.4 with KOH. For Na+-free solution, 120 NaCl is replaced with 120 mM NMDG-Cl. 
Intracellular: 3 M KCl.   
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RESULTS 
 
Structures of DA and AMPH Stereoisomers 
Racemic AMPH consists of equal amounts of S(+)amphetamine (S(+)AMPH) and 
R(–)amphetamine (R(–)AMPH). The AMPH stereoisomers share similarity with the 
unique structure of DA (Figure 28). Although DA, S(+)AMPH, and R(–)AMPH have 
similar structures, they have markedly distinct effects on hDAT with regard to the current 
they induce under voltage clamp of hDAT-expressing oocytes  (Figure 29).   
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Figure 28. Structures of DA and stereoisomers of AMPH. Chemical composition of 
DA, S(+)amphetamine, and R(–)amphetamine (labeled S(+)AMPH and R(–)AMPH, 
respectively), showing their structural similarity. Adapted from Rodriguez-Menchaca, 
Solis et al. 2012. 
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DA and S(+)AMPH Affect hDAT Differentially 
Xenopus laevis oocytes expressing hDAT were exposed to DA or S(+)AMPH (10 
µM, –60 mV) for time periods ranging from 20-200 s (Figure 29). Adding 10 µM DA 
elicits an inward current ranging from 10 to 70 nA at –60 mV, depending on the level of 
hDAT expression. We confined ourselves to expression levels in this range. Control 
oocytes (not expressing hDAT) display no currents in response to substrate (DA or 
AMPH) exposure (data not shown). In hDAT-expressing oocytes, when DA is removed, 
the DA-induced current returns to baseline (Figure 29A) regardless of exposure time. As 
with DA, a brief exposure to 10 µM S(+)AMPH (30 s or less) elicits currents that return 
to baseline following S(+)AMPH removal. However, for exposures greater than 30 s, the 
hDAT current induced by 10 µM S(+)AMPH persists despite removal of external 
S(+)AMPH. Furthermore, the amplitude of the persistent current depends on the length of 
exposure to S(+)AMPH (Figure 29B). S(+)AMPH-induced persistent currents, also 
referred to as ‘shelf’ currents, may last as long as 30 min. The relationship between the 
amplitude of the shelf current and the duration of S(+)AMPH exposure (normalized to 
the initial hDAT-mediated peak current) shows that the shelf current amplitude saturates 
as a function of S(+)AMPH exposure time (Figure 29C). The existence of a shelf after 
removal of S(+)AMPH is tied not only to the duration of S(+)AMPH, but also to 
extracellular S(+)AMPH concentration. If the concentration of external S(+)AMPH is 
elevated from 10 to 30 µM, an exposure time that is too brief to elicit a bona fide shelf 
current (10 s) is now capable of doing so (Figure 29D). 
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Figure 29. S(+)AMPH induces a persistent “shelf” current through hDAT. (A) 
External DA (10 µM) induces a large inward ‘peak’ current at V = –60 mV that returns to 
baseline when DA is removed, regardless of DA exposure time. DA peak currents are 
normalized to the briefest exposure time. (B) S(+)AMPH (10 µM) induces a similar 
inward peak current for exposures less than 30 s; however, for longer exposure times a 
current that we term ‘leak’ or ‘shelf’ remains long after S(+)AMPH is removed, and the 
amplitude of the shelf is proportional to the length of exposure.  S(+)AMPH peak 
currents are normalized to the briefest exposure time. (C) Amplitude of the shelf current 
relative to the initial peak current plotted against exposure time of external S(+)AMPH, 
compared with the corresponding DA currents (n = 4, ± SEM). (D) A relatively brief and 
initial exposure to S(+)AMPH (20 s), which ordinarily would not produce a shelf current, 
does so if the concentration of S(+)AMPH increases from 10 to 30 µM.  For the same 
exposure range of times and concentrations, neither DA nor S(+)AMPH induce peak or 
shelf currents in mock-injected oocytes (data not shown).	   Adapted from Rodriguez-
Menchaca, Solis et al. 2012. 
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The Current-voltage Relationship of DA- and S(+)AMPH-induced Currents 
At –60 mV, R(–)AMPH consistently induces a peak current slightly smaller than 
DA, whereas S(+)AMPH induces a slightly larger current; these differences diminish 
below –60 mV and exaggerate above –60 mV. Strikingly, R(–)AMPH has no authentic 
shelf compared with S(+)AMPH, but at –60 mV always meanders to its pre-stimulus 
value (Figure 30). For sufficiently long exposure, however, S(+)AMPH induces a 
prominent shelf current that is blocked by subsequent exposure of the hDAT inhibitor, 
COC (Figure 30). COC also blocks the peak currents for DA, R(–)AMPH, and 
S(+)AMPH (not shown) and in all cases returns the current to positive values compared 
with the pre-stimulus baseline, as shown in Figure 30. Thus hDAT, like other co-
transporters in this family, has cocaine sensitive DA- and AMPH-induced currents and 
cocaine sensitive leak currents (Sonders, Zhu et al. 1997; Amara and Sonders 1998), to 
which we have added the cocaine sensitive shelf current. Because Na+ plays a major role 
in the transport of substrate by monoamine transporters (Nelson 1998; Rudnick 1998), we 
investigated its effect on DA- and S(+)AMPH-induced currents. The peak currents 
induced by DA, S(+)AMPH, and R(–)AMPH are abolished when external Na+ is replaced 
with NMDG+, as well as the shelf current, suggesting all these currents are dependent on 
Na+.  We generated I(V) curves of initial current and shelf current for DA, S(+)AMPH 
peak, and S(+)AMPH shelf (Figure 31). The I(V) for DA bends downward (toward more 
negative currents) at more positive potentials. This is due to blockade of the endogenous 
leak current for DAT (Sonders, Zhu et al. 1997; Ingram and Amara 2000), similar to 
SERT (Galli, Petersen et al. 1997), and NET (Galli, Blakely et al. 1998). When external 
S(+)AMPH is present, the I(V) curve shifts to the left (between –20 and +20 mV), 
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possibly reflecting the co-conductance of Na+ and S(+)AMPH cations. The shelf current 
I(V) is further shifted to the left, which implies not only the absence of S(+)AMPH, since 
at physiological conditions S(+)AMPH is protonated, but the likely presence of Cl- ions 
which are known to carry current in DAT (Ingram, Prasad et al. 2002; Carvelli, Blakely 
et al. 2008). In addition, the fact that the reversal potential for the shelf current is 
different than the reversal potential for the peak currents suggests a change in hDAT 
trafficking does not play a role in producing the shelf current.  
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Figure 30.  Effect of AMPH enantiomers on hDAT. At –60 mV, neither 10 µM DA 
nor 10 µM R(–)AMPH induce a shelf but always return to baseline after their removal.  
S(+)AMPH on the other hand induces a prominent shelf current that is blocked by 
cocaine (10 µM). The peak currents are approximately the same at -60 mV for 10 µM 
DA, R(–)AMPH, or S(+)AMPH. Note that 10 µM cocaine returns the current to values 
positive to the initial baseline, indicating the presence of an endogenous leak current. 
Adapted from Rodriguez-Menchaca, Solis et al. 2012. 
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Figure 31.  DA- and S(+)AMPH-induced I(V) curves. Cocaine subtracted I(V) curves 
for DA, S(+)AMPH peak, and S(+)AMPH shelf. The S(+)AMPH peak I(V) is left shifted 
above -60 mV compared with the DA peak, consistent with the conductance of both Na+ 
and S(+)AMPH through hDAT. The S(+)AMPH shelf I(V) is further shifted to the left, 
consistent with the absence of S(+)AMPH and presence of Cl- ions flowing through 
hDAT. Adapted from Rodriguez-Menchaca, Solis et al. 2012. 
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S(+)AMPH Operates on hDAT From the Inside 
Until now, we had applied S(+)AMPH externally and shown that an exposure of 50 s 
or more (at 10 µM, –60 mV) activates the shelf current. Because of this relatively long 
time to elicit an effect, and because increasing S(+)AMPH concentration reduces the time 
required to activate a shelf current (Figure 29D), we suspected that S(+)AMPH was being 
transported into the cell to exert its effect internally. To test this possibility we injected 
S(+)AMPH into the oocyte to obtain a range of internal concentrations (see Methods) and 
correlated the internal concentration with the degree of persistent leak current. Whereas a 
brief application (10 s) of 10 µM external S(+)AMPH is insufficient to induce a shelf 
current, after injecting S(+)AMPH into the oocyte the same application induced a 
prominent shelf (Figure 32A). Remarkably, using external DA instead of S(+)AMPH also 
resulted in a shelf current (Figure 32B, center trace) and increasing internal S(+)AMPH 
(in a  different oocyte) generates a larger shelf (Figure 32B, right most trace). Injecting 
DA or water into the oocyte had no similar effect for either external S(+)AMPH or DA 
(data not shown).  These data suggest that S(+)AMPH is a use-dependent drug, and the 
ability to elicit the shelf current depends on its accessibility to hDAT from the inside. 
Thus, when hDAT has been previously exposed to S(+)AMPH, either external 
S(+)AMPH or external DA have the potential to generate persistent currents, though for 
the same external and internal concentrations, S(+)AMPH has a stronger effect (Figure 
32C). Following the protocol in Figure 32B in different oocytes, we methodically titrated 
internal S(+)AMPH by repeated injections at the same concentration or stronger 
concentrations in different oocytes (see Experimental Procedures). Application with 10 
µM external DA for 10 s after S(+)AMPH has been injected shows that the greater the 
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internal S(+)AMPH concentration the greater the shelf current (i.e., less recovery). The 
shelf saturates at 80% full recovery, with a Hill coefficient n = 1.7 and km = 37 µM.  
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Figure 32. S(+)AMPH injection promotes the shelf current. (A) A brief exposure of 
external S(+)AMPH (10 s) does not elicit a shelf current as previously shown; however, 
after injection of 25 µM S(+)AMPH, the same external exposure reveals a prominent 
shelf current. (B) DA exposure does not elicit a shelf current; however, after injections of 
25 µM S(+)AMPH, DA now elicits a shelf similar to the S(+)AMPH-induced shelf 
current. Increasing internal S(+)AMPH with repeated injections generates a larger shelf 
(right trace). Injecting DA into the oocyte had no similar effect for external S(+)AMPH 
or DA (data not shown). (C) Percent recovery after external exposure to 25 µM 
S(+)AMPH or DA for 10 s with (+) or without (–) S(+)AMPH injection. (D) Baseline 
recovery following S(+)AMPH injections at increasing concentrations. Pooled data for 10 
µM external DA applied for 10 s: the greater the internal S(+)AMPH concentration the 
greater the DA-induced shelf current, i.e., in the presence of internal S(+)AMPH, less of 
the DA-induced current is able to return to baseline after external DA is removed. For a 
DA challenge, the shelf current saturates at 80% full recovery, with a Hill coefficient n = 
1.7 and km = 37 µM. Adapted from Rodriguez-Menchaca, Solis et al. 2012. 	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Internal S(+)AMPH is Silent Without External S(+)AMPH and Na+ 
Based on our experiments, we formulated a model of the S(+)AMPH-induced 
persistent current based on two gates in the hDAT protein: an external gate operated by 
S(+)AMPH and Na+ and blocked by cocaine, and an internal gate operated by S(+)AMPH 
(Figure 33). Previous work suggests that Na+ plays a regulatory role at the internal face of 
hDAT (Khoshbouei, Wang et al. 2003); however, this possibility was not explicitly tested 
in the present work. In stage (1) of Figure 33, we would expect hDAT to maintain a small 
leak current even in the absence of substrate. This endogenous leak, which can be 
revealed by cocaine, is present even without prior exposure to substrate (Figure 30) as 
had been shown previously (Sonders and Amara 1996). Here we ignore this background 
leak and focus only on the substrate-induced currents. In our model opening the outer 
gate requires both Na+ and S(+)AMPH; however, R(–)AMPH or DA can also operate the 
gate. Opening the gate generates the peak (or steady state) current in phase (2), which is 
likely carried by Na+ and S(+)AMPH cations though Cl- is also implicated (Figure 31), 
which is substantiated by previous work (Ingram, Prasad et al. 2002; Carvelli, Blakely et 
al. 2008). As transport ensues, the inner gate becomes exposed to S(+)AMPH and, once 
occupied, remains open and holds the outer gate open even though external S(+)AMPH 
has been removed. This allosteric action between the inner and outer gate acts as a 
molecular stent that holds the transporter in an open state (3). The molecular stent 
requires external Na+, and removing Na+ returns the current to baseline (4).  However, 
merely reintroducing Na+ does not restore the current (5); rather, S(+)AMPH and Na+ 
must both be present to regenerate the peak (6) and shelf (4). Unless this dual condition is 
fulfilled, internal S(+)AMPH is silent.  
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Figure 33. Model for S(+)AMPH-induced, hDAT-mediated peak and shelf currents.  
(A) Phase  : The baseline current at Vhold = –60 mV in standard external physiological 
solution containing Na+. Phase  : In the presence of external Na+, S(+)AMPH (10 µM) 
induces an initial peak current. Also, S(+)AMPH is transported and accumulated in the 
cell. Phase  : Removing external S(+)AMPH reduces the S(+)AMPH-induced current 
to a fraction of its initial peak value (the shelf current). At a fixed voltage, the shelf 
amplitude depends on exposure time and concentration of external S(+)AMPH. Phase  : 
Replacing Na+ with NMDG introduces a shift in baseline that was removed from the 
figure (dashed line); however, reintroducing Na+ during phase   (Phase ) does not 
restore the shelf current but returns the current to the original baseline. Phase  : 
Reintroducing external S(+)AMPH in the presence of Na+ induces a new peak current. 
Note that the second application of S(+)AMPH is normally too brief to elicit a shelf 
current; however, S(+)AMPH is already present inside the cell from the first application. 
After removing S(+)AMPH for the second time, the shelf current again manifests itself. 
The new peak is smaller than the first peak, possibly due to hDAT internalization. (B) 
States of hDAT during S(+)AMPH-induced shelf current. The hatched transporter 
indicates internal occupancy by S(+)AMPH and a long lasting ‘molecular stent’ 
configuration. The numbers above each state of the transporter correspond to the traces in 
part (A). Transition (a) opens the top and bottom gates, which for brief external 
S(+)AMPH exposures would close. Transition (b) occurs after longer exposures and 
S(+)AMPH has built up inside to the extent that the inner S(+)AMPH site remains 
occupied and holds both gates open (molecular stent hypothesis), even in the absence of 
external S(+)AMPH.  Transition (c) Removing external Na+ closes the outer gate, which 
does not reopen without external Na+ and S(+)AMPH both present (transitions d and e), 
rendering the transporter capable of (and indeed more prone to) forming the molecular 
stent (transition f), because internal S(+)AMPH is still present. Adapted from Rodriguez-
Menchaca, Solis et al. 2012. 
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DISCUSSION 
 
Novel Mechanism of Action of S(+)AMPH on hDAT  
In this work, we present a novel finding for the action of S(+)AMPH on hDAT. Our 
results suggest a model in which S(+)AMPH is transported into the cell through hDAT, 
whereupon the drug has access to an internal site on the transporter that induces a 
persistent “shelf” current.  Bound to the internal site, S(+)AMPH induces a molecular 
stent in hDAT that holds the transporter open long after external AMPH is removed.  The 
internally accessible site is in addition to an external site for S(+)AMPH, which initiates 
the transport of the drug to the inside. Although, the existence of two substrate binding 
sites for neurotransmitter transporters is controversial, with evidence for (Shi, Quick et al. 
2008; Shan, Javitch et al. 2011; Zhao, Terry et al. 2011) and against (Piscitelli, 
Krishnamurthy et al. 2010), our model (Figure 33) is consistent with two binding sites for 
S(+)AMPH. 
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S(+)AMPH is a Use-Dependent Drug  
Regardless of the specific mechanism, the existence of the shelf current has 
physiological consequences for synaptic transmission. At rest, the persistent leak current 
could depolarize the presynaptic membrane and increase the probability of transmitter 
release.  Furthermore, once it is exposed to S(+)AMPH, the presynaptic membrane would 
respond to DA abnormally for as long as S(+)AMPH remains inside the terminal (30 
min) at a significant concentration (30 µM). S(+)AMPH is therefore a use-dependent 
drug that could pre-condition hDAT to generate a persistent leak when subsequently 
challenged by endogenous transmitter DA, or exogenous AMPH.  The half-life of AMPH 
inside cells is not well known (Seiden, Sabol et al. 1993), but it ranges from 2 hours up to 
12 hours if measured from body fluids (Mofenson and Greensher 1975; Verstraete 2005; 
Verstraete and Heyden 2005). 
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Composition of the Persistent Leak Current  
The persistent leak flows in the absence of external S(+)AMPH or DA and must 
therefore be entirely composed of co-transported ions, most likely Na+ and Cl-. We 
explicitly tested the dependence of S(+)AMPH-induced currents on external Na+, and the 
results are consistent with well-known criteria for coupled co-transport (Gu, Caplan et al. 
1998; Rudnick 1998; Rudnick 1998). Near the resting potential of most cells (–60 mV), 
the persistent leak current is constant as long as the voltage is held constant. In a free 
running cell, however, the depolarizing leak current would be self-quenching as the 
voltage becomes more positive. 
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Implications of AMPH-induced Shelf Current on Synaptic Neurotransmission 
It was already known that DA acting on DAT elicits inward currents through a 
channel-like mechanism that can depolarize dopaminergic neurons and increase their 
excitability (Ingram, Prasad et al. 2002; Carvelli, McDonald et al. 2004; Carvelli, Blakely 
et al. 2008). Ingram and colleagues suggest that tonic activity excites dopaminergic 
neurons by activating an uncoupled Cl- conductance mediated by DAT. In this study, the 
increase in cell excitability induced by DA or AMPH in voltage-clamped neurons was 
tested during the external perfusion that corresponds to the peak or steady state current in 
our model (illustrated in Figure 34 as “acute depolarization”). As discussed above, in 
addition to the established peak current, in which S(+)AMPH and DA both participate, a 
persistent leak current exists, which in similar conditions would prolong depolarization 
and increase midbrain dopaminergic neuron excitability long after AMPH is removed 
(shown in Figure 34 as “prolonged depolarization”). This additional experiment is 
warranted to validate the concept that the AMPH-induced hDAT-mediated persistent leak 
current has a physiological role in the brain. As postulated, prolonged depolarization of 
the presynaptic membrane (as illustrated in the model of shelf-induced prolonged 
synaptic depolarization in Figure 34) is expected to further increase the excitability of 
neurons and the probability of neurotransmitter release (Ingram, Prasad et al. 2002).  
A full understanding of this effect and its magnitude is at present unknown and 
would require a complete knowledge of current-generating channels and receptors on the 
presynaptic membrane. In particular, D2 DA receptors are known to be involved in 
transmitter release (Schmitz, Lee et al. 2001). It has been suggested that released DA may 
feed back onto D2 autoreceptors to depress neuronal activity (Sulzer and Galli 2003). In 
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addition, AMPH may regulate hDAT indirectly by targeting or modulating proteins that 
then impact DAT function. These possible responses extend the range of synaptic states 
regulated by neurotransmitters, to which the newly discovered leak current will 
undoubtedly contribute for a more complete understanding of AMPH action. One caveat 
that should be noted is that oocyte experiments lack associated proteins that alter 
transporter currents, such as syntaxin, which eliminates SERT currents (Quick 2003). If 
DAT requires a protein, such as syntaxin, to produce currents, persistent leak currents 
might not be produced in neurons; however, studies have shown the presence of 
uncoupled depolarizing currents in neurons (Ingram, Prasad et al. 2002; Carvelli, 
McDonald et al. 2004). 
The density of DAT expression would also be a contributing factor to the relative 
effect of DA- or AMPH-induced currents. Rapid treatment of rat striatal synaptosomes 
with low-doses of AMPH increases surface expression of DAT. Either DA or AMPH 
increased surface DAT within 10 s of substrate addition and steadily increased surface 
DAT until removal 2 min later. In these experiments exocytosis of DAT was blocked 
with tetanus and botulinum neurotoxins. These data demonstrate that DA and AMPH can 
rapidly increase surface DAT possibly to respond rapidly during DA secretion (Furman, 
Chen et al. 2009). However, it is also known that long-term exposure to AMPH can 
decrease surface DAT expression (Saunders, Ferrer et al. 2000; Galici, Galli et al. 2003).  
Thus, increase in surface DAT occurs within a minute and has a fairly short life of a few 
minutes, whereas longer treatments of AMPH, especially at doses equal to or greater than 
10 µM, cause down-regulation.  We believe that a decrease in surface hDAT is 
responsible for the consistently observed decrease in the second application of 
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S(+)AMPH, as seen in Figure 33.  Nevertheless, even a brief exposure to AMPH, 
normally too brief to elicit a shelf current, readily demonstrates a shelf current due to the 
previous exposure and S(+)AMPH pre-conditioning of the cell.  
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Figure 34. Model of shelf-induced prolonged synaptic depolarization. In this work, 
we present a new model for the action of AMPH on DAT in which AMPH is transported 
through DAT and concentrates inside the cell (at the presynaptic terminal) over time, 
where it is becomes available to bind at an internal site in the transporter. This produces a 
sustained inward “shelf” current under voltage clamp that remains even after the external 
substrate is removed. Our data support a model of an acute AMPH-induced 
depolarization (left synapse) and a chronic shelf current that leads to prolonged 
depolarization (right synapse). Acute depolarization by AMPH elicits inward currents in 
DAT via a channel-like mechanism that depolarizes dopaminergic neurons and increases 
neuronal firing. Prolonged depolarization would lead to further increased excitability and 
firing of dopaminergic neurons.  
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Conclusions 
Persistent depolarizing currents following AMPH exposure would be relevant to any 
model of presynaptic physiology and transmitter release. The resulting persistent 
depolarization of dopaminergic neurons caused in particular by S(+)AMPH, a component 
of street AMPH and prescription drugs, could play an important role in behavioral 
effects,  including craving, withdrawal, and relapse, as well as the pleasurable effects of 
AMPH, such as rush and euphoria. 	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CHAPTER IV.  
 
A COMPARISON OF PEAK AND PERSISTENT LEAK CURRENTS INDUCED 
BY METHAMPHETAMINE AND 3,4-METHYLENE-
DIOXYMETHAMPHETAMINE IN THE HUMAN DOPAMINE AND 
SEROTONIN TRANSPORTERS 
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STUDY OVERVIEW 
 
Background and Purpose  
Despite their structural similarities methamphetamine (METH) and 3,4-
methylenedioxy-methamphetamine (MDMA or ecstasy) elicit distinct behavioral 
responses in rodents and humans. METH is a psychoactive stimulant that increases the 
levels of DA, NE, and 5HT in the brain reward pathways, and thus, has a high potential 
for abuse and addiction. Since MDMA can induce euphoria in humans, it has become a 
widely abused recreational drug; however, MDMA offers therapeutic benefit to some 
individuals presumably through an increase in serotonergic signaling. Furthermore, many 
studies have shown differences in behaviors elicited by the stereoisomers of both METH 
and MDMA.  
 
Experimental Approach  
We record electrical currents mediated by hDAT or hSERT expressed in Xenopus 
laevis oocytes in response to S(+)MDMA, R(–)MDMA, S(+)METH, or R(–)METH. 
Each compound induces an inward (depolarizing) current when the oocyte is held near 
rest at –60 mV and each acts as an hDAT or hSERT agonist.  
 
Key Results and Conclusions  
In both hDAT and hSERT the METH and MDMA stereoisomers induce inward peak 
currents. In hDAT, out of the four compounds tested (METH and MDMA stereoisomers), 
only S(+)METH results in a persistent leak current after it is removed. In hSERT, 
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S(+)METH, S(+)MDMA, and R(–)MDMA (but not R(–)METH) induce a persistent leak 
current.  
 
Implications 
Structurally similar METH and MDMA stereoisomers induce electrophysiological 
responses in hDAT and hSERT that correlate with the known effects of these drugs to 
release specific neurotransmitters in the brain. 
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INTRODUCTION 
 
Amphetamine 
Amphetamine (AMPH) is a prototypical phenylisopropylamine stimulant. AMPH-
like psychostimulants interact with multiple monoamine transporters as releasing agents 
or as transmitter reuptake competitors (Sulzer, Sonders et al. 2005; Chen, Tilley et al. 
2006). The behavioral effects associated with these agents are closely linked to enhanced 
dopaminergic activity (Howell, Carroll et al. 2007; Howell and Kimmel 2007). 
Particularly, an increase in DA levels in the nucleus accumbens by the actions of AMPH 
on DAT produces rewarding and hyperlocomotor effects (Sellings and Clarke 2003; 
Williams and Galli 2006). Interestingly, it is known that the S(+)AMPH enantiomer is a 
stronger stimulant than the R(–)AMPH enantiomer (Mendelson, Uemura et al. 2006). 
Furthermore, S(+)AMPH is more potent at inducing release of extracellular DA in the 
brain than R(–)AMPH (Kuczenski, Segal et al. 1995). Consequently, since S(+)AMPH 
has higher potency than R(–)AMPH (Phillips, Brooke et al. 1975; Holmes and Rutledge 
1976; Kuczenski, Segal et al. 1995), therapeutic agents used clinically to treat medical 
conditions, such as attention-deficit hyperactivity disorder and narcolepsy (Burnette, 
Bailey et al. 1996; Fleckenstein, Volz et al. 2007), are composed primarily of 
S(+)AMPH. For example, Adderall is composed of 3:1 S(+)AMPH to R(–)AMPH (Cody, 
Valtier et al. 2003), and Vyvanse (lisdexamphetamine) is a pro-drug that is metabolized 
entirely to S(+)AMPH (Najib 2009). 
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METH 
The AMPH analog METH is a potent locomotor stimulant (Van der Schoot, Ariens 
et al. 1961; Biel and Bopp 1978) and a widespread drug of abuse (Mendelson, Uemura et 
al. 2006) that possesses a monoamine transporter release profile similar to AMPH and a 
potency for DA release nearly identical to that for AMPH (Rothman and Baumann 2006). 
Interestingly, in humans S(+)METH is a stronger stimulant than R(–)METH (Mendelson, 
Uemura et al. 2006). In fact, in the United States illicit METH is predominately 
distributed as the S(+) enantiomer (Mendelson, Uemura et al. 2006). Also, similarly to 
AMPH, the S(+) isomer for METH is more potent at inducing release of extracellular DA 
in the brain than the R(–) counterpart (Kuczenski, Segal et al. 1995). In addition, in 
humans, the S(+) enantiomers of AMPH and METH are 2 to 10 times more potent in 
producing CNS stimulation than the corresponding R(–) enantiomers (Mendelson, 
Uemura et al. 2006).  
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MDMA 
The “club drug” 3,4-methylenedioxy-methamphetamine (MDMA, also known as 
“ecstasy”) belongs to the AMPH family of compounds. MDMA is commonly used as a 
recreational drug and is thought to produce neurotoxic effects (Lyles and Cadet 2003). 
MDMA is similar in structure to METH (it is a ring-substituted analog of METH), but 
like DA it bears oxygen moieties at the meta- and para- ring-positions (see Fig. 1 for a 
comparison of chemical structures). MDMA can produce AMPH-like effects in various 
animal species (Green, Mechan et al. 2003), yet in humans, unlike AMPH or METH, 
MDMA induces a sense of euphoria, feelings of well-being, and diminished anxiety 
leading to the therapeutic potential of MDMA for post-traumatic stress disorder 
(Johansen and Krebs 2009; Mithoefer, Wagner et al. 2011). It is thought that the unique 
psychopharmacological profile of MDMA is derived from its property to promote the 
release of DA and 5HT in the brain (Gudelsky and Yamamoto 2008). Similar to AMPH 
and METH, the stimulant actions of MDMA are believed to involve the release of DA in 
the nucleus accumbens (Gold, Hubner et al. 1989); however, MDMA has higher potency 
(than METH) to induce 5HT release through hSERT (Rothman and Baumann 2006). In 
rats, the motor actions of racemic MDMA have been correlated with increased levels of 
both 5HT and DA in specific brain regions (Baumann, Clark et al. 2008). In addition to 
evoking an acute release of DA, which is reduced in the striatum, MDMA also causes 
release of DA metabolites, homovanillic acid (HVA), and dihydroxyphenylacetic acid 
(DOPAC), 3 h after the last administration of the drug (O'Shea, Esteban et al. 2001). 
However, the rise in DA concentration elicited by acute application of MDMA is modest 
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unless followed by subsequent doses of MDMA (Colado, Camarero et al. 2001; Sanchez, 
Camarero et al. 2001). 
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MDMA Stereoisomers Display Pharmacological Differences 
MDMA is normally a racemic mixture; however, the S(+) and R(–) stereoisomers 
have different pharmacological properties. S(+)MDMA is a potent psychomimetic 
compared to R(–)MDMA, and studies have suggested only S(+)MDMA is neurotoxic 
causing long-term  depletion of 5HT and SERT (Lyles and Cadet 2003; Baumann, Clark 
et al. 2008). Differences in the effect of each MDMA enantiomer may be related to 
differences in metabolism and it may not be surprising that the stereoisomers have 
different pharmacokinetic properties (Fantegrossi, Murai et al. 2009). Although 
S(+)MDMA is nearly equipotent at the DA, NE, or 5HT transporters, the R(–)MDMA 
enantiomer is 5-fold less potent than S(+)MDMA at releasing NE or 5HT, and more than 
25-fold less potent at DAT (Setola, Hufeisen et al. 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
	   141 
MDMA Stereoisomers Elicit Distinct Behavioral Effects in Rodents 
The hyperlocomotor effects of racemic MDMA were first described in mice 
(Glennon, Yousif et al. 1988) and rats (Gold, Koob et al. 1988; Gold, Hubner et al. 1989) 
more than 20 years ago. The behavioral effects of MDMA isomers in mice have shown 
variability across studies, but S(+)MDMA is generally more potent than the R(–)MDMA 
enantiomer (Glennon, Yousif et al. 1988; Young and Glennon 2008). For example, 
S(+)MDMA and racemic MDMA were more potent than R(–)MDMA at stimulating 
many different measurements of motor activity in mice (Young and Glennon 2008). 
Another study in mice, showed that S(+)MDMA, but not R(–)MDMA, produces 
hyperthermia and increased locomotor activity that is reversed with fluoxetine and 5HT2A 
receptor antagonists (Fantegrossi, Godlewski et al. 2003). 
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Drug Discrimination Studies Using Rodents Elucidate Distinct Effects of the MDMA 
Stereoisomers 
Several elegant drug discrimination studies have been performed to elucidate the 
reason the stereoisomers of MDMA produce distinct behavioral responses in rodents. 
These studies employ the high perceptive resolution rodents exhibit when exposed to 
different drugs to categorize them based on the effects they confer on the subject. The 
objective is to tease apart compounds that are related structurally, but may evoke distinct 
behavioral effects. In these studies, rodents are trained to respond to a specific drug (i.e. 
stimulant, hallucinogen), and the drug is substituted with the experimental drug. If 
responding is maintained, then it is inferred that the compound elicited a comparable 
effect; however, if the responding drops, it is interpreted as the compound eliciting 
distinct behavioral effects in the animal. In one such study, in which rats were taught to 
discriminate S(+)AMPH from vehicle, both S(+)METH and S(+)MDMA were able to 
substitute for the training drug (Glennon 1999), suggesting similarities in the stimulus 
effects these drugs elicit in the rats.  
Another study sought to study discriminative stimulus effects of psychostimulants 
and hallucinogens in S(+)MDMA- and R(–)MDMA-trained mice (Murnane, Murai et al. 
2009). The psychostimulant S(+)AMPH substitutes in S(+)MDMA-trained animals, but 
not in R(–)MDMA-trained animals, suggesting S(+)MDMA confers stimulant effects on 
mice. Both S(+)MDMA- and R(–)MDMA-trained animals respond to cocaine, but 
S(+)MDMA-trained animals respond to cocaine to a greater extent. While R(–)MDMA-
trained mice generalize to hallucinogenic drugs, S(+)MDMA-trained mice do not respond 
to a dose of the hallucinogenic drug 2-[2,5-dimethoxy-4-(propylthio)phenyl]ethanamine 
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(2C-T-7). Both S(+)MDMA- and R(–)MDMA-trained animals respond to 
dipropyltryptamine (DPT), a drug with mixed hallucinogenic and stimulant actions. A 
reasonable conclusion from this study was that R(–)MDMA mediates effects of 
hallucinogenic drugs, whereas S(+)MDMA predominantly mediates stimulant behavior 
(Murnane, Murai et al. 2009). 
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MDMA Stereoisomers Induce Reinforcing Effects in Primates 
In rhesus monkeys, the MDMA stereoisomers act as reinforcers; however, 
S(+)MDMA behaves as a more potent reinforcer than R(–)MDMA (Fantegrossi, Ullrich 
et al. 2002). Furthermore, in long-term self-administration protocols in rhesus monkeys, 
reinforcement effects of racemic and R(–)MDMA, but not of S(+)MDMA, are reduced 
over months of self-administration (Fantegrossi, Woolverton et al. 2004), implying 
weaker reinforcement effects for racemic and R(–)MDMA. Furthermore, the 
reinforcement effects of S(+)MDMA are more resistant to reduction than reinforcement 
effects for racemic and R(–)MDMA (Fantegrossi, Woolverton et al. 2004). 
In addition, the R(–)MDMA reinforcing effect is abolished with 5HT2A receptor 
antagonists, whereas the S(+)MDMA reinforcing effect can only be attenuated 
(Fantegrossi, Ullrich et al. 2002; Fantegrossi 2008), which implies a non-serotonergic 
mechanism underlying the reinforcing effect, presumably dopaminergic. Further work 
demonstrated that S(+)MDMA is less susceptible to tolerance after long term 
administration than racemic and R(–)MDMA (Fantegrossi 2008). Lastly, by employing 
positron emission tomography (PET) neuroimaging, it was found that R(–)MDMA does 
not display much DAT occupancy, whereas reasonable DAT interaction is seen with 
S(+)MDMA (Fantegrossi 2008). 
In a different study in using non-human primates (rhesus and squirrel monkeys), 
behaviorally relevant doses of MDMA did not induce stimulant (DAT-mediated) effects 
(Fantegrossi, Bauzo et al. 2009). Also, at a certain dose of MDMA self-administration, 
responding is suppressed, and this effect seems to be mediated by the serotonergic system 
(Fantegrossi, Bauzo et al. 2009). 
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Comparing Relative Reinforcing Strength of METH and MDMA Stereoisomers 
The difference METH and MDMA exhibit in their selectivity for monoamine 
neurotransmitters may explain why they differ in their relative reinforcing strength 
(Wang and Woolverton 2007). To compare their relative reinforcement, a long-term self-
administration study was performed in which responses to racemic (+/-) METH, 
S(+)MDMA, R(–)MDMA, or racemic (+/-)MDMA by rhesus monkeys were measured 
using a progressive-ratio schedule (Wang and Woolverton 2007). This study showed that 
METH, racemic MDMA, and S(+)MDMA act as positive reinforcers with relative 
reinforcer strength (from strongest to weakest): METH > S(+)MDMA > racemic 
MDMA. In other words, racemic MDMA and S(+)MDMA were weaker reinforcers than 
METH, and R(–)MDMA was at best a weak reinforcer (Wang and Woolverton 2007). 
The reinforcing strength of racemic MDMA appears to derive from S(+)MDMA.  
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What Accounts for the Distinct Behavioral Effects Produced by AMPH-like Drugs of 
Abuse?  
While drugs considered psychostimulants, such as AMPH and METH, possess high 
abuse potential and can cause hyperlocomotor activity, severe psychotic episodes, 
cardiovascular activation, increased energy and decreased need for sleep (Rothman and 
Baumann 2006; Rothman, Blough et al. 2008), drugs that are related structurally; in 
particular, MDMA, can elicit distinct behavioral effects, such as euphoria (feelings of 
elation), a sense of well-being, happiness, feelings of emotional closeness to others, and 
diminished aggression (Green, Mechan et al. 2003; Lyles and Cadet 2003; Baumann, 
Clark et al. 2008; Gudelsky and Yamamoto 2008). MDMA also has weaker 
reinforcement strength than AMPH and METH, and therefore, confers lower abuse 
potential (Fantegrossi, Ullrich et al. 2002).  
Regardless of mechanism, ultimately, drugs of abuse, such as AMPH, METH, and 
MDMA lead to elevated levels of the endogenous monoamine neurotransmitters (DA, 
NE, 5HT) through actions on the monoamine transporters (DAT, NET, SERT) that are 
surmised to be responsible for the range of behavioral responses they induce. 
Furthermore, these agents (AMPH, METH, and MDMA) display different affinities at the 
monoamine transporters, which could be the main factor underlying the distinct 
behavioral effects they elicit. For example, METH is much more potent at releasing DA 
and NE (from DAT and NET, respectively) than at releasing 5HT through SERT 
(Rothman and Baumann 2006).  
It has long been known that AMPH-induced reinforcing behavior, such as self-
administration, is mediated by increases in DA concentrations in the mesolimbic reward 
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circuits, particularly, in the nucleus accumbens, which holds true for related AMPH-like 
stimulants (Wise 1996; Rothman and Baumann 2006). In contrast, MDMA-mediated 
behavioral effects are attributed to high-affinity transport of MDMA by SERT, which 
leads to 5HT release (Verrico, Miller et al. 2007). Interestingly, some evidence suggests 
that enhanced serotonergic activity is negatively associated with reinforcing effects, and 
compounds that selectively increase 5HT neurotransmission have been found neither to 
maintain self-administration by animals nor to have abuse liability in humans (Wang and 
Woolverton 2007), which would agree with the lower reinforcing strength MDMA (a 
primarily 5HT-releasing agent) possesses as relative to addictive agents such as METH 
and AMPH (Wang and Woolverton 2007).  
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Effect of AMPH Stereoisomers on the Persistent Leak Current 
In previous work, we demonstrated that S(+)AMPH and R(–)AMPH both produce 
inward currents mediated by hDAT in Xenopus laevis oocytes voltage-clamped to –60 
mV (Rodriguez-Menchaca, Solis et al. 2012). In this regard both AMPH isomers produce 
an effect similar to hDAT’s endogenous substrate DA; however, only the S(+)AMPH 
enantiomer induced the recently characterized long-lasting inward leak current, which 
persists long after the drug is removed from the extracellular milieu (Rodriguez-
Menchaca, Solis et al. 2012).  
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Purpose of Study 
In the current study, we sought to determine whether the recently characterized 
AMPH-induced persistent leak current at hDAT (Rodriguez-Menchaca, Solis et al. 2012) 
would also be elicited by the stereoisomers of MDMA and METH in both hDAT and 
hSERT. We employed two-electrode voltage-clamp to measure the response to 
application of METH and MDMA stereoisomers in Xenopus laevis oocytes expressing 
either hDAT or hSERT. Although we expected the METH stereoisomers to behave 
similarly to the AMPH stereoisomers when applied to hDAT, we did not know what 
would happen if METH was applied to hSERT. Until now, there are no reports of the 
existence of a persistent leak current induced by hSERT; therefore, if successful, this 
study would demonstrate the persistent leak current induced by hSERT. We hypothesized 
that, in particular, S(+)MDMA would induce an hSERT-mediated persistent leak current 
since it has high potency at hSERT, and we had seen that S(+)AMPH, which has high 
potency at hDAT, does induce an hDAT-mediated persistent leak current.  
In our studies we found that whereas hSERT exhibits the persistent leak current in 
response to S(+)METH and the MDMA stereoisomers, hDAT only shows a persistent 
leak current in response to S(+)METH. Since the persistent leak currents elicited by 
METH and MDMA would alter excitability differentially in distinct neuronal populations 
and evoke release of neurotransmitter by hSERT and hDAT, we posit these findings 
could contribute to the behavioral effects induced by MDMA and METH.  
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EXPERIMENTAL PROCEDURES 
 
Expression of hDAT and hSERT in Xenopus Laevis Oocytes  
Oocytes are harvested and prepared from adult Xenopus laevis females following 
standard procedures (Machaca and Hartzell 1998; Iwamoto, Blakely et al. 2006). We 
select stage V-VI oocytes for cRNA injection within 24 h of isolation. cRNA is 
transcribed from the pOTV vector using mMessage Machine T7 kit (Ambion Inc., 
Austin, TX). Oocytes are injected with either 50 ng hDAT cRNA or 30 ng hSERT cRNA 
(Nanoject AutoOocyteInjector, Drummond Scientific Co., Broomall, PA) and incubated 
at 18oC for 4-8 days in Ringers solution supplemented with NaPyruvate (550 µg/ml), 
streptomycin (100 µg/ml), tetracycline (50 µg/ml) and 5% dialyzed horse serum. 
 
Electrophysiology  
We performed two-electrode voltage-clamp (TEVC) experiments as previously 
described (Wang, Li et al. 2006). Recordings were done at RT (23-25°C). Electrodes 
having resistances from 1-5 MΩ are filled with 3 M KCl. Xenopus laevis oocytes 
expressing hSERT or hDAT are voltage-clamped to -60 mV with a GeneClamp 500 
(Axon Instruments), and the holding current is recorded using Clampex 10 (Axon 
Instruments). Extracellular buffer consists of (in mM): 120 NaCl, 7.5 HEPES, 5.4 
KGluconate, 1.2 CaGluconate, pH 7.4. In a typical recording extracellular buffer is 
perfused until stable baseline currents are obtained, followed by experimental drugs 
(perfusion duration is indicated by a horizontal line on the trace).  
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Analysis 
To control for transporter expression between different drugs (in the raw traces in 
Figure 36 and Figure 37), for hDAT we normalized each drug-induced trace (including 
DA) obtained in individual hDAT-expressing oocytes to the DA-induced current 
(recorded prior to application of each compound tested), and for hSERT we normalized 
each drug-induced trace (including 5HT) obtained in hSERT-expressing oocytes to the 
5HT-induced current (recorded prior to application of each compound tested). To 
examine the persistent leak current among the different time point traces obtained in 
individual oocytes (in Figure 38, Figure 39, and Figure 40), the traces for each treatment 
(S(+)METH or S(+)MDMA) are normalized to the largest drug-induced response and 
aligned to start of drug perfusion. Concentration-response curves (in Figure 41 and 
Figure 42) are obtained by fitting values to the Hill 1 equation: y = Vmax + (Vmin - Vmax) * 
xn / (kn + xn) (Origin 8). Values for peak amplitude of each drug–induced response are 
selected at time = 30 s during drug application, and values for persistent leak current are 
selected at time = 60 s during washout with extracellular buffer. For peak amplitude fit all 
concentration values recorded are used (0.1, 0.5, 1, 3, 10, 30 µM). For persistent leak 
current fit only values in response to 1, 3, 10, and 30 µM drug exposure were used 
because only these concentrations induced measurable persistent leak currents. 
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RESULTS 
 
METH and MDMA Stereoisomers Produce Currents Through hDAT and hSERT  
METH and MDMA both have a chiral center at the α-carbon, therefore, there are 
two enantiomers possible for each substrate (as shown in Figure 35). To test their effect 
on hDAT and hSERT, we first recorded currents from hDAT-expressing oocytes in 
response to application of 10 µM 5HT, DA, R(–)MDMA, S(+)MDMA, R(–)METH, and 
S(+)METH, and observed that all substrates induce inward currents (Figure 36). As 
expected, hDAT’s endogenous substrate DA induced a larger inward current than 5HT, 
and all MDMA and METH stereoisomers induced substantial currents. Both S(+) 
enantiomers (S(+)METH and S(+)MDMA) induce larger currents than their R(–) 
counterparts (R(–)METH and R(–)MDMA, respectively).  
Whereas S(+)METH yielded the persistent leak current (characterized by lack of 
return to baseline after removal of S(+)METH by wash out), neither MDMA enantiomer 
nor R(–)METH induced a discernable persistent leak current (Figure 36, unpublished). 
Next, we recorded currents from hSERT-expressing oocytes in response to application of 
10 µM 5HT, DA, R(–)MDMA, S(+)MDMA, R(–)METH, and S(+)METH, and observed 
that hSERT produced inward currents in response to all substrates tested (Figure 37, Solis 
2012, unpublished). The endogenous substrate for hSERT, 5HT, induced a larger inward 
current than DA. Although the inward current induced by 5HT is comparable to the R(–
)METH-induced current, S(+)MDMA, R(–)MDMA, and S(+)METH produce hSERT-
mediated inward currents that are much larger than the 5HT-induced currents (Figure 37). 
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In addition, R(–)METH induced a modest persistent leak current whereas S(+)MDMA, 
R(–)METH, and S(+)METH produced a stronger persistent leak current (Figure 37). 
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Figure 35. Structures of substrates acting on hDAT and hSERT. Abbreviations: 
dopamine (DA), S(+)amphetamine (S(+)AMPH), R(–)amphetamine (R(–)AMPH), 
S(+)methamphetamine (S(+)METH), R(–)methamphetamine (R(–)METH), serotonin 
(5HT), S(+)methylenedioxy-methamphetamine (S(+)MDMA), R(–)methylenedioxy-
methamphetamine (R(–)MDMA), and para-chloroamphetamine (pCA). 
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Figure 36. Currents generated by hDAT in response to METH and MDMA 
stereoisomers. Voltage-clamped (Vcom = –60 mV) hDAT-expressing oocytes produce 
inward currents of varying magnitude and shape in response to application of 10 µM DA, 
5HT, R(–)METH, S(+)METH, R(–)MDMA, and S(+)MDMA (100 s exposure, traces 
normalized to maximum 5HT response). Washing out the compound generally results in 
a complete return to baseline except for S(+) METH, which maintains a persistent current 
even after its removal.  
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Fig. 37. Currents generated by hSERT in response to METH and MDMA 
stereoisomers. Voltage-clamped (Vcom = –60 mV) hSERT-expressing oocytes produce 
inward currents of varying magnitude and shape in response to application of 10 µM 
5HT, DA, R(–)METH, S(+)METH, R(–)MDMA, and S(+)MDMA (100 s exposure, 
traces normalized to maximum 5HT response). Washing out the compounds generally 
results in a complete return to baseline except for S(+) METH, R(–)MDMA, and 
S(+)MDMA, which even after their removal a persistent current remains. Unpublished 
data from Solis, 2012. 	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METH and MDMA Stereoisomers Produce hSERT-mediated Persistent Leak Currents 
that are Time-dependent 
To further characterize the persistent leak current in hSERT, we tested the effect of 
varying time exposure of the stereoisomers of METH and MDMA (S(+)METH, R(–
)METH,  S(+)MDMA, and R(–)MDMA) on hSERT-mediated currents (Figure 38, Solis 
2012, unpublished). To control for hSERT expression variability in different oocytes, we 
normalized each drug-induced inward current to a 5HT-induced exposure. The MDMA 
stereoisomers produced larger hSERT-mediated inward currents than the METH 
stereoisomers. Although the S(+)MDMA-induced current was slightly larger than R(–
)MDMA-induced current, the S(+)METH-induced hSERT current was substantially 
larger than the R(–)METH-induced current (about twice as large). Accordingly, the 
compounds inducing the largest inward currents (S(+)METH, S(+)MDMA, and R(–
)MDMA) induced measurable persistent leak currents with strength corresponding to the 
order of the drug’s induced hSERT-mediated peak amplitudes (S(+)MDMA > R(–
)MDMA > S(+)METH). This effect holds true for all time exposures tested, and is 
discernable more clearly at the longer time exposure (150 s, Figure 38).  
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Figure 38. Effect of varying time of exposure of MDMA and METH stereoisomers 
on hSERT currents. Exposing voltage-clamped (Vcom = –60 mV) hSERT-expressing 
oocytes to the stereoisomers of MDMA and METH yield distinct peak and persistent leak 
currents. S(+)MDMA, R(–)MDMA, and S(+)METH induce persistent leak currents more 
appreciable at longer exposure times (150 s treatment), whereas R(–) METH yields no 
discernable persistent peak current. Unpublished data from Solis, 2012. 
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The Persistent Leak Currents Induced by S(+)METH and S(+)MDMA on hDAT and 
hSERT are Time-dependent  
Since the S(+) enantiomers for METH and MDMA (S(+)METH and S(+)MDMA, 
respectively) have been attributed to more potent behavioral effects, we narrowed our 
study to these two species. In hDAT-expressing cells, increasing the time of exposure to 
10 µM S(+)METH in individual oocytes (from 30-200 s) produced more pronounced 
persistent leak currents (Figure 39A, Solis 2012, unpublished); however, 10 µM 
S(+)MDMA did not elicit persistent leak currents regardless of time exposure (Figure 
39B, Solis 2012, unpublished). In contrast, both S(+)METH and S(+)MDMA induced 
persistent leak currents in hSERT-expressing oocytes that were enhanced with increased 
time exposure (from 30-200 s) to the drugs (effect of S(+)METH shown in Figure 40A, 
and effect of S(+)MDMA shown in Figure 40B, Solis 2012, unpublished).  
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Figure 39. Time-dependence of S(+)METH- and S(+)MDMA-induced hDAT-
mediated currents. Voltage-clamped (Vcom = –60 mV) hDAT-expressing oocytes were 
exposed to different durations of 10 µM S(+)METH or 10 µM S(+)MDMA (30, 60, 100, 
or 200 s). (A) Exposure to S(+)METH induced larger persistent leak currents with 
increased time exposure. (B) S(+)MDMA did not produce persistent leak currents 
regardless of time exposure. Traces were obtained in individual oocytes, normalized to 
the largest drug-induced response, and aligned to the beginning of drug application. 
Unpublished data from Solis, 2012. 
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Figure 40. Time-dependence of S(+)METH- and S(+)MDMA-induced hSERT-
mediated currents. Voltage-clamped (Vcom = –60 mV) hSERT-expressing oocytes were 
exposed to different durations of 10 µM S(+)METH or 10 µM S(+)MDMA (30, 60, 100, 
or 200 s). Exposure to both (A) S(+)METH  and (B) S(+)MDMA induced larger 
persistent leak currents with increased time exposure. Traces were obtained in individual 
oocytes, normalized to the largest drug-induced response, and aligned to the beginning of 
drug application. Unpublished data from Solis, 2012. 
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While S(+)METH and S(+)MDMA Induce Concentration-dependent hDAT-mediated 
Peak Currents, Only S(+)METH Induces hDAT-mediated Persistent Leak Currents  
We further characterized the effect of S(+)MDMA and S(+)METH on hDAT by 
performing concentration response curves. We recorded currents in voltage-clamped (–60 
mV) hDAT-expressing oocytes in response to 0.1-30 µM S(+)METH and S(+)MDMA 
application (100 s duration, data not shown). Increasing S(+)METH concentration 
produced increasingly larger hDAT-mediated inward currents, and beginning at 3 µM 
S(+)METH exposure, discernable persistent leak currents are observed, which are 
inhibited by the hDAT inhibitor cocaine (COC, 1 µM) (data not shown). The 
concentration-response values for S(+)METH-induced hDAT-mediated peak amplitude 
(selected points 30 s after drug exposure, 0.1-30 µM values used) were fit to the Hill 1 
equation, which yielded a km value of 0.25 µM. In contrast, although hDAT-mediated 
inward currents became larger in response to increasing S(+)MDMA concentration, there 
was no persistent leak currents produced in response to any S(+)MDMA concentration 
tested (data not shown). The concentration-response values for S(+)MDMA-induced 
hDAT-mediated peak amplitude (selected points 30 s after drug exposure, 0.1-30 µM 
values used) were fit to the Hill 1 equation, which yielded a km value of 1.66 µM (see 
Table 3 for available affinity values for S(+)METH and S(+)MDMA to induce peak and 
persistent leak currents at hDAT). While S(+)METH produced an effect comparable to 
DA in regards to the hDAT-mediated amplitude, S(+)MDMA produced only about 70% 
of the effect of S(+)METH and was nearly seven-fold less potent. 
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Both Peak and Persistent Leak Currents Induced by S(+)METH and S(+)MDMA on 
hSERT are Concentration-dependent  
To further characterize the effect of S(+)MDMA and S(+)METH on hSERT, we 
performed concentration response curves. We recorded currents in voltage-clamped (–60 
mV) hSERT-expressing oocytes in response to 0.1-30 µM S(+)METH and S(+)MDMA 
application (100 s duration, Figure 41 and Figure 42, respectively, Solis 2012, 
unpublished). Increasing S(+)METH concentration produced increasingly larger hSERT-
mediated inward currents (Figure 41A), and beginning at 3 µM S(+)METH exposure, 
discernable persistent leak currents are observed, which are inhibited by the SSRI 
fluoxetine (FLX, 1 µM) (data shown for 30 µM S(+)METH, Figure 41A). The 
concentration-response values for S(+)METH-induced hSERT-mediated peak amplitude 
(selected points 30 s after drug exposure, 0.1-30 µM values used) and persistent leak 
current (selected 60 s after drug washout, 1-30 µM used) were fit to the Hill 1 equation 
(Figure 41B and Figure 41C), which yielded km values of 4.55 ± 0.40 µM (n = 1.27 ± 
0.09) and 8.76 µM (n = 2), respectively. Similarly, hSERT-mediated inward currents 
became larger in response to increasing S(+)MDMA concentration, and persistent leak 
currents were produced beginning at 1 µM S(+)MDMA exposure, which were inhibited 
by 1 µM FLX  (data shown for 30 µM S(+)MDMA, Figure 42A). The concentration-
response values for S(+)MDMA-induced hSERT-mediated peak amplitude (selected 
points 30 s after drug exposure, 0.1-30 µM values used) and persistent leak current 
(selected 60 s after drug washout, 1-30 µM values used) were fit to the Hill 1 equation 
(Figure 42B and Figure 42C), which yielded km values of 1.58 ± 0.15 µM (n = 1.39 ± 
0.13) and 15.80 µM (n = 2), respectively.  
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Fig. 41. Concentration-dependence of S(+)METH-induced hSERT-mediated 
currents. (A) Voltage-clamped (Vcom = –60 mV) hSERT-expressing oocytes generate 
inward currents in response to increasing [S(+)METH] (from 0.1 – 30 µM, labeled 0.1, 
0.5, 1, 3, 10, 30). Fluoxetine (1 µM, FLX) is applied during the persistent leak current 
induced after application of 30 µM S(+)METH, which inhibits the persistent leak current 
and elicits an outward current. (B) Fitting peak currents from several recordings as in A 
(amplitude point taken 30 second after drug application) to the Hill 1 equation, y = Vmin + 
(Vmax - Vmin) * xn / (kn + xn), yields km = 4.55 ± 0.40 µM and n = 1.27 ± 0.09 for 
S(+)METH. (C) Fitting persistent leak currents from several recordings (amplitude point 
taken 60 second after drug application) to the Hill 1 equation yields km = 8.76 µM and n 
= 2 for S(+)METH. N = 5 and error bars represent SEM. Unpublished data from Solis, 
2012. 
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Fig. 42. Concentration-dependence of S(+)MDMA-induced hSERT-mediated 
currents. (A) Voltage-clamped (Vcom = –60 mV) hSERT-expressing oocytes generate 
inward currents in response to increasing [S(+)MDMA] (from 0.1 – 30 µM, labeled 0.1, 
0.5, 1, 3, 10, 30). Fluoxetine (1 µM, FLX) is applied during the persistent leak current 
induced after application of 30 µM S(+)MDMA, which inhibits the persistent leak current 
and elicits an outward current. (B) Fitting peak currents from several recordings as in A 
(amplitude point taken 30 seconds after drug application) to the Hill 1 equation, y = Vmin 
+ (Vmax - Vmin) * xn / (kn + xn), yields km = 1.58 ± 0.15 µM and n = 1.39 ± 0.13. (C) 
Fitting persistent leak currents from several recordings (amplitude point taken 60 seconds 
after drug application) to the Hill 1 equation yields km = 15.80 µM and n = 2. N = 5 and 
error bars represent SEM. Unpublished data from Solis, 2012. 
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Table 3. Affinity values for S(+)METH and S(+)MDMA on hDAT and hSERT. 
Values for peak and persistent leak currents were obtained from voltage-clamped (Vcom = 
–60 mV) Xenopus laevis oocytes expressing either hSERT or hDAT. Efflux values are 
from studies measuring reverse transport (efflux) of radiolabeled endogenous transmitters 
through DAT and SERT in synaptosome preparations (Rothman and Baumann 2006). 
Abbreviations:  Peak (peak current), ILC (induced leak current or persistent leak current), 
DNE (does not exist). 
 
 
 
 
 
 
 
 
 
 
hDAT hSERT
Peak (µM) ILC (µM) Efflux (nM) Peak (µM) ILC (µM) Efflux (nM)
S(+)METH 0.87 13.25 24.1 ± 2.1 4.55 ± 0.40 8.76 736 ± 45
S(+)MDMA 2.68 DNE 142 ± 4 1.58 ± 0.15 15.8 74 ± 3
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A Large hSERT Persistent Leak Current is Elicited by Para-chloroamphetamine 
Since the hSERT persistent leak currents induced by METH and MDMA were not as 
large as the ones observed in hDAT – induced by S(+)METH or S(+)AMPH (Rodriguez-
Menchaca, Solis et al. 2012), we sough to identify a larger persistent leak current in 
hSERT. Certain compounds that are structurally related to AMPH are known to elicit a 
greater effect on SERT. Specifically, the AMPH derivative para-chloroamphetamine 
(pCA), has been shown to selectively kill serotonergic neurons (Berger, Grzanna et al. 
1992; Zhou, Schreinert et al. 1996; Brown and Molliver 2000), is transported by hSERT, 
and induces substantial hSERT-mediated 5HT efflux (Hilber, Scholze et al. 2005). Also, 
hSERT-expressing mammalian cells (HEK293 cells transiently transfected with hSERT) 
under whole-cell patch-clamp (Vhold –70 mV) display depressed currents after exposure 
to pCA that resembles our METH- or MDMA- induced hSERT-mediated persistent leak 
currents (Hilber, Scholze et al. 2005). In this same study, hSERT-mediated currents 
elicited by other hSERT substrates, including tyramine, MPP+, and MDMA, seem to 
return to baseline.  
We deemed pCA to be a great candidate to induce a persistent leak current at 
hSERT, and therefore, exposed hSERT-expressing oocytes to 10 µM pCA, which 
produced an hSERT-mediated inward current that was larger than the 5HT-induced peak 
current, and also a potent persistent leak current at short (60 s, Figure 43A, Solis 2012, 
unpublished) and long time exposure (200 s, Figure 43B, Solis 2012, unpublished), which 
can be inhibited by fluoxetine application. The longer pCA time exposure (200 s) yields 
an enhanced persistent leak current. The persistent leak current evoked by pCA is larger 
than the one produced in response to either stereoisomer of METH or MDMA (Figure 37 
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and Figure 38) or the more potent S(+) isomers for METH (Figure 40A and Figure 41) 
and MDMA (Figure 40B and Figure 42). 
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Figure 43. Exposure to para-chloroamphetamine (pCA) produces a strong hSERT-
mediated persistent leak current. Application of 10 µM pCA to voltage-clamped (Vcom 
= –60 mV) hSERT-expressing oocyte for (A) 60 s or (B) 200 s induces a potent hSERT-
mediated persistent leak current that is blocked by the SSRI fluoxetine (FLX, Prozac). 
Unpublished data from Solis, 2012. 
 	  
 
 
 
 
 
 
	   170 
DISCUSSION 
 
METH and MDMA Stereoisomers Produce Distinct Behavioral Actions 
It is recognized that the behavioral actions of MDMA are more complex than those 
of AMPH and METH; nevertheless, given that AMPH, METH, and MDMA are 
locomotor stimulants, drugs of abuse, and optically-active phenylisopropylamines that 
are related structurally, they seemed like ideal examples to evaluate in the present 
investigation. Despite chemical and behavioral similarities, it is well-established that the 
stereoisomers of METH and MDMA produce distinguishable clinical effects (Green, 
Mechan et al. 2003). The distinct behavioral effects exerted by METH and MDMA are 
attributed to their differences in affinity at their molecular targets – hSERT and hDAT. 
While METH displays higher affinity than MDMA at hDAT, MDMA is more potent at 
hSERT.  
Furthermore, the stereoisomers of METH and MDMA also confer distinct behavioral 
effects. Though both S(+)METH and R(–)METH are psychoactive, the R(–)METH 
isomer generally produces less pleasurable effects than doses containing S(+)METH in 
humans (Mendelson, Uemura et al. 2006). Similarly, in rhesus monkey, S(+)MDMA 
isomer displays stronger reinforcing effects than the R(–)MDMA isomer (Fantegrossi 
2008). These differences in enantiomer-specific behavioral effects could be attributed to 
the selectivity of the compounds at the monoamine transporters. S(+)METH displays 
better affinity than R(–)METH at hDAT, and similarly, S(+)MDMA displays better 
affinity than R(–)MDMA at both hDAT and hSERT (Rothman and Baumann 2006; 
Fantegrossi 2008). Lastly, it cannot be discounted that the distinct behavioral actions 
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elicited by METH and MDMA are partly caused by these drugs having effects on other 
targets, such as receptors. In fact, METH and MDMA interact at central nicotinic 
receptors (Garcia-Rates, Camarasa et al. 2007), which have been targeted to prevent 
neurotoxicity induced by METH and MDMA (Escubedo, Camarasa et al. 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   172 
In Search of Persistent Leak Currents  
The question arises whether the persistent leak current is a phenomenon common to 
abused drugs that are structurally similar to AMPH, and whether other monoamine 
transporters exhibit the same phenomenon. Based on our previous work, we might expect 
the enhanced leak current to be of particular interest with regard to DA release at 
dopaminergic synapses; and furthermore, identifying a persistent leak current at SERT 
would have implications for neurotransmission at the serotonergic synapse. Since AMPH 
induces a persistent leak current through hDAT (Rodriguez-Menchaca, Solis et al. 2012), 
we expect that the AMPH analog METH, which displays high affinity at hDAT, would 
also produce a persistent leak current through hDAT. MDMA seemed like a prudent 
candidate to evoke a persistent leak current through hSERT because it has high affinity at 
hSERT and is closely related to AMPH and METH. 
Since S(+)METH displays better affinity than R(–)METH at hDAT, and 
S(+)MDMA displays better affinity than R(–)MDMA at hSERT (Rothman and Baumann 
2006), we posited the S(+) enantiomers of METH and MDMA would confer a stronger 
effect on hDAT and hSERT, respectively. In addition, the fact that METH and MDMA 
target hDAT and hSERT non-specifically opens the possibility that various substrates can 
evoke a persistent leak current through each monoamine transporter. Thus, we extended 
our original studies (Rodriguez-Menchaca, Solis et al. 2012) to test whether the structural 
attributes of the stereoisomers of MDMA or METH would enable them to generate the 
persistent leak current in either hDAT or hSERT.  
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Implications of Peak Currents on Synaptic Neurotransmission 
The inward currents elicited by METH and MDMA through hDAT and hSERT (in 
oocytes clamped to –60 mV) are depolarizing currents. These inward currents, also called 
peak currents, can be significant for synaptic neurotransmission because they would 
depolarize the plasma membrane of neurons containing these transporters. Since 
transporters are located at the presynaptic terminal of monoaminergic neurons, the 
terminal would be depolarized and the release of the monoamine neurotransmitter would 
be precipitated either through vesicular fusion or by non-vesicular mechanisms including 
reverse transport (Kahlig, Binda et al. 2005; Sulzer, Sonders et al. 2005).  
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Implications of the Persistent Leak Current on Synaptic Neurotransmission 
The persistent leak current, which is the monoamine transporter-mediated current 
that persists after application and removal of a stimulant, such as S(+)AMPH or 
S(+)METH for hDAT, results in prolonged depolarization of transporter-expressing 
oocytes. In excitable cells, such as neurons, the cell membrane would be depolarized to a 
potential more proximal to the threshold of the voltage-gated sodium channels 
responsible to initiate an action potential; therefore, depolarization induced by the 
persistent leak current favors neurotransmitter release. Thus, the existence of a persistent 
leak current at monoaminergic neurons implies a mechanism for long-lasting DA or 5HT 
release at a dopaminergic or serotonergic synapse, respectively. 
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Structural Determinants to Induce the Persistent Leak Current in hDAT 
Only the S(+), but not the R(–), enantiomer of METH is capable of producing the 
persistent leak current through hDAT. This result is consistent with our previous work, in 
which only the S(+) enantiomer of AMPH evoked a persistent leak current through 
hDAT (Rodriguez-Menchaca, Solis et al. 2012). Hence, stereochemistry seems to play a 
role in producing the persistent leak current at least for hDAT. However, it is yet to be 
determined if this difference could be attributed to diminished uptake of the R(–) 
enantiomers due to their lower affinity at hDAT. Further experiments accounting for 
uptake of these substrates are warranted.  
Unlike S(+)AMPH and S(+)METH, however, neither MDMA optical isomer 
produced a persistent shelf current through hDAT once they were washed out. 
Structurally, DA and AMPH are primary amines. Because S(+)METH behaves similar to 
S(+)AMPH, it is unlikely that the N-methyl group is responsible for the observed 
differences. DA lacks an α-methyl group, whereas both AMPH and METH possess this 
functionality. Thus, it might be thought that the presence of the α-methyl group is 
responsible for the shelf; however, although S(+)MDMA bears such a group, it does not 
produce the persistent leak current at hDAT. There is a possibility that the lower affinity 
of S(+)MDMA at hDAT precludes its transport into the cell, and thus, the internal 
S(+)MDMA concentration is not enough to bind and activate the internal hDAT binding 
site surmised to be responsible for producing the persistent leak current. Another 
possibility is that the pentameric ring in S(+)MDMA disallows for the compound to bind 
at the binding site. Perhaps, a smaller chemical structure than S(+)MDMA, without the 
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pentameric ring, is required in order to bind at the internal binding site of hDAT, such as 
S(+)METH or S(+)AMPH. 
Lastly, perhaps the presence of the oxygenated ring group impedes induction of the 
hDAT–mediated persistent leak current. Fittingly, the one structural feature common to 
MDMA and DA (a substrate that does not inducing a persistent leak current), but lacking 
in AMPH and METH, is the presence of these oxygen substituents; therefore, they may 
account for some of the observed differences. Additional compounds will need to be 
examined to test these hypotheses and form a complete structure-activity relationship 
(SAR) analysis. 
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Structural Determinants to Induce the Persistent Leak Current in hSERT 
Similarly to hDAT, only the S(+) enantiomer of METH is able to induce a persistent 
leak current through hSERT, which validates a role for stereochemistry in generating a 
persistent leak current across different monoamine transporters. Surprisingly, the MDMA 
stereoisomers are able to produce a persistent leak current at hSERT, which, if the drugs 
act directly on the transporter, implies that hSERT possesses a less selective internal 
binding site. Further studies to investigate whether a direct interaction of drugs to the 
transporter induce the persistent leak current are warranted. An adequate technique to 
perform these studies is the voltage-clamp, cut-open oocyte preparation (Adams and 
DeFelice 2003). 
The peak and persistent leak currents induced by S(+)METH and S(+)MDMA on 
hSERT seem qualitatively similar. The affinity values for the inducing hSERT-mediated 
peak currents by S(+)METH and S(+)MDMA are 4.55 and 1.58 µM, respectively, which 
is approximately three times better for S(+)MDMA than S(+)METH. Since the affinity to 
induce the persistent leak current is comparable for S(+)METH and S(+)MDMA (8.76 
and 15.8 µM, respectively), this might indicate a relationship between affinity and ability 
to produce a persistent leak current.   
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Relationship Between METH/MDMA Reinforcement and the Persistent Leak Current 
It is thought that if a drug produces mostly a dopaminergic stimulus, it will produce 
stimulant behavior and will have more potential to be addictive (Rothman and Baumann 
2006). Since S(+)MDMA activates a DA response (by releasing DA through hDAT), it 
would be expected to mediate addictive behaviors; moreover, since R(–)MDMA only 
activates a mild DA response (due to its weak affinity for hDAT) it is expected to confer 
diminished addictive properties than S(+)MDMA. This is exactly what happened in a 
study comparing the reinforcing strength of MDMA stereoisomers that showed both 
enantiomers possess reinforcing effects, but S(+)MDMA was clearly stronger than R(–
)MDMA as a reinforcer and had better affinity at DAT (Fantegrossi 2008). However, the 
reinforcing effects of MDMA (racemic or of either enantiomer of MDMA) are weaker 
than the reinforcing effects of METH; furthermore, the reinforcing effects of racemic 
MDMA, which is the chemical form that would be used in the streets, is weaker than the 
reinforcing of S(+)MDMA (Wang and Woolverton 2007). This would be in agreement 
with the finding that MDMA and its analogs do not tend to exhibit behavioral effects 
congruent with those of AMPH-like drugs; in particular, it is known that MDMA is 
typically taken intermittently by people, usually in the context of raves or dance parties, 
rather than in the compulsive binge pattern characteristic of psychostimulants 
(Fantegrossi 2008). Since MDMA elicits more 5HT to DA release (as compared to 
METH), these findings support the hypothesis that greater 5HT to DA releasing potency 
(increasing 5HT releasing potency relative to DA) leads to weaker reinforcing effects 
(Wang and Woolverton 2007).  
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In the context of our study, the fact that S(+)METH induces a diminished persistent 
leak current through hSERT and produces a strong one through hDAT, indicates that the 
long-lasting effects this drug produces are primarily mediated by DA, and is consistent 
with the high abuse potential S(+)METH is known to have. Since inducing a persistent 
depolarizing leak current through hSERT would be proficient at prolonging serotonergic 
neurotransmission, perhaps having an hSERT-mediated persistent leak current induced 
by S(+)MDMA is partially responsible for reducing the reinforcing effects S(+)MDMA 
possesses relative to S(+)METH (again, S(+)METH induces a substantial persistent leak 
current through hDAT and a small one through hSERT). In the case of R(–)MDMA, 
qualitatively it does elicit a slightly smaller hSERT-mediated persistent leak current than 
S(+)MDMA, which could indicate its action as a weaker reinforcer (as compared to 
S(+)MDMA), but the electrophysiological actions of R(–)MDMA on hSERT need to 
explored further.  
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Increasing Serotonergic Involvement Decreases Abuse Potential 
Studies supporting the hypothesis that as serotonergic involvement increases, 
addictive potential decreases include that treating rats with the 5HT precursor L-
tryptophan, which increases 5HT levels, decreases self-administration of cocaine and 
AMPH, pre-treating rats and squirrel monkeys with SERT reuptake inhibitors reduces 
intravenous cocaine self-administration, and cocaine analogs that are more potent at 
SERT are weaker at maintaining self-administration behavior than cocaine analogs with 
weak affinity for SERT (Rothman, Blough et al. 2008). 
Since these and other lines of evidence support the hypothesis that elevating synaptic 
5HT concentrations counteract the stimulant and reinforcing effects mediated by 
elevations in synaptic DA levels, an emerging idea to decrease abuse liability in the 
development of therapeutic agents is to add 5HT-releasing properties to these drugs 
(Rothman, Blough et al. 2008). In addition to measurements of potency of drugs to 
release neurotransmitters by distinct monoamine transporters, perhaps inclusion of the 
ability for a candidate compound to elicit a persistent leak current, in particular by SERT, 
could help strengthen the contribution of serotonergic signaling and diminish the abuse 
potential of the candidate compound.   
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Contribution of Persistent Leak Currents to Predicting Behavioral Effects  
It is already known that substrate-induced monoamine transporter-mediated peak 
currents increase neuronal excitability, which would result in enhanced neurotransmitter 
release (Ingram, Prasad et al. 2002; Branch and Beckstead 2012); in like manner, 
assuming persistent leak currents lead to long-lasting release of monoamine 
neurotransmitters, we would expect for drugs that induce persistent leak currents 
selectively through hDAT to confer higher abuse potential than drugs that elicit persistent 
leak currents through hSERT.  
Moreover, we would expect any contribution of the serotonergic system to diminish 
the reinforcing effects of the drugs that are more selective at inducing hDAT currents. 
Therefore, a shift in drug selectivity from hDAT to hSERT to induce a persistent leak 
current would be predictive of abuse potential. In addition, it is probable that the 
existence of persistent leak currents could be a measure used to predict the behavioral 
effects, and abuse liability, of drugs that are substrates for monoamine transporters.  
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Relationship Between Monoamine Release and Transporter Currents  
The main contributing factor underlying the different behavioral effects produced by 
related AMPH-like drugs of abuse is thought to be their distinct affinities to release 
monoamine neurotransmitters through the monoamine transporters. It is known that drugs 
such as AMPH and phentermine, which release [3H]-DA more potently than [3H]-5HT in 
vitro, increase endogenous extracellular DA more than extracellular 5HT in vivo; and 
likewise, drugs such as fenfluramine and chlorphentermine, which release [3H]-5HT 
more potently than [3H]-DA in vitro, increase endogenous extracellular 5HT more than 
extracellular DA. Furthermore, while METH is much more potent at releasing DA and 
NE (from DAT and NET, respectively) than at releasing 5HT through SERT, structurally 
related MDMA produces a rapid, acute release of both 5HT and DA from nerve terminals 
in experimental animals (Rothman and Baumann 2006). Making a correlation between 
releasing affinity of compounds tested in this study and their ability/affinity to produce 
(peak and shelf) currents would validate a relationship between these mechanisms.  
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Comparing METH- and MDMA-induced DAT-mediated Peak Currents and DAT-
mediated Neurotransmitter Release 
In terms of peak currents, first, we determined that when applied to hDAT, METH 
and MDMA stereoisomers produced hDAT-mediated inward currents that are 
comparable those in response to DA. Pertaining to the more active METH and MDMA 
enantiomers we studied, S(+)MDMA produced a visibly smaller peak current than 
S(+)METH and was nearly seven-fold less potent. The relative difference in affinities for 
S(+)METH and S(+)MDMA at inducing hDAT-mediated peak currents (km = 0.25 and 
1.66 µM, respectively) are in agreement with the six-fold affinity difference reported for 
the ability of these isomers to release [3H]-DA from DAT in synaptosomes (km = 24.1 
and 142 nM, respectively) (Rothman and Baumann 2006). Obtaining the km for both R(–
)METH- and R(–)MDMA-induced hDAT-mediated peak currents would enable to 
further compare this property to DAT-mediated neurotransmitter release. 
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Comparing METH- and MDMA-induced DAT-mediated Persistent Leak Currents and 
DAT-mediated Neurotransmitter Release 
Regarding persistent leak currents, since S(+)METH (and not R(–)METH, 
S(+)MDMA, nor R(–)MDMA) induces an hDAT-mediated persistent leak current, 
S(+)METH is expected to induce the greatest DA release (at least as compared to the 
other agents tested here), which correlates with it having the highest affinity at hDAT. 
Since neither MDMA enantiomer induces an hDAT-mediated persistent leak current, we 
can deduce racemic MDMA has minimal effect on long-term DAT-mediated 
neurotransmitter release. Furthermore, although S(+)MDMA has substantially higher 
affinity than R(–)MDMA to release neurotransmitter at DAT (km = 142 and 3700 nM, 
respectively), perhaps the contribution of R(–)MDMA in racemic MDMA weakens the 
overall affinity of MDMA resulting in lessened DAT-mediated release. In regards to 
METH, it is known that S(+)METH has nearly 20 times better affinity than R(–)METH 
to release DA through DAT (km = 24.1 and 416 nM, respectively), which would be in 
agreement with the fact that only S(+)METH induces an hDAT-mediated persistent leak 
current.  
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Comparing METH- and MDMA-induced SERT-mediated Peak Currents and SERT-
mediated Neurotransmitter Release 
In terms of peak currents, akin to 5HT-induced currents, all four compounds tested 
induced hSERT-mediated inward currents. However, S(+)MDMA, R(–)MDMA, and 
S(+)METH induced hSERT-mediated currents that were substantially larger than the one 
induced by R(–)METH. Pertaining to the more active METH and MDMA enantiomers 
we studied, the relative difference in affinities for S(+)METH and S(+)MDMA at 
inducing hSERT-mediated peak currents (km = 4.55 and 1.58 µM, respectively) are in 
agreement with the ten-fold affinity difference reported for the ability of these isomers to 
release [3H]-5HT from SERT in synaptosomes (km = 736 and 74 nM, respectively) . 
Obtaining the km for both R(–)METH- and R(–)MDMA-induced hSERT-mediated peak 
currents would enable to further compare this property to SERT-mediated 
neurotransmitter release. 
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Comparing METH- and MDMA-induced SERT-mediated Persistent Leak Currents 
and SERT-mediated Neurotransmitter Release 
Regarding persistent leak currents, S(+)MDMA, R(–)MDMA, and S(+)METH, but 
not R(–)METH, induce substantial hSERT-mediated persistent leak currents, which 
might induce long-lasting hSERT-mediated 5HT release. In terms of the MDMA 
stereoisomers, the slightly smaller R(–)MDMA-induced persistent leak current (as 
compared to the one induced by S(+)MDMA) might correlate with the respective 
affinities to induce neurotransmitter release by SERT (S(+)MDMA km = 74 nM and R(–
)MDMA km = 340 nM). S(+)METH and S(+)MDMA display comparable affinities at 
inducing hSERT-mediated persistent leak currents induced (km = 8.76 µM and km = 15.80 
µM, respectively), which does not seem to correlate with the ability for these isomers to 
release [3H]-5HT from SERT in synaptosomes (km = 736 and 74 nM, respectively). To 
further study if this discrepancy is consistent, we would have to compare affinities to 
induce the persistent leak current with the R(–) isomers of both METH and MDMA at 
both hSERT and hDAT. Regardless, as noted, S(+)METH is strongest acting on DAT, 
both for release and at inducing persistent leak current. The weak km for persistent leak 
current (and therefore neurotransmitter release) by SERT agrees with the fact that METH 
induces very little 5HT release in the brain. Lastly, the affinity for R(–)METH at 
inducing SERT-mediated release is relatively much weaker (km = 4640 nM) than its 
S(+)METH counterpart (km = 736 nM), which agrees with the ability of only S(+)METH 
to induce a persistent leak current. In conclusion, the effects S(+)METH and S(+)MDMA 
induce on current and efflux are in agreement at both hDAT and hSERT.  	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MONOAMINE TRANSPORTER SUBSTRATES AND INHIBITORS: 
CLOSING REMARKS 
 
Although we have grouped compounds that act on the monoamine neurotransmitter 
transporters into two categories, substrates, which are taken up by transporters, and 
inhibitors, which bind to transporters and block their ability to take up substrates, through 
the work described here (and in other studies), we are now seeing that this categorization 
is not the entire story. For example, we now know that ASP+ can act as a substrate for 
hNET, but has inhibitor-like actions at hSERT and can also be taken up by hSERT at a 
slower rate than other substrates. On the other hand, APP+ is a superior fluorescent 
substrate for hSERT that, once inside the cell, binds to organelles and even intercalates 
DNA. Moreover, the AMPH-like transmitter-releasing compounds constitute a different 
class of substrates than the endogenous “classic” transmitters. These “releaser” 
compounds are even able to produce the persistent induced leak current, which illustrates 
further complexities in the classification of compounds acting on transporters. Thus, 
compounds can be more complex than simply being deemed substrates or inhibitors.  
Yet, knowing whether a compound is a substrate or an inhibitor is useful to help 
understand how transporters operate. Accordingly, the advent of distinct experimental 
techniques in combination with substrates and inhibitors has allowed for our 
understanding of transporters to increase. Whether it is fluorescent compounds, such as 
APP+ or ASP+, which can be employed to study monoamine transporter activity in live-
cells in real-time using fluorescence microscopy, or drugs of abuse, such as cocaine or 
AMPH-like compounds, which produce distinct responses that are measureable through 
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electrophysiological approaches, we have the instruments and are in the position to 
continue expanding our knowledge of transporter function. The persistent shelf current 
described in my work is an example of a transporter property at an inchoate level of 
understanding, and through use of relevant synthetic compounds (related to AMPH) and 
multiple experimental techniques we can elucidate the structural determinant underlying 
this interesting property. In like manner, researchers are performing structure-activity 
relationship (SAR) studies that require series of chemical compounds (substrates or 
inhibitors) and a functional assay to learn what the specific chemical moieties of 
compounds are that contribute to their action (as substrates or inhibitors) on transporters. 
Since new advances, such as the FlexStation, allow for high-throughput measurement of 
fluorescent compounds, perhaps introduction of fluorescent analogs of APP+ would be 
appropriate for SAR studies. Moreover, homology models based on the crystallized 
leucine transporter belonging to the same neurotransmitter symporter family as the 
monoamine transporters, in combination with docking techniques, provide an additional 
resource to study the action of substrates and inhibitors on monoamine transporters (the 
models can even be employed for SAR studies).  
We have come a long way from the time we were limited to the use of radiolabeled 
compounds to study uptake through monoamine transporters in nerves. My work is only a 
small step forward in the advancement of our understanding into the complex nature of 
monoamine transporters. Surely, much more knowledge will be uncovered in the 
upcoming years, which will hopefully benefit the efforts to alleviate medical conditions 
that implicate these transporters and will lead to improvements in the quality of life of 
people.  
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